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Abstract
The phosphoinositide lipids Ptdlns(3)P and Ptdlns(3,5)P2 play 
important roles on the endocytic pathway. Ptdlns(3)P localises to early 
endosomes and multivesicular bodies (MVBs) and is proposed to recruit 
proteins involved in fusion of early endosomes and internalisation of 
ubiquitinated receptors. Ptdlns(3,5)P2 is proposed to be involved in terminal 
maturation of lysosomes and endosome to Golgi transport, but the precise 
role of this lipid in mammalian cells remains unclear. Studies in yeast have 
identified various proteins associated with Ptdlns(3,5)P2 metabolism, for 
which mammalian homologues have been found. These are the Ptdlns(3)P- 
5-kinase Fab1/PIKfyve, Fig4 a 5-phosphatase that dephosphorylates 
Ptdlns(3,5)P2, Vac14 which has been shown to act as an upstream activator 
of PIKfyve, and WIPI-2/Svp1 a putative downstream effector of Ptdlns(3,5)P2.
In this study I have further characterised three of these proteins and 
examined the cellular roles of all four with respect to a variety of trafficking 
pathways in which Ptdlns(3,5)P2 has been implicated. siRNA was used to 
examine the knockdown phenotypes of each of these proteins. Furthermore, 
I directly compared for the first time the effects of knockdown of PIKfyve, with 
acute pharmacological inhibition of its enzymatic activity. Loss of PIKfyve
activity caused a failure in the retrieval of a variety of different cargos to the 
trans-Golgi network (TGN), including mannose-6-phosphate receptors, 
responsible for efficient delivery of lysosomal enzymes, and the TGN 
resident protein TGN46, leading to their accumulation in dispersed punctae. 
A failure in tyrosine kinase receptor downregulation was also observed 
following combined knockdown of PIKfyve with either Vac14 or Fig4 or 
following pharmacological inhibition of PIKfyve. PIKfyve knockdown alone 
had no effect, suggesting a low threshold of Ptdlns(3,5)P2 is necessary and 
sufficient for this pathway.
Svp1 is the best characterised Ptdlns(3,5)P2 effector in yeast and is 
also an autophagy-related gene (Atg18), thereby implicating Ptdlns(3,5)P2 in 
this process. A family of putative mammalian Svp1 homologues have been 
identified, known as the WIPI family. I investigated the role of Ptdlns(3,5)P2 
and WIPI-2 in mammalian autophagy. By monitoring formation of the 
autophagosome marker GFP-LC3 II, PIKfyve and WIPI-2 were found to have 
opposite effects. Furthermore, WIPI-2 redistributes to punctate structures 
upon induction of autophagy, which partially colocalise with autophagosome 
markers, in a manner dependent not on PIKfyve but on Pl(3)-kinase activity.
The evidence presented suggests that Ptdlns(3,5)P2 may play a role 
in mediating the maturation of a subset of MVBs, leading to swelling of 
endosomal compartments and rendering the MVB/late endosome or 
autophagosomes refractory to fusion with the lysosome in cells depleted of 
PIKfyve.
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Chapter One: Introduction
CHAPTER ONE
Introduction
1.1 Phosphatidylinositol lipids
1.1.1 Phosphatidylinositol
Anderson and Roberts first identified inositol as a lipid constituent in 
mycobacterium in 1930 (Hawthorne, 1960). The term phosphoinositide 
came from Folch, to describe a brain phospholipid containing inositol (Folch, 
1949). The most widely distributed phosphoinositide is phosphatidylinositol 
(Ptdlns) in which a phosphatidic acid residue is attached to the 1-hydroxyl of 
inositol. Ptdlns makes up less than 10% of membrane lipid in eukaryotic 
cells, approximately 20% in yeast, and 5% in Protozoa. It is rarely found in 
bacteria, mycobacteria being the exception. It is an acidic phospholipid that, 
in essence, consists of a phosphatidic acid backbone, linked via the 
phosphate group to inositol (hexahydroxycyclohexane). The structure of 
Ptdlns is shown in figure 1.1. Of the possible stereoisomers, only myo­
inositol has been found in naturally occurring phosphoinositides, with one 
axial hydroxyl in position two, and the remainder equatorial. The fatty acid 
composition can be as much as 80% 1-stearoyl 2-arachidonoyl (18:0, 20:4), 
with much smaller quantities of other species (Hawthorne and White, 1975). 
The biosynthetic route for the synthesis of Ptdlns is shown in figure 1.1, as 
first identified by Agranoff and expanded upon by the work of Paulus and 
Kennedy (Agranoff et al., 1958; Paulus and Kennedy, 1960).
1
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1.1.2 Di and triphosphoinositides
In the 1950’s and 60’s Mabel and Lowell Hokin, two of the key players 
in early phosphoinositide research, made a series of vital discoveries to this 
field. Using a method for analysis of individual phospholipids introduced by 
Rex Dawson (Dawson, 1954), they extracted lipids from pancreatic slices 
incubated with [2-3H]inositol and identified seven phospholipids (Hokin and 
Hokin, 1958, 1964a). Much later it became clear that Ptdlns could be 
differentially phosphorylated at the 3, 4 and 5 positions of its inositol ring to 
generate seven distinct di and triphosphoinositides. These are found on the 
cytoplasmic face of cell membranes and act as substrates for a number of 
enzymes, including phospholipase C (PLC) and the phosphoinositide 
phosphatases and kinases that catalyse the conversion of phosphoinositides 
from one form to another (Martin, 1998). The seven mammalian 
phosphoinositides and their metabolising enzymes are shown in figure 1.2.
Hokin and Hokin also demonstrated that muscarinic cholinergic 
stimulation of pancreatic fragments increased the turnover of cellular Ptdlns 
(Hokin and Hokin, 1955, 1958). This subsequently came to be known as the 
‘PI effect’ and was the focus of much research not just by the Hokins but 
numerous other groups. It soon became obvious that Ptdlns turnover was a 
reaction associated with a wide variety of receptors linked to diverse 
biological processes. In 1964, the Hokins suggested that PLC-catalysed 
Ptdlns hydrolysis might initiate the PI effect, as they observed an increase in 
phosphatidic acid, which they hypothesised would be formed from the 
diacylglycerol (DAG) product of Ptdlns breakdown (Hokin and Hokin, 1964b). 
It was not until the 1980’s, following a series of controversial discoveries,
3
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Chapter One: Introduction
that experimental evidence began to indicate that this initial reaction in 
stimulated Ptdlns turnover was not the breakdown of Ptdlns itself, but of one 
of its phosphorylated derivatives Phosphatidylinositol(4,5)bisphosphate 
(Ptdlns(4,5)P2) (Abdel-Latif et al., 1977; Kirk etal., 1981).
Phosphoinositides have since been shown to play a role in a vast 
range of vital cellular processes such as cell growth, cell survival, and 
calcium signalling. The hydrolysis of Ptdlns(4 ,5 )P2 by PLC, for example, was 
subsequently shown to generate inositol(1,4,5)triphosphate (IP3) and DAG 
(Berridge, 1983). IP3 liberates intracellular stores of calcium and thereby has 
a key function in calcium signalling (Berridge and Irvine, 1989), whereas 
DAG activates Protein kinase C (PKC), initiating a multitude of cell specific 
downstream pathways of this kinase (Bell, 1986). The first evidence for the 
role of phosphoinositides in cell growth and transformation stems from the 
observation that Ptdlns(3,4)P2 and Ptdlns(3 ,4 ,5 )P3 can only be found after 
stimulation with platelet-derived growth factor receptor (PDGFR) (Auger et 
al., 1989), but that in NIH3T3 cells transformed with polyoma virus, the levels 
of these phosphoinositides is elevated, even in the absence of serum 
(Serunian et al., 1990).
1.1.3 Phosphoinositide binding domains
Phosphoinositides are able to orchestrate this wide range of cellular 
functions through the recruitment of a vast array of different proteins to a 
target membrane via specific phosphoinositide binding domains. The PH 
(pleckstrin homology) domain was the first binding domain reported and has 
been shown to be the eleventh most common domain in the human
5
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proteome, in over 250 proteins (Harlan et al., 1994; Lemmon and Ferguson, 
2000). But over the years a range of others have been identified, including 
ENTH (Epsin N-terminal homology) (Itoh etal., 2001), PX (phox homology) 
(Cheever etal., 2001; Kanai etal., 2001; Xu etal., 2001), FYVE (Fab1, 
YOTB, Vac1, EEA-1) (Stenmark et al., 1996; Gaullier etal., 1998; Patki etal., 
1998), FERM (Band 4.1, Ezrin, Radixin, Moeisin) (Niggli et al., 1995; Hirao et 
al., 1996), BAR (Bin 1, Amphiphysin, Rvs167) (Zhang and Zelhof, 2002), 
GRAM (glucosyltransferase Rab-like GTPase activator and myotubularin) 
(Berger et al., 2003; Tsujita et al., 2004) and C2 domains (Davletov and 
Sudhof, 1993). These domains are frequently found in combination with 
additional modules that are involved in the formation of protein-protein or 
protein-lipid interaction networks. Some of them show specific and high 
affinity binding to a particular phosphoinositide as outlined in figure 1.3. 
These domains act to recruit their host proteins to particular sites on the 
plasma or other intracellular membranes. Furthermore, they provide 
valuable tools to assess the localisation of phosphoinositides in the cell. A 
number of phosphoinositides, including Ptdlns(3,5)P2, have been found to 
play a role in membrane trafficking events. These trafficking pathways are 
reviewed in section 1.2.
1.2 Compartmentalisation of cells and membrane trafficking pathways
1.2.1 Intracellular trafficking pathways
A key feature of eukaryotic cells is the presence of internal 
membrane-bound organelles that are in continual exchange with one another
6
Domain Protein (eg.) Target lipid
0 PLCia
GRP1
Ptdlns(4,5)P2
Ptdlns(3,4,5)P3
FAPP1 Ptdlns(4 )P
Akt/PKB
p40phox
Ptdlns(3,4)P2, Ptdlns(3,4,5)P3 
Ptdlns(3)P
p47phox Ptdlns(3,4)P2
SNX-1 Ptdlns(3)P, Ptdlns(3,5)P2
SNX-2 Ptdlns(3 )P
SNX-3 Ptdlns(3 )P
FYVE EEA-1 Ptdlns(3)P
Hrs Ptdlns(3 )P
Fabl/PIKfyve Ptdlns(3)P
ENTH Epsin 1 Ptdlns(4,5 )Pj
EpsinR Ptdlns(4 )P
GRAM MTM1 Ptdlns(3,5)P2
MTMR3 Ptdlns(5)P
MTMR6 Ptdlns(5 )P
MTMR2 Ptdlns(3,5)P2, Ptdlns(5)P
WD40 WIPI family Ptdlns(3,5)P2
Figure 1.3. Phosphoinositide binding domains.
Key phosphoinositide binding domains, examples of proteins that possess 
them and their lipid binding specificity. Adapted from Takenawa and Itoh, 
2006.
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and the plasma membrane. Most of these organelles are elements of the 
exo- and endocytic pathways; inward and outward-directed pathways 
whereby material passes through the organelles in an orderly and sequential 
fashion by means of specific transport vesicles and membrane fission and 
fusion reactions. Development of high-resolution electron microscopy and 
ultracentrifugation techniques in the 1950’s permitted the visualisation of this 
subcellular compartmentalisation of cells and their biochemical pathways for 
the first time (Dalton and Felix, 1954; Baudhuin et al., 1965; De Duve, 1965). 
Subsequently, autoradiographic electron microscopy studies of the secretory 
pathway in pancreatic acinar cells demonstrated that newly synthesised 
proteins are transported to the cell surface through distinct secretory 
compartments and small membrane-bound organelles (Jamieson and 
Palade, 1967). This lead to the development of the intracellular vesicular 
transport hypothesis, whereby transport vesicles continually bud off from one 
membrane and fuse with another, carrying membrane components and 
soluble molecules that are collectively termed ‘cargo’ (Palade, 1975). 
Mechanisms for membrane retrieval are also in place to ensure balance in 
membrane flow.
Intracellular trafficking events can be broadly divided into two 
pathways. The internalisation of extracellular material at the plasma 
membrane is termed the endocytic pathway, and the opposing traffic of 
newly synthesised proteins from the cell interior to the plasma membrane 
occurs via the biosynthetic pathway.
8
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1.2.2 The endocytic pathway
Endocytosis is the general term used for the internalisation of 
extracellular material by invagination and pinching off of membrane-bound 
vesicles at the plasma membrane. Reknowned cytologist Christian de Duve 
first proposed the term endocytosis at a CIBA foundation meeting in 1963. It 
is a broad term that encapsulates various processes such as phagocytosis, 
pinocytosis, clathrin-dependent receptor-mediated endocytosis, and clathrin- 
independent endocytosis. It occurs in all animal cell types, can result in the 
uptake of a huge variety of different materials, and plays essential roles in a 
number of physiological processes in both individual cells and whole 
organisms. These include nutrient uptake, removal of activated signalling 
receptors, antigen presentation and maintenance of cell polarity (Mukherjee 
et al., 1997). The best-characterised form of endocytosis is clathrin- 
dependent receptor-mediated endocytosis. This is dependent upon the coat 
protein clathrin, which assembles into a polyhedron to coat a new vesicle as 
it forms, and coordinates vesicle formation and protein sorting. The 
membrane invagination subsequently buds off to form a clathrin-coated 
vesicle (CCV). In general, material that enters the endocytic pathway has 
several potential fates: recycling to the plasma membrane, degradation in the 
lysosome, or delivery onto the biosynthetic pathway through a series of 
membrane-bound compartments that are identified by a range of established 
markers (van Meel and Klumperman, 2008). An overview of the endocytic 
and biosynthetic pathways is shown in figure 1.4.
9
0 o recycling
0 Tf-TfR —  LBPA —  Rab4 Rab9 —  SNX4
|  EGF-EGFR —  Ptdlns(3)P —  Rab5 —  Rab11
|  ciM6PR —  LAMP’S —  Rab7 —  SNX-1/2
Figure 1.4. Trafficking on the endocytic and biosynthetic pathways.
Summary of the current understanding of the compartmentalisation of the 
endocytic and biosynthetic pathways, the membrane proteins that define 
each compartment and the trafficking itineraries of exemplary cargoes. 
Clathrin-mediated endocytosis is shown as the best understood example. 
Cargo enters the early endosome when uncoated CCV’s fuse. The 
tubulovesicular early endosome mediates the sorting of different cargos to 
the lysosome or into recycling pathways. Biosynthetic cargo also joins the 
endocytic pathway at the early and late endosome and likewise cargo can 
be retrieved from these locations.
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1.2.3 Early endosomes
After entering the cytoplasm, CCV’s rapidly lose their clathrin coat and 
fuse with early endosomes scattered throughout the periphery. Cargo 
accumulates here within two to five minutes after internalisation (Besterman 
et al., 1981; Griffiths et al., 1989). They are pleiomorphic structures of mildly 
acidic pH (5.9-6.0), composed of vacuolar and tubular domains that exhibit 
extensive connectivity but maintain their identity at least in part by virtue of 
their complement of Rab GTP-ases (Hopkins, 1983; Mellman et al., 1986; 
Chavrier et al., 1990). Their acidic nature is maintained by the presence of 
vacuolar H+ ATPase pumps in the limiting membrane (Mellman et al., 1986). 
Originally described as the CURL (compartment of uncoupling receptor and 
ligand) in 1983 by Geuze and Slot (Geuze et al., 1983), they are also often 
referred to as sorting endosomes as they represent major sorting stations on 
the endocytic pathway. From here, internalised cargo can be recycled back 
to the plasma membrane, passed on to the degradative or biosynthetic 
pathways or in certain cells sorted into regulated secretory vesicles.
For most receptor-ligand complexes, their ultimate fate is to be 
directed to the proteolytic machinery in the lysosome, at this site, either or 
both of the components are degraded. In the case of Epidermal Growth 
Factor (EGF), both it and its receptor are targeted for destruction. However, 
in the case of Low-Density Lipoprotein (LDL), whilst the ligand is destined for 
lysosomal degradation, the receptor is dissociated from the ligand and 
recycled back to the plasma membrane. Alternatively, as in the case of 
Transferrin (Tf) and its receptor, both ligand and receptor are recycled back
to the plasma membrane together. The use of specific membrane
11
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permeable vacuolar ATP-ase inhibitors, showed that the acidic environment 
of endosomes is crucial for the dissociation of some ligands from their 
receptors at this stage (Presley et al., 1997).
1.2.3.1 Geometric sorting
The mechanism through which these different receptor-ligand 
complexes are sorted has been a subject of much interest over the years and 
has lead to a number of proposed theories. The ‘geometric sorting’ model 
suggests that recycling back to the plasma membrane is a default pathway, 
as no specific sorting motifs for this pathway have been identified as yet. 
Instead, the geometry of the endosome regulates separation of membrane- 
bound receptors into tubular extensions of the early endosome, with a high 
surface to volume ratio that is well suited to carrying membrane protein cargo 
from one compartment to another, whilst acid-releasable ligands are 
distributed throughout the volume of the vesicular endosome and follow the 
bulk flow to the degradation pathway (Mayor et al., 1993).
Despite the lack of identified sorting motifs, sorting of proteins into
recycling endosomes could still occur by a regulated mechanism. Conserved
sorting motifs occur in proteins on other trafficking pathways, such as the
DXXLL motif to which the GGA (Golgi-associated y-ear containing ARF-
binding) proteins bind, directing specific cargo proteins into CCV’s at the
trans-Golgi network (TGN) (Hirst et al., 2007). Recent evidence has also
identified a highly conserved tripeptide motif in the cytoplasmic tail of the
cation-independent mannose-6-phosphate receptor (ciM6PR), necessary for
its retrieval from endosomes to the TGN (as discussed in section 1.2.7),
12
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which lends support to the selectivity of a variety of sorting events (Seaman, 
2007). Furthemore, different cargos have been found in distinct tubules. 
For example, ciM6PR are retrieved to the TGN in tubules formed by the 
action of the retromer coat complex (Mari et al., 2008), whereas late 
endosomal proteins LAMP-1 and LAMP-2 (lysosomally associated 
membrane proteins), to be delivered to the lysosomal limiting membrane, are 
found in tubules associated with the adaptor protein complex AP-3 (Peden et 
al., 2004), and Tf receptors are found in yet more distinct tubules, recently 
shown to be associated with the sorting nexin protein, SNX4 (Traer et al., 
2007). Together these results suggest that a range of morphologically 
distinct transport intermediates arise from the early endosome. Whether or 
not this segregation is selective remains to be determined.
1.2.3.2 Sorting-by-retention
The ‘sorting-by-retention’ model (Sachse et al., 2002) proposes that 
receptor-ligand complexes targeted for lysosomal degradation are 
concentrated in bilayered coated areas of the endosomal membrane in a 
manner dependent on clathrin, for subsequent inclusion into the intralumenal 
vesicles (ILVs) by the endosomal sorting apparatus that governs this process 
(described in detail in section 1.2.4.1; see also figure 1.5). The fate of 
receptor-ligand complexes may also be dependent on the intracellular 
concentration of ligand, and in fact internalised receptors could also actively 
promote the remodelling of this compartment to suit their needs; there is 
evidence that EGFR itself increases the number of ILVs upon internalisation 
(White et al., 2006).
13
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A recent study of in depth examination of early endosome dynamics 
has found that there are seemingly two populations, a static fraction, and a 
rapidly maturing, motile fraction. CCV’s bearing cargo destined for lysosomal 
degradation are proposed to be ‘fast-tracked’ into the degradation pathway 
by delivery to the motile fraction. For example, around 80% of EGF was 
found to be associated with the motile fraction, whilst 65% of recycling Tf 
receptor was associated with the static population. Furthermore, this study 
suggested that the sorting of receptors could begin at an even earlier stage 
and that their fate could also be governed by entry into different sub-classes 
of CCV at the plasma membrane and delivery to distinct endosomes 
(Lakadamyali et al., 2006).
1.2.3.4 Recycling to the plasma membrane
After leaving early endosomes, recycling can occur by a direct, fast 
route through transport intermediates, mediated by the Rab GTP-ase Rab4, 
or a slow route through recycling endosomes, sometimes referred to as 
endosomal recycling compartments (ERC’s), which are morphologically and 
functionally distinct from the early/sorting endosome (Sheff et al., 1999; 
Sonnichsen et al., 2000). ERC’s are characterised by the acquisition of the 
Rab GTP-ase Rab11, in contrast to the Rab5 complement on early 
endosomes, and they do not contain ligands and receptors destined for 
degradation (ie. LDL), and are less acidic. Transport along the recycling 
pathway is dependent on the actin cytoskeleton and unconventional myosin 
motors, and it is possible that these may play a role in the biogenesis of the
prerequisite tubules (Huber et al., 2000; Apodaca, 2001). As the early
14
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endosome matures it gradually acquires intralumenal vesicles of 40-90nm 
diameter, into which cargo targeted for lysosomal degradation is sorted. The 
number of ILVs often represents another means for classification of different 
compartments on the endocytic pathway, early endosomes are described as 
compartments having between 1 and 8 ILVs (van Meel and Klumperman, 
2008).
1.2.4 Multivesicular bodies
Multivesicular bodies (MVBs) were described by electron 
microscopists over 30 years ago (Gorden et al., 1978; Haigler et al., 1979). 
They are classified as containing more than 8 ILVs, contain molecules that 
have been internalised through endocytosis or biosynthetic material received 
from the TGN (Woodman and Futter, 2008), and possess a different 
complement of proteins on their limiting membrane, such as the Rab GTP- 
ases Rab7 and Rab9 and the lysosomal associated proteins LAMP-1 and 2. 
Once formed they are thought to rapidly acidify and move towards the 
lysosome in a microtubule and motor-dependent fashion, and fuse with the 
lysosome in a manner dependent on conventional docking and fusion 
machinery. In specialised cell types MVBs serve as intermediates in the 
formation of secretory lysosomes, which under the appropriate stimulus, fuse 
with the plasma membrane and shed the ILVs into the extracellular space (ie. 
melanosomes, MHC II compartments and lytic granules) (Blott and Griffiths, 
2002). In the majority of mammalian cell types they constitute endosomal 
intermediates formed from the early endosome.
15
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1.2.4.1 Formation of intralumenal vesicles
Much of our knowledge of the sorting of lysosomaly directed cargo 
into ILVs has come from studying the internalisation of EGFR. Endocytosed 
receptors are able to signal from the limiting membrane of endosomes and 
MVBs, thus internalisation represents a means to terminate the signal by 
separating the receptor from the cytosol. Indeed, impairment of MVB 
formation has been found to attenuate EGFR signalling (Lloyd e ta i, 2002). 
Sorting of many proteins for lysosomal degradation requires the post­
translation modification ubiquitin, a group of proteins known as the ESCRT 
(endosomal sorting complex required for transport) and the AAA ATPase 
Vps4.
The ESCRT complexes were identified from a screen of yeast 
vacuolar protein sorting (Vps) mutants, which identified a class of mutants 
dubbed the class E mutants (Banta et al., 1988; Raymond et al., 1992). 
Each of these mutants is characterised by an absence of ILVs and the 
formation of a multilamellar cup-shaped compartment known as the class E 
compartment (Rieder et al., 1996; Babst et al., 1997). These class E 
mutants are found in all of the ESCRT complexes, of which there are three, 
and are evolutionarily conserved with each yeast protein having a 
mammalian homologue (Babst, 2005; Winter and Flauser, 2006). ESCRT I is 
composed of the proteins Vps28, TSG101 (tumour suppressor gene 101), 
and Vps37. ESCRT II is made up of ELL (RNA polymerase II elongation 
factor complex)-associated proteins EAP30, EAP25 and EAP45, is recruited 
transiently to the endosomal membrane, and is required for the subsequent
recruitment of ESCRT III. ESCRT III is the most recently characterised
16
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complex, made up of a group of charged MVB associated proteins or CHMPs 
(2A and B, 3, 4A, B and C and 6). It has also been suggested that another 
complex of proteins represents an ESCRT 0 complex, that functions prior to 
ESCRT I. This is the Hrs (Hepatocyte growth factor regulated tyrosine 
kinase substrate) and STAM (signal transducing adaptor molecule) complex.
The ESCRT complexes form a network that sequentially recruits 
monoubiquitinated proteins to the surface of MVBs and drives their 
internalisation into ILVs, potentially through direct involvement in the 
formation of the ILVs. Current models suggest that ESCRT 0 binds to 
ubiquitinated cargo proteins and recruits ESCRT I, which in turn recruits 
ESCRT II and ESCRT III. Cargo is deubiquitinated and the ESCRT 
complexes are removed, allowing the cargo to be sorted into the inward 
budding vesicle (Babst, 2005; Winter and Hauser, 2006). The ESCRT 
machinery is detailed in figure 1.5.
Direct evidence for a role in ILV formation remains elusive, but recent 
structural data suggests that the ESCRT III proteins can multimerise to form 
a flat lattice on the endosomal membrane, which could drive ILV formation in 
one of two ways (Muziol et al., 2006; Shim et ai, 2007). Either by modifying 
the lipid composition of the underlying membrane to induce budding, or by 
bridging the gap over invaginating buds to promote fusion (Hanson et al., 
2008).
17
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1.2.4.2 Different populations of ILVs
MVBs can appear to be either mutlilamellar (onion-like) or 
multivesicular (pomegranate-like), and this together with the finding that 
different ILVs often have different protein and lipid compositions, has lead to 
the suggestion that not all ILVs are functionally equivalent (White et ai, 
2006). In fact, accumulating evidence suggests that different populations of 
ILVs or different lipid microdomains on their surface could be involved in 
regulating multiple fates of ILVs and their internalised cargos. ILVs display 
lysobisphosphatidic acid (LBPA) or Ptdlns(3)Pon their limiting membrane 
(Kobayashi et al., 1999; Gillooly et al., 2000). LBPA is thought to be involved 
in sphingolipid hydrolysis and transport of cholesterol. It is also proposed to 
be relatively resistant to intracellular lipases, and thus seems a strange 
choice for ILVs that are to be degraded in the lysosome. ILVs are also 
known to be rich in tetraspannins (such as CD63) and GPI-linked proteins, 
both of which associate with sphingolipid and cholesterol-rich rafts 
(Kobayashi et ai, 2000). These findings have lead to the suggestion that 
clustering of proteins within lipid rafts once inside ILVs may lead to further 
protein sorting and recycling. This is further reinforced by the fact that 
ciM6PRs have been found on the limiting membrane of ILVs, and antibodies 
against LBPA impair their retrieval from the late endosome (Corvera et ai, 
1999), these receptors are therefore also thought to recycle from the later 
stages of the endocytic pathway.
19
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1.2.5 Lysosomal degradation
The mature MVB/late endosome contains some lysosomal enzymes, 
has a similar pH to the lysosome and the same glycoproteins on its limiting 
membrane. Lysosomes can only be identified by virtue of their physical 
properties on gradients, and their electron dense appearance by EM, and the 
fact that they lack various proteins such as ciM6PR, Rab7 and Rab9 and 
phosphorylated hydrolase precursors (Luzio etal., 2000). Christian de Duve 
first introduced the term lysosome in 1955, following his studies of the 
intracellular distribution of enzymes using centrifugal fractionation (de Duve, 
1983). By 1959, the concept of the lysosome as a membrane-bound 
organelle that contains acid hydrolases involved in digestion of substances 
that enter the cell by endocytosis, was born. EM analysis found that they 
constitute up to 5% of the intracellular volume, and are of heterogeneous 
size and morphology. As with earlier stages of the endocytic pathway they 
possess proton-pumping vacuolar ATP-ases that maintain the lumenal 
environment at a pH of 4.6-5.0, essential for lysosomal degradation functions 
(Mellman etal., 1986).
1.2.6 Theories of endolysosomal progression
There is still much debate about how the different endocytic 
compartments form, and how cargo is passed from one compartment to 
another. Theories of endolysosomal progression are summarised in figure 
1.6. The endosomal maturation model suggests that early endosomes are 
formed de novo, and that they progressively mature into MVBs/late
endosomes as the formation of tubular recycling/sorting compartments is
2 0
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exhausted, and the compartment becomes refractory to fusion with incoming 
material and is instead able to fuse with the lysosome (Murphy, 1991; Dunn 
and Maxfield, 1992).
The second model proposes that the early endosome is a stable 
compartment, maintained by the balance of incoming and outgoing material 
and that transport between compartments is mediated not by fusion or 
maturation, but by endosomal carrier vesicles (ECV’s) that form from the 
early endosome and fuse with the MVB/late endosome (Griffiths and 
Gruenberg, 1991). It remains to be conclusively demonstrated which 
hypothesis is correct, and indeed the two may not be mutually exclusive. In 
fact, recent live cell imaging studies have reconciled mechanistic aspects of 
both models. Marino Zerial’s group explored the dynamics of Rab proteins 
during intracellular transport and described a model of the conversion of Rab 
proteins as a mechanism of progression. It’s proposed that degradative 
cargo becomes highly enriched in progressively fewer and larger 
endosomes, which are removed from the tubular endosomal network and 
undergo a conversion in which they lose Rab5 and gain Rab7 (Rink et al., 
2005).
There are several other theories to suggest how the MVB/late 
endosome fuses with the lysosome. The ‘kiss-and-run’ model (a continuous 
cycle of transient contacts between late endosomes and lysosomes during 
which material is transferred), and the hybrid organelle theory (a direct fusion 
of late endosomes and lysosomes to form a distinct hybrid organelle) (Luzio 
et al., 2000). Recent time-lapse and electron microscopy experiments have
lead to the general belief that progression from late endosome to lysosome is
21
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Chapter One: Introduction
most likely a combination of direct fusion and kiss and run events resulting in 
a transient hybrid organelle from which lysosomes reform (Storrie and 
Desjardins, 1996; Luzio et ai, 2000; Mullins and Bonifacino, 2001; Luzio et 
ai, 2003).
1.2.7 The biosynthetic pathway
The biosynthetic pathway involves the trafficking of newly synthesised 
proteins from the Endoplasmic Reticulum (ER) through the Golgi apparatus, 
to various intracellular destinations (Palade, 1975). The Golgi complex is 
composed of polarised stacks of flattened membrane bound compartments 
called cisternae (Rambourg and Clermont, 1990), which have a cis (entry) 
face and a trans (exit) face. The stacks are made up of 5 regions, the cis- 
Golgi network (CGN), the cis, medial and trans cisternae, and the frans-Golgi 
network (Dunphy and Rothman, 1985). The CGN is a collection of fused 
tubulovesicular clusters that receives vesicles containing proteins from the 
ER. As they pass through the Golgi cisternae these proteins undergo 
various post-translational modifications, such as ordered remodelling of their 
N-linked oligosaccharide side chains, performed by a range of 
transmembrane processing enzymes associated with each cisterna (Dunphy 
and Rothman, 1985). They then pass to the TGN, a major cellular protein 
sorting station (Griffiths and Simons, 1986; Mellman and Simons, 1992). At 
least four post-golgi anterograde transport pathways exist in most cell types: 
two pathways to the plasma membrane (constitutive and regulated 
secretion), one pathway direct to the lysosome, and at least one pathway to
the lysosome via endosomes. Constitutive secretion pathways to the plasma
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membrane are thought to be the default pathway, as no specific signal for 
transport on this pathway has yet been identified. Regulated secretion 
involves the packaging of proteins into secretory vesicles that then release 
their contents at the plasma membrane in response to a certain stimulus.
1.2.7.1 TGN to endosome anterograde transport
Probably the best understood sorting mechanism at the TGN is for 
proteins destined for transport to the lysosome. A subset of the 
oligosaccharide modifications added to proteins as they pass through the 
Golgi complex serve as tags to direct these proteins to the lysosome. The 
hydrolytic enzymes that perform the degradative function of the lysosome are 
synthesised in the ER and modified in the Golgi by the addition of mannose- 
6-phosphate groups. These groups are recognised by the mannose-6- 
phosphate receptors (M6PRs) resident in the TGN membrane (Kornfeld and 
Mellman, 1989; Kornfeld, 1992). There are two distinct M6PRs in 
mammalian cells, the 46kDa cation-dependent M6PR (cdM6PR) and the 
300kDa cation-independent M6PR (ciM6PR), both of which are type I 
transmembrane proteins that share some sequence homology in their 
lumenal domains (Kornfeld, 1992).
M6PRs are sorted into CCV’s at the TGN along with their cargo. This
process was initially thought to involve the adaptor protein complex 1 (AP-1),
part of a family of heterotetrameric proteins consisting of two large subunits
termed adaptins (y and |3i in the case of AP-1), a medium-sized subunit ([xi)
and a small subunit (cr-i). This structure is highlighted in figure 1.7. These
adaptor protein complexes bind to clathrin and select cargo proteins and
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regulate the formation of CCV’s (Gallusser and Kirchhausen, 1993; Traub et 
al., 1995). However, AP-1 does not directly bind the acidic-cluster-dileucine 
residues in M6PRs (Honing etal., 1997; Zhu etal., 2001).
Recent evidence suggests that Golgi-to-endosome trafficking is 
mediated by the GGA proteins, of which there are three in mammalian cells 
(GGA1, 2 and 3). GGA proteins are monomeric proteins with a modular 
structure consisting of a VHS (Vps27, Hrs and STAM) domain, which 
recognises the acidic-cluster-dileucine signals in M6PRs, a GAT domain, 
which interacts with the GTP-bound form of ADP ribosylation factor (ARF), a 
hinge domain, which binds clathrin, and a GAE domain, which interacts with 
y-synergin and other potential regulators of coat assembly (Dell'Angelica et 
al., 2000; Hirst et al., 2000). The domain structure of GGA-1 is shown in 
figure 1.7. In fact, GGA proteins have also recently been shown to bind AP-1 
(Doray etal., 2002), suggesting that the two may cooperate to mediate 
packaging of cargo into CCV’s at the Golgi.
1.2.7.2 Endosome to TGN retrograde transport
Certain proteins that are transported onto the endocytic pathway 
require retrieval to the TGN for recycling, and this occurs via retrograde 
transport pathways. For example, to maintain the efficient transport of acid 
hydrolases to the lysosome, the M6PRs need to be recycled to the TGN to 
avoid degradation in the lysosome and for use in subsequent rounds of 
transport. Until recently, this recycling process had remained relatively 
poorly characterised, and only a few putative candidates for mediating it had
been identified. The best characterised of these were the small GTP-ase
25
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Rab9, its effector protein p40, and the protein TIP-47 (tail interacting protein 
47). As the name suggests TIP-47 can interact with the cytoplasmic tail of 
M6PRs, and this complex has been shown to regulate the retrograde 
transport of these receptors (Riederer et al., 1994; Diaz and Pfeffer, 1998).
It has now become widely accepted that multiple parallel pathways 
exist to regulate endosome-to-TGN transport. A number of cargoes, such as 
the B-subunit of the Shiga toxin (an AB5 type toxin produced by Escherichia 
coli that is thought to hijack endosome to TGN transport pathways) and 
TGN46 (a TGN resident protein that is thought to cycle to the plasma 
membrane and return via the endocytic pathway) have been found to traffic 
to the TGN via early/recycling endosomes, bypassing the late endocytic 
pathway and therefore independently of the Rab9/TIP47 complex (Ghosh et 
al., 1998; Mallard et al., 1998). Analysis of Vps mutants in S. cerevisiae 
identified three mutants with phenotypes that were basically the same as the 
yeast protein Vps10 (Seaman et al., 1997), a protein that performs an 
identical function to the mammalian M6PRs. These proteins were 
subsequently found to be components of a vesicle coat complex known as 
retromer, that mediates retrieval of Vps10 to the TGN. Subsequently, the 
mammalian homologues of yeast retromer were identified. It is composed of 
the Vps proteins Vps35, Vps29 and Vps26, which are involved in cargo 
recognition, and two members of the sorting nexin family SNX-1 and SNX-2, 
which are thought to regulate membrane binding through their 
phosphoinositide-binding PX domain, and membrane curvature through their 
BAR domain (Haft et al., 2000; Arighi et al., 2004). The structure of the 
mammalian retromer complex is outlined in figure 1.7.
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Figure 1.7 Structure of proteins involved in transport pathways 
between the TGN and endocytic pathway.
A) Domain structure layout of the GGA proteins (numbering from GGA-1 ).
B) Structure of the Adaptor protein complex 1 (AP-1 ).
C) Structure of the mammalian retromer complex. Vps35 interacts with 
cargo such as the ciM6PR and also with Vps26 and Vps35 through its N 
and C terminus respectively. SNX-1 is able to bind to the Vps35-29-26 
complex. SNX1 and SNX2 have PX domains through which they bind 
Ptdlns(3)P and BAR domains that are proposed to regulate membrane 
curvature.
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1.3 Phosphoinositides and membrane trafficking
Whilst Ptdlns(3,4)P2, Ptdlns(4,5)P2 and Ptdlns(3,4,5)P3 are localised 
predominantly to the plasma membrane (Gray et al., 1999; Watt et al., 2002), 
the other phosphoinositides, Ptdlns(3)P, Ptdlns(4)P and Ptdlns(3,5)P2 are 
enriched in intracellular organelle membranes, where they play a role in 
intracellular membrane trafficking. The localisation of the key 
phosphoinositides involved in membrane trafficking and examples of their 
effector proteins is illustrated in figure 1.8.
1.3.1 Pl(3)-kinases
The first indication that phosphoinositides played a role in membrane 
trafficking came from genetic studies of transport to the yeast vacuole. 
Examination of mutants of the Vps genes required for transport from the 
Golgi to the vacuole identified a gene that encoded a Pl(3)-kinase, Vps34. 
Subsequent cloning of this gene and sequence comparison revealed that 
Vps34p was 37% identical in its primary sequence to a mammalian Pl(3)- 
kinase p110a (Herman and Emr, 1990; Hiles et al., 1992; Schu étal., 1993). 
Vps34 specifically phosphorylâtes Ptdlns at the 3 position on its inositol ring 
to produce Ptdlns(3)P (Schu et a i, 1993). In S. cerevisiae, temperature 
sensitive Vps34 mutant cells exhibited a defect in protein sorting to the 
vacuole and Pl(3)-kinase activity when shifted to a non-permissive 
temperature (Stack et ai, 1995). It was subsequently shown to be the sole 
Pl(3)-kinase in S. cerevisiae (Stack and Emr, 1994).
In contrast multiple mammalian Pl(3)-kinases (8 catalytic subunits in 
total) have been identified and classified according to their substrate
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Figure 1.8 Localisation of phosphoinositides and selected effectors on 
the endocytic pathway.
Ptdlns(4,5)P2 is highly enriched at the plasma membrane where it recruits 
the adaptor complex AP-2 to promote CCV formation and internalisation of 
cell surface receptors, such as Tf receptor. It has also been implicated in 
AP-2 independent internalisation of LDL receptor probably through the 
effector protein DAB2. Ptdlns(3)P and Ptdlns(3,5)P2 play key roles in 
regulating endo-lysosomal compartments. EEA-1 is recruited to early 
endosomes by Ptdlns(3)P and GTP-bound Rab5, where it regulates 
homotypic fusion. Ptdlns(3)P also binds components of the ESCRT 
machinery, such as Hrs, to coordinate internalisation of ubiquitinated 
receptors, as well as components of the Retromer complex, including 
SNX-1, involved in retrograde transport of ciM6PRs. Ptdlns(3,5)P2 binds 
Svp1/Atg18, which may regulate endosome to TGN transport.
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specificities (Zvelebil et al., 1996). These multiple isoforms can be divided 
into three classes, but all share a homologous region consisting of a catalytic 
core domain, a Ptdlns-kinase domain, and a C2 domain. Class I Pl(3)- 
kinases are heterodimeric molecules composed of a 100kDa catalytic subunit 
(p110) and a regulatory subunit (p85, p55, p50 or p101), of which there are 
multiple isoforms. They are further subdivided into class IA and class IB, 
which are activated by receptor tyrosine kinases and heterotrimeric G-protein 
coupled receptors respectively. Class I primarily use Ptdlns(4,5)P2 as their 
substrate in vivo (Fry, 1994; Vanhaesebroeck and Waterfield, 1999).
Class II Pl(3)-kinases comprise three catalytic subunits, C2a, C2|3 and 
C2y. They possess a C-terminal C2 domain, which allows phospholipids to 
bind in a Ca2+-independent manner (MacDougall et al., 1995), and they 
exhibit a substrate specificity for Ptdlns, Ptdlns(4)P and Ptdlns(4,5)P2 in vitro 
(Vanhaesebroeck and Waterfield, 1999).
Finally, the sole class III Pl(3)-kinase is hVps34, a ubiquitously 
expressed kinase that specifically phosphorylates Ptdlns to produce 
Ptdlns(3)P. In both humans and yeast Vps34 associates with the N- 
terminally myristoylated serine/threonine kinase Vps15/p150, which recruits 
Vps34 to cell membranes and enhances its lipid kinase activity (Stack et al., 
1993; Murray etal., 2002; Stein eta t, 2005).
A role for mammalian Pl(3)-kinases in membrane trafficking was
identified through the use of Pl(3)-kinase inhibitor Wortmannin, an anti-fungal
compound (Brian, 1957). Wortmannin completely inhibits the class I, II (3 and
Y and class III Pl(3)-kinases at doses below 100nM (Fruman etal., 1998).
Wortmannin treatment was found to inhibit the fusion of early endosomes
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(Jones and Clague, 1995; Li et al., 1995), reduce the rate of recycling of 
internalised Tf receptor (Martys et al., 1996; Spiro et al., 1996), disrupt the 
lysosomal transport of PDGF receptor (Shpetner et al., 1996), and inhibit the 
formation of internal vesicles in MVBs (Futter et al., 2001) or the sorting of 
EGFR (Petiot et al., 2003). However, it was not clear from these studies 
which isoforms of Pl(3)-kinase were responsible for these effects. As a result 
of this, different experimental techniques such as siRNA treatment, hVps34 
inhibitory antibodies and overexpression studies, all of which have their 
individual caveats, have lead to different assignments of hVps34 function in 
mammalian cells. To date, small specific inhibitors of hVps34 have yet to be 
identified.
1.3.2. Ptdlns(3)P
Despite the lack of specific hVps34 inhibitors, Ptdlns(3)P has been 
shown to play a vital role in endocytic membrane trafficking. In the 1990’s 
early endosomal antigen-1 (EEA-1) protein was identified as a wortmannin- 
sensitive component of endocytic vesicles (Patki et al., 1998). This lead to 
the identification of the FYVE domain as a specific Ptdlns(3)P binding 
domain that directed EEA-1 to the early endosomal membrane, where it was 
subsequently shown to be involved in early endosome homotypic fusion 
(Mills et al., 1998; Simonsen et al., 1998). Since then more than 70 proteins 
have been shown to possess Ptdlns(3)P binding domains, including PX, 
GRAM, and FYVE domains, implicating this lipid in a range of membrane 
trafficking functions, such as the internalisation of ubiquitinated receptors into
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MVBs through recruitment of components of the ESCRT machinery (Urbe et 
al., 2000; Raiborg et al., 2001).
1.3.3 Other phosphoinositides involved in membrane trafficking
Other phosphoinositides have been shown to play a role on the 
endocytic pathway. Ptdlns(4,5)P2 is localised predominantly to the plasma 
membrane, and here it has been shown to regulate the internalisation of 
CCV’s. Clathrin coats of internalised endocytic vesicles are rapidly removed 
through dephosphorylation of Ptdlns(4,5)P2 by the 5-phosphatase 
synaptojanin, rendering them competent to fuse with the early endosome 
(Jost et al., 1998). Ptdlns(4)P has been found to localise to the Golgi 
membrane by visualisation of a GFP-tagged PH domain from the Ptdlns(4)P 
binding protein FAPP1. At the Golgi it is proposed to be involved in 
regulating transport pathways to the cell surface (Godi et al., 2004).
1.4 Ptdlns(3,5)P2
A relatively novel phosphoinositide, Ptdlns(3,5)P2, is also proposed to 
be involved in endocytic membrane trafficking, as discussed in section 1.9. 
The presence of this phosphoinositide was confirmed independently in 
mouse fibroblasts and S. cerevisiae in 1997 (Dove et al., 1997). It 
constitutes a small proportion of the total phospholipid in a cell, typically 0.1% 
or less. However, cellular levels increase dramatically in response to 
hyperosmotic stress, 30-fold in yeast, 2 to 6-fold in plants and in some animal 
cells also, and in other mammalian cells in response to other stresses, such
as UV radiation, interleukin-2 and fibrinogen in platelets (Dove et ai, 1997;
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Banfic et al., 1998; Cooke et al., 1998; Jones et al., 1999; Sbrissa and 
Shisheva, 2005). It is present in all eukaryotic cells examined thus far, 
including yeast, plants, protozoa and mammalian cells (Dove et al., 1997; 
Whiteford e ta t, 1997; Odorizzi et al., 2000; Shisheva, 2001; Cooke, 2002; 
Efe et al., 2005; Leondaritis eta!., 2005). In the years since Ptdlns(3,5)P2 
was first described, a variety of key proteins associated with its metabolism 
have been identified. Four of these proteins are detailed in the following 
sections.
1.5 Ptd!ns(3)P 5-kinase
1.5.1 Fab1
Ptdlns(3,5)P2 is made by the consecutive actions of a Pl(3)-kinase 
and the sole Ptdlns(3)P 5-kinase, Fab1 (Cooke et al., 1998; Gary et al., 
1998; Odorizzi et al., 2000; Morishita et al., 2002). Fab1 was originally 
identified from a screen for abnormal nuclear segregation (hence formation 
of aploid and binucleate cells) (Yamamoto et al., 1995). It is part of an 
evolutionarily ancient gene family, and the protein is the product of a single 
gene in most species. It is predicted to encode a 257kDa protein in yeast 
with significant sequence homology to other known phosphoinositide 
phosphate kinases at its C terminus (Yamamoto et al., 1995).
The majority of our understanding of the cellular localisation and 
function of Ptdlns(3,5)P2 has come from the study of cells defective in the 
activity of this kinase. Yeast Fab1 mutant cells produce undetectable levels 
of Ptdlns(3,5)P2 (Gary et al., 1998) and generate a characteristic grossly
enlarged vacuole (the yeast equivalent of the mammalian lysosome) that fills
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much of the cell. Further to this, the vacuole is improperly acidified 
(Yamamoto et al., 1995; Cooke et at., 1998; Gary et a/., 1998). Some yeasts 
also show a sensitivity to certain types of stresses, such as heat, and others 
inefficient mating, meiosis or sporulation (Rabitsch et al., 2001; Briza et al., 
2002), and a failure to properly respond to mating factors (Morishita et al., 
2002; Onishi et al., 2003), all of which are proposed to reflect a general 
slowing of both the endo- and exocytic machinery (Shaw et al., 2003; 
Osborne et al., 2008). Candida albicans yeast demonstrate a failure in 
hyphal growth on solid media (Zheng et al., 1998; Rabitsch et al., 2001; 
Augsten et al., 2002; Bidlingmaier and Snyder, 2002; Briza et al., 2002; 
Morishita et al., 2002; Onishi etal., 2003; Shaw et al., 2003; Osborne et al., 
2008).
1.5.2 PIKfyve
The first full-length orthologues of Fab1 were identified in the yeast 
Schizosacchoromyces pombe (SpFabl) (McEwen etal., 1999) and in murine 
adipocytes (Shisheva et al., 1999). The murine protein was termed p235 or 
PIKfyve (Phosphoinositide kinase for five position containing a fyve domain). 
It was originally cloned from a mouse adipocyte library through a screen for 
transcripts that are enriched in fat and muscle. The human gene was 
recently assembled based on a human EST database, and the generated 
PCR product was found to be 2098 residues (Cabezas et al., 2006), it is 
located on chromosome 2 (2q34) and comprises 41 exons.
NCBI (National Centre for Biotechnology lnformation)-Blast analyses
and various characterisation in the literature demonstrate that PIKfyve is
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evolutionarily conserved, with homologues in Caenorhabditis elegans, 
Drosophila melanogaster and a number of other organisms. The mouse 
homologue is 85% identical to human PIKfyve, that of D. melanogaster is 
28% identical and C. elegans and S. cerevisiae sequences show less than 
30% identity (Cabezas et al., 2006). All of these proteins have come to be 
known as type III phosphatidylinositol phosphate (PIP) kinases, to distinguish 
them from the type I PIP kinases that are Ptdlns(4)P 5-kinases, and the type
II PIP kinases that are Ptdlns(5)P 4-kinases (Cooke, 2002).
1.5.3 PIKfyve/Fab1 domains
With the possible exception of Arabidopsis thaliana (the only genome 
which encodes more than one potential Ptdlns(3)P 5-kinase), all of the type
III PIP-kinases contain four domains. These domains are highlighted in 
figure 1.9.
The FYVE domain is a Zinc finger domain found in proteins that bind 
to Ptdlns(3)P (Burd and Emr, 1998; Gaultier ef a/., 1998; Patki et al., 1998). 
The FYVE domain of Fab1 has been shown to bind to Ptdlns(3)P in vitro, 
albeit more weakly than other FYVE domains. However, this lower affinity 
was thought to be due to the construct used lacking the final 36 amino acids 
of the FYVE domain (Burd and Emr, 1998). The PIKfyve FYVE domain has 
also been shown to bind Ptdlns(3)P. A GST-FYVE fusion protein from 
PIKfyve, localises to endosomal membranes in a manner dependent on 
cellular Ptdlns(3)P levels (Sbrissa et al., 2002b).
The TCP-1 (T complex protein 1)/chaperonin-like domain is
homologous to a subunit of the chaperonin domain-containing protein TCP-1,
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Figure 1.9. Domain structures of mammalian Ptdlns(3,5)P2 
associated proteins.
Diagram illustrating the domain structures of the mammalian proteins 
WIPI-2, Fig4 and Vac14 and PIKfyve as predicted by protein motif 
analysis with PFAM (http://pfam.sanger.ac.uk/) and detailed in previous 
studies of PIKfyve. WIPI-2 contains 7 WD40 domains within the indicated 
area, each of which is found within one blade of the beta-propeller.
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an 8 sub-unit chaperone that binds exclusively to actin and tubulin. Although 
no specific role for this domain has been characterised, a PIKfyve mutant 
lacking residues 560-1231, which includes this domain, is catalytically 
inactive (Sbrissa et a!., 1999). PIKfyve is also known to be involved in the 
pathology of Francois Neetens Mouchetee Fleck Corneal Dystrophy, an 
autosomal dominant human syndrome characterised by the presence of 
numerous white flecks scattered in all layers of the stroma. Interestingly, 
most mutations involved in this disease are of the nonsense and frameshift 
type and are found in and around this domain in PIKfyve (Li et ai, 2005).
The cysteine rich domain is unique to the type III PIP-kinases and as 
yet has no defined role (McEwen et at., 1999; Shisheva et at., 1999) and the 
PIP-kinase domain is the C-terminal catalytic domain. Mutations in this 
domain in both Fab1 and PIKfyve abrogate its kinase activity (Sbrissa etal., 
2000). Finally, PIKfyve orthologues from Mus musculus, Homo sapiens and 
D. melanogaster also contain a DEP domain (Shisheva, 2001), named for 
three of the proteins it was first identified in (Dishevelled, Egl-10 and 
Pleckstrin) (Ponting and Bork, 1996). Again this has no characterised role, 
but is not present in lower organisms, and has been identified in a number of 
signalling molecules and implicated in their membrane targeting (Wong etal., 
2000).
1.5.4 Lipid kinase activity
In S. cerevisiae Fab1 mutants have undetectable levels of 
Ptdlns(3,5)P2, even following hyperosmotic stress, a condition that normally
provokes a marked increase in the levels of this lipid (Cooke etal., 1998;
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Gary et al., 1998). A GST-fusion protein has been shown to exhibit 
Ptdlns(3)P 5-kinase activity when assayed in vitro, with the following 
substrate specificity; P tdlns(3)P» Ptdlns(4)P > Ptdlns (Cooke et al., 1998; 
McEwen et al., 1999). This lipid kinase activity is abrogated by the mutation 
of an aspartic acid residue to an arginine at position 2134 in vivo, and a 
lysine to a methionine at position 2059 in vitro (Gary et al., 1998; McEwen et 
al., 1999).
All other type III PIP-kinases from other organisms, have also been 
found to have 5-kinase activity in vitro, and display similar substrate 
specificity to Fab1. Expression of PIKfyve in a Fab1 mutant strain restores 
Ptdlns(3,5)P2 synthesis and reverts the Fab1 mutant phenotype in vivo, 
suggesting a conserved physiological function of these proteins (Sbrissa et 
al., 1999). Although in vitro Ptdlns(3,5)P2 can be produced by the action of a 
type I PIP-kinase on Ptdlns(3)P, non equilibrium labelling experiments have 
shown that the majority of Ptdlns(3,5)P2 must be synthesised by a Ptdlns(3)P 
5-kinase, and a type I PIP-kinase also does not restore levels of 
Ptdlns(3,5)P2 or complement the Fab1 mutant phenotype (Dove et al., 1997; 
Whiteford etal., 1997; McEwen et al., 1999).
PIKfyve has also been proposed to synthesise Ptdlns(5)P, the most 
recently identified phosphoinositide (Rameh etal., 1997) in vitro and in vivo 
(Shisheva et al., 1999; Shisheva, 2001). The opinion on this matter remains 
somewhat divided. Some groups believe that the type III PIP-kinases are 
most likely dedicated to the production of Ptdlns(3,5)P2 and that any 
production of Ptdlns(5)P is of limited biological significance (McEwen et al.,
1999; Cooke, 2002). Furthermore, they believe that the major route of
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Ptdlns(5)P synthesis in the cell is through hydrolysis of Ptdlns(3,5)P2 (this is 
discussed in more detail in section 1.6).
Another school of thought suggests that direct phosphorylation of 
Ptdlns by PIKfyve is also a major route of Ptdlns(5)P synthesis in addition to 
hydrolysis of Ptdlns(3,5)P2. Indeed, PIKfyve has been shown to readily 
produce Ptdlns(5)P in vitro, and HEK293 cell lines expressing wildtype or 
kinase-deficient PIKfyve show 2-fold higher and 2-fold lower mass levels of 
Ptdlns(5)P respectively (Shisheva, 2001; Sbrissa et al, 2002a). The counter 
argument to these findings states that evidence from in vitro kinase assays 
must be treated with caution as these are carried out in non-physiological 
conditions that can affect binding specificities. Furthermore, the 
complementation of Ptdlns(3,5)P2 production in Fab1 mutants by 
overexpression of PIKfyve, does not also lead to an increase in Ptdlns(5)P 
(McEwen et al., 1999), and although this has been revised recently, based 
on more effective expression of PIKfyve (Michell et al., 2006), the debate 
remains inconclusive. Furthermore, Ptdlns(5)P is not thought to be present 
in yeast (Walker et al., 2001; Schaletzky et al., 2003) and the data 
suggesting that PIKfyve is required for Ptdlns(5)P synthesis in FIEK293 cells 
does not distinguish between the requirement of PIKfyve activity to directly 
make Ptdlns(5)Pand the requirement of PIKfyve to make Ptdlns(3,5)P2 as a 
substrate for Ptdlns(5)Pby its subsequent hydrolysis. Hence, this subject 
requires further investigation.
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1.5.5 Localisation
In S. cerevisiae Fab1 localises to the vacuolar and endosomal 
membranes and the cytosol (Gary et al., 1998). Although the methods used 
in this study cause osmotic stress and stimulate Ptdlns(3,5)P2 production, 
subsequent experiments using HA and GFP-tagged fusion proteins found 
that they did indeed localise to the vacuolar membrane, and HA-Fab1 was 
shown to colocalise with Vac8, a known vacuolar protein (Gary et a i, 1998; 
Dove et ai, 2002).
Despite the production of anti-PIKfyve antibodies by a number of 
different groups, none of these antibodies proved useful for testing the 
localisation of endogenous PIKfyve, this has only been examined in 3T3-L1 
adipocytes (Shisheva et ai, 1999). In both these studies, and in other 
mammalian cell lines, using overexpression contructs, PIKfyve was found to 
localise to peripheral vesicular structures and the cytoplasm. 
Overexpression studies went on to determine that there was no 
colocalisation with Tf (recycling endosomes), Dextran (late endosomes) or 13- 
COP (Golgi), and that treatment with Brefeldin A, which disrupts the Golgi 
stacks, did not affect the localisation of PIKfyve (Shisheva et a i, 1999; 
Shisheva et ai, 2001).
It was initially reported that the vesicular structures were 
predominantly MVB/late endosome compartments, as they colocalised with 
ciM6PR. However, more recent studies in HeLa cells using low expression 
levels of GFP-PIKfyve, have demonstrated that PIKfyve is predominantly 
found on EEA-1 labelled tubulovesicular early endosomes (Cabezas et ai,
2006; Rutherford et ai, 2006). Closer inspection revealed that PIKfyve is
40
Chapter One: Introduction
actually localised to microdomains on early endosomes distinct from EEA-1 
and Hrs (Cabezas et al., 2006).
1.5.6 PIKfyve functions
The potential fundamental significance of PIKfyve-dependent 
functions to human physiology is hinted at by the embryonic lethality of D. 
melanogaster and C. elegans PIKfyve null mutants (Nicot et al., 2006; 
Rusten et al., 2006). PIKfyve has been shown to be potentially important in a 
number of different processes. Its most widely studied function is in the 
maintenance of endosomal membrane homeostasis. The key feature of 
Fab1 mutants, as described in section 1.4, is the formation of a massively 
swollen vacuole (Gary et al., 1998). Various studies have examined the 
effects of manipulating PIKfyve activity in mammalian cells where the result 
of overexpression of a kinase-deficient mutant, depletion of PIKfyve through 
siRNA or treatment with a specific inhibitor of PIKfyve (discussed in section 
1.5.7), is a progressive accumulation of dilated endosomes and swollen 
cytoplasmic vacuoles (Sbrissa et al., 1999; Ikonomov et al., 2003a; 
Rutherford et al., 2006; Jefferies et al., 2008). However, despite the similar 
phenotypes, the requirement for PIKfyve activity has been suggested to be at 
different compartments in yeast and mammalian cells (Ikonomov et al., 
2006), whilst Fab1 is proposed to act at the yeast vacuole (Gary et al., 2002; 
Rudge et al., 2004), PIKfyve function has been placed at both the early 
endosome and MVB in mammalian cells (Cabezas etal., 2006; Rutherford et 
al., 2006), and at the late endosome in C. elegans (Nicot et al., 2006). The
origin of the swollen vacuoles remains an unanswered question of
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mammalian Ptdlns(3,5)P2 biology. They are proposed to be the result of 
reduced ILV internalisation and membrane retrieval to the TGN (Ikonomov et 
al., 2001; Rutherford et al., 2006). In support of these hypotheses, PIKfyve 
interacts with components of the endosome-to-TGN retrograde transport 
machinery. Furthermore, a functional relationship between PIKfyve and the 
mammalian AAA ATPase Vps4 homologue, SKD1 has been established. 
Ectopic expression of catalytically inactive SKD1 in Cos7 cells leads to 
vacuolation, and this can be partially rescued by overexpression of wildtype 
PIKfyve, suggesting a role for PIKfyve in the final step of ILV formation 
(Ikonomov et al., 2002b).
A number of proteins have been shown to interact with PIKfyve, which 
have hinted at a variety of cellular functions. Perhaps the best characterised 
of these is the interaction with Vac14, also referred to as ArPIKfyve, which 
serves as an allosteric activator of PIKfyve activity. Vac14 also forms a 
complex with the proposed Ptdlns(3,5)P2 5-phosphatase Fig4. As such 
these three proteins may potentially form a ternary complex in both yeast and 
mammalian cells, which tightly regulates the levels of Ptdlns(3,5)P2. These 
interactions will be discussed in more detail in the relevant sections for these 
proteins. PIKfyve has also been shown to interact with the Rab9 effector p40 
through its chaperonin domain (Ikonomov et al., 2003b), which forms a 
complex with TIP-47 to regulate the retrieval of ciM6PR in a retromer- 
independent manner from the late endosome (Diaz and Pfeffer, 1998). 
Intriguingly, all of these proteins, including PIKfyve have been shown to be 
important for HIV viral replication, as this pathway facilitates the late
endosome-to-TGN transport of the virus such that HIV Env is sorted into
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virions for budding at the plasma membrane (Ikonomov et al., 2003b; Murray 
et al., 2005).
In addition to its lipid kinase function, PIKfyve also demonstrates a 
protein kinase function. A key target of this function is autophosphorylation 
at serine residues, which is thought to regulate the lipid kinase activity, as it 
caused a 70% decrease in the lipid product and is largely abrogated by lipid 
substrates in vitro. The lipid and protein kinase activity are mediated by the 
same residues, including lysine 1831, which is thought to contribute to the 
ATP-binding pocket. PIKfyve is also proposed to transphosphorylate other 
proteins; the only example demonstrated thus far is p40. PIKfyve is found to 
be principally a phosphoprotein in vivo although the role of this 
phosphorylation has yet to be clearly established (Sbrissa et al., 2000; 
Ikonomov et al., 2003b).
1.5.7 Specific inhibitor of PIKfyve
Recent work has characterised a novel specific inhibitor of PIKfyve; 
compound YM201636, from a drug discovery programme directed at Pl(3)- 
kinase (Hayakawa et al., 2006). Previously, the overexpression of a kinase- 
inactive PIKfyve and siRNA knockdown, were the only tools available to 
study PIKfyve. These methods have a variety of limitations, not least of 
which is side effects of a gradual onset of Ptdlns(3,5)P2 depletion. An 
inhibitor of PIKfyve allows a more acute, immediate loss of PIKfyve kinase 
activity and Ptdlns(3,5)P2. This inhibitor is a pyridofuropyrimidine compound 
shown to specifically inhibit PIKfyve in vitro with a half-maximal inhibitory
concentration (IC5o) of 33nM. Under cell culture conditions, in NIH3T3 cells
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stimulated with serum, YM201636 inhibits the production of Ptdlns(3,5)P2 by 
80% at a concentration of 800nM (Jefferies et al., 2008). The PIKfyve 
inhibitor used in this study (MF4) is identical to YM201636, save for an amino 
group on the back-end of the molecule. The structures of MF4 and its 
inactive analogue MF2, which lacks an oxygen molecule on the morpholine 
ring, are shown in figure 1.10 and were synthesized and tested by Dr Kevan 
Shokat (University of California, San Francisco, USA). MF4 inhibits PIKfyve 
with an IC50 of 23nM, whereas MF2 shows no activity even at 5pM. 
Corresponding MF4 values for class I Ptdlns 3-kinases are 0.25pM (p110a), 
1pM (p11013), 0.9pM (p110y), 0.8pM (p110S).
1.6 Fig4 and other phosphatases
1.6.1 Phosphoinositide 5-phosphatases
In yeast there is evidence that the turnover of Ptdlns(3,5)P2 is
principally mediated by the protein Fig4. It was originally identified as a
pheromone-induced gene in a screen for enhanced or reduced beta-
galactosidase activity in response to a-mating factor pheromone (Erdman et
al., 1998). A role in Ptdlns(3,5)P2 regulation was first proposed upon the
discovery that Fig4 mutations suppressed the vacuole size defects and
temperature sensitivity associated with mutants of the Fab1 activator Vac7
(see section 1.7), and restored Ptdlns(3,5)P2 levels (Gary et al., 2002). It is
one of four genes (Sac1, Sjl2, and Sjl3) in S. cerevisiae whose gene
products contain a sac domain, named after the protein in which it was first
identified, Sac1 (Hughes et al., 2000). In vitro the sac domains of Sad, Sjl2,
and Sjl3 dephosphorylate Ptdlns(3)P, Ptdlns(4)P and Ptdlns(3,5)P2 (Guo et
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Figure 1.10. Structure of PIKfyve inhibitor.
Structure of PIKfyve inhibitor (MF4) and inactive analogue (MF2). These 
compounds were obtained from Kevan Shokat at UCSF following 
independent testing of activity and specificity in vitro. MF4 ICso against 
PIKfyve is 23nM. The generation of MF4 and MF2 is outlined in materials 
and methods.
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a/., 1999). Sjl2 and Sjl3 also possess a C-terminal type II 5-phosphatase 
domain (Srinivasan etal., 1997; Stolz etal., 1998).
There are two types of mammalian 5-phosphatases that share a 
conserved CX5R(T/S) catalytic domain. Only the type II 5-phosphatases 
hydrolyse phosphoinositide phosphates (type I are protein and inositol 
polyphosphate 5-phosphatases) and they have an extended region N- 
terminal to the catalytic domain that is characterised by further regulatory 
domains, including the sac domain. The first mammalian sac-domain 
containing protein identified was Synaptojanin (McPherson etal., 1996). It 
has since become clear that there are two types of mammalian sac-domain 
containing proteins, those like Synaptojanin and those more like the yeast 
Sac1. The sac domain is able to hydrolyse the phosphate from any position 
on the inositol ring, but is unable to dephosphorylate adjacent phosphates, 
thus it cannot hydrolyse Ptdlns(4,5)P2 to Ptdlns, for example. Synaptojanin- 
like mammalian 5-phosphatases, as with the yeast proteins Sjl2 and Sjl3, 
also possess a 5-phosphatase domain that overcomes the inability of the sac 
domain to dephosphorylate adjacent phosphates (Hughes et al., 2000).
The sac domain is composed of seven conserved motifs that define 
phosphoinositide phosphatase enzymatic activity (Guo etal., 1999). The 
sixth of these motifs contains the CXsR(T/S) sequence that is thought to 
represent the catalytic residues, although the activity of this motif has only 
been examined in any great detail in the type I 5-phosphatases. The 
structure of the sac domain and the conserved residues in each motif are 
illustrated in figure 1.11.
46
p  p  hi H h  fe O m m £ £ £ g P£  £s s
M P
pr_( [n
P w w co p' (i w J  QQ W Q P
w w w w w w
H  P  EH H  P  E-t
rsl
o  o
p p
P
£
H
P
Q
a  a  a
p p p 
p  p  x  o
P  EH
>H >H
Eh Eh  
>h P 
CO CO 
f t  f t
e  e
p  co
CO Q
X 
£ 
p
p
X
p
w
p
p 
£ 
p
M P P Q Q Q 
>H  >H  f t  
CO 
>Hin in in
P P >h
£ ^
P
ft CO CO 
P CO 2 
P P CO 
P Q P 
P >  P P 2 P  P O P  
P P P
O P o 
p > >
p
>H
Eh 
CO 
P 
P
P P 
P P 
P P P 
Eh P  P
. ?-> P
P P
£  co
CO 
£ ¡3 
CO EH 
P
P
>H 
P 
P
CO CO CO>H >H >H
>H >H
f t  f t  f t  
P  Eh CO O O P  
£ P 
p  co 
P P 
p p 
ft ft
co 
P 
s
p 
. £ 
P P P 
P P
ft ft ftf t p  f t ncv i mPCN H O ' i O i n i f l i n o  
o rt cn to ft  ft ft  nj r t OJ- HWCCCCQ 
P P f t P H H M j C
l
(T5
Eo
TJ
u
ro
t o
p
p
p
p
p
H P" p p n n tXTT
> M r , p p P £
CJ co co co co g co
£ £ £ £ JZ £ P ¡z;
P P Eh P p> EH M
P P P p p p p
P U B> ft
>
ft Pm p p
>
M M P> M M > M
CO co P CO co CO CO cof—l 
Pm
cC
p_i
Eh ft ft p X Fh w
C> Qt Ol Qi a c? o Ol
P M w £ p w p p
X VO
M
Q
Q
>
COfH
ft p p P p p p g
O o Eh ft EH Eh p o
£ P P p p p p
M M > p p M >
P
w
o
p
p
P p p P p p 1—1p
£ £ £ £ £ *z £
i M i l H 1—1
i 1—1 i l 1—1p> M M
> i P P X p >
P > M M > !>• o
H
P
P
P
ft
ft
Q
Q
P
P
ft
>H i a M p p p
£ a M M CO CO CO 1
ft p EH p P ft >H 1
l i CO p p p p 1
l i CO i p p p 1ID co CO co pM > Fh p
>H >H >H Pm P p P >H
P 1--1 p p P £ M
w H o a W P £
p > u* Pm Pm 1—1Pm P
o a p £ X X p a
o p £ O w p p w
p p Q P p p p w
P P P P P P P P
in
O O P  P O P  
h  o  g 
P P Po o  o
X  X
M M
p
U >H 
O P 
p p 
£  ¡2
>
P
P
P
P
p p q p co
ro
P  P  H  
f t  ft C*
g  o  >ft >H ft
o o o P P o
M
> 
p 
p
p . 
p p
o o
P H 
P M
o o o
P CO p 
5  £ 
>H P 
P M 
p p  p H > ft
co m  co o  o  o 
p  p  p
£  > Ho o o
ft o
g  CO
i  e g
H i> P 
p p 
>  t-H 
CO COo  o
p  p
p po o
p  
p
CO CO g 
P CO >-t
CO CO
p g
S £ U
O P oft ft ft
E S S
> P > 
P P P
H M >
P P Po o  o
P £ P
M ^  p
o o o
p p > 
ft >H ft 
g p p >H ft ft
Fi
gu
re
 1
.1
1.
 T
he
 S
ac
 d
om
ai
n 
(a
da
pt
ed
 fr
om
 H
ug
he
s 
et
al
, 2
00
0)
.
Th
e 
sa
c 
do
m
ai
n 
co
nt
ai
ns
 7
 h
ig
hl
y 
co
ns
er
ve
d 
m
ot
ifs
. 
Th
e 
ca
ta
ly
tic
 C
x5
R(
T/
S)
 m
ot
if 
is 
hi
gh
lig
ht
ed
 in
 m
ot
if 
6. 
Sh
ow
n 
ar
e 
th
e 
sa
c 
do
m
ai
ns
 o
f t
he
 y
ea
st
 a
nd
 m
am
m
al
ia
n 
SC
IP
’s.
 
In
p5
1 
do
es
 n
ot
 c
on
ta
in
 s
ev
er
al
 o
f t
he
 re
sid
ue
s 
th
at
 a
re
 h
ig
hl
y 
co
ns
er
ve
d 
in 
th
e 
ot
he
r p
ro
te
in
s,
 w
hi
ch
 m
ay
 a
cc
ou
nt
 fo
r t
he
 la
ck
 o
f p
ho
sp
ha
ta
se
 a
ct
ivi
ty
 it
 d
isp
la
ys
.
Chapter One: Introduction
1.6.2 Fig4/Sac3
There are three mammalian proteins with homology to the yeast Sac1, 
hSad, hSac2 and hSac3. hSac3 (referred to as hFig4 in this study) has 
40%/58% identity/similarity respectively to S. cerevisiae Fig4, and is 
therefore thought to represent the mammalian homologue of this protein. 
Neither the yeast protein nor its mammalian homologue possesses the 
transmembrane domain found within the other Sac1 like proteins, which 
could reflect the proposed recruitment of Fig4 to the membrane by its 
interaction with the Fab1/PIKfyve activator Vac14 (as discussed later). 
Database searches (ie. PFAM) suggest that hFig4/Sac3 possesses multiple 
phosphorylation sites for serine/threonine kinases, indicating that this protein 
may be regulated by phosphorylation. It also possesses several putative 
motifs known to interact with the endocytic machinery, such as the FxDxF 
motif found in Epsin, Eps15 and synaptojanin, which binds the alpha subunit 
of the AP-2 adaptor complex, and a clathrin box (LVIID), which binds the 
beta-propeller structure of clathrin heavy chain (Sbrissa et ai, 2007). The 
domain structure of Fig4 is shown in figure 1.9.
Fig4 was first confirmed to be a phosphoinositide 5-phosphatase in S. 
cerevisiae by Rudge and colleagues, who showed that it is a magnesium- 
activated Ptdlns(3,5)P2-specific phosphatase, which localises to the yeast 
vacuole membrane (Rudge et al., 2004). More recently, phosphatase activity 
was demonstrated for the mammalian protein in vitro, with different 
phosphoinositide specificity demonstrated for different overexpression 
constructs. Although a preference for Ptdlns(4,5)P2 was displayed for myc-
Sac3, at least a portion of this can be attributed to the activity of
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phosphatases associated with myc-Sac3 coimmunoprecipitates, as a 
preference for Ptdlns(3,5)P2 was demonstrated with GFP-Sac3 and 
Ptdlns(4,5)P2 hydrolysis was not detected in intact cells (Sbrissa et al., 
2007). It is therefore most likely that the role of hFig4/Sac3 as a 
Ptdlns(3,5)P2 specific 5-phosphatase, is conserved in higher organisms.
1.6.3 Dual role of Fig4
In S. cerevisiae Fig4 has been shown to be the major phosphatase in 
vivo required for the rapid turnover of Ptdlns(3,5)P2 during hyperosmotic 
stress. Following hyperosmotic shock there is a rapid and transient increase 
in Ptdlns(3,5)P2 levels, which reach a maximum 20-fold increase after 5 
minutes that then persists for 10 minutes. However, this subsequently 
returns to basal levels after 30 minutes of hyperosmotic shock, suggesting 
that the Ptdlns(3,5)P2 is being rapidly turned over. In Fig4 mutants this 
return to basal levels is delayed until 60 minutes, suggesting that turnover of 
Ptdlns(3,5)P2 is defective in these cells. However, the fact that turnover is 
delayed and not blocked completely, and that under basal conditions Fig4 
mutants show no change in Ptdlns(3,5)P2 levels or in vacuole size, suggests 
that there may be other pathways for degrading Ptdlns(3,5)P2 (Duex et al., 
2006a; Duex et ai, 2006b). Indeed, although knockdown of other sac 
domain containing proteins alone does not affect the levels of Ptdlns(3,5)P2, 
a combined knockdown of multiple genes does cause elevated Ptdlns(3,5)P2 
levels under basal conditions (Duex et al., 2006a).
Fig4 has since been shown to play a more complex role in the
regulation of Ptdlns(3,5)P2 levels than first thought. Intriguingly, it interacts
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with Vac14, an activator of Fab1/PIKfyve kinase activity, and therefore plays 
a role in regulating both synthesis and turnover of Ptdlns(3,5)P2. Indeed, in 
S. cerevisiae maximal elevation of Ptdlns(3,5)P2 following hyperosmotic 
stress requires both Vac14 and Fig4, and Fig4 mutants synthesise only 25% 
of wildtype Ptdlns(3,5)P2 (Duex et al., 2006b). The localisation of each 
protein may be dependent on the other; therefore this may simply represent 
an indirect effect of Vac14 mislocalisation. However, even in Fig4 mutants 
that do not affect Vac14 localisation there is still a defect in Ptdlns(3,5)P2 
synthesis, suggesting that Fig4 plays a more direct role in both synthesis and 
turnover of this lipid (Duex et al., 2006a).
Recent evidence suggests that Fab1 may regulate the vacuolar 
localisation of both Vac14 and Fig4 through its chaperonin domain, leading to 
the suggestion that all three proteins form part of a common lipid kinase 
complex that is recruited to the vacuolar membrane through the interaction of 
the Fab1 FYVE domain with Ptdlns(3)P (Botelho etal., 2008). This has also 
been suggested in mammalian cells where a direct interaction between 
Vac14 and PIKfyve as well as Vac14 and Fig4 has been demonstrated, with 
the three proteins forming a proposed ternary complex (Sbrissa et al., 2007).
1.7 Vac 14
1.7.1 Identification of Vac14 and Vac7 as upstream activators of Fab1
The fact that overexpression of Fab1 in S. cerevisiae does not result 
in a significant increase in Ptdlns(3,5)P2 levels (Gary et al., 1998) suggests 
that there must be limiting regulatory factors. Indeed, various different
screens in S. cerevisiae have subsequently identified two upstream
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activators of Fab1 kinase activity. Vac7 and Vac14 were identified from 
yeast genetic screens, to uncover vacuole inheritance mutants distinct from 
the Vps mutants which also often display defects in vacuolar segregation 
(Gomes de Mesquita et al., 1996; Wang et al., 1996). Three classes of so- 
called vacuolar (Vac) mutants were identified. Vac14 and Vac7 were 
classified as class III Vac mutants, sharing an unlobed, enlarged vacuole that 
fills nearly the entire cytoplasm. Subsequently, they were also identified from 
a screening of the Eurofan II panel of yeast deletion mutants, for mutants 
with a swollen vacuole phenotype similar to that observed in Fab1 mutants 
(Dove et al., 2002).
Both Vac14 and Vac7 have been shown to act as upstream activators 
of Fab1 kinase activity (Bonangelino et al., 1997; Bonangelino et al., 2002). 
All three mutants share similar phenotypes, overexpression of Fab1 is able to 
rescue both Vac14 and Vac7 mutants, and simultaneous overexpression of 
Fab1 and Vac14 results in 48% more Ptdlns(3,5)P2 production than Fab1 
overexpression alone (Bonangelino et al., 2002), consistent with the notion 
that the two act in concert and that Vac14 acts upstream of Fab1 as an 
activator of its kinase activity, rather than a negative regulator of 
phosphatase activity, despite the fact that it also interacts with the 5- 
phosphatase Fig4, as discussed in section 1.6.
1.7.2 Role in hyperosmotic stress
Vac14 and Vac7 both localise to the yeast vacuole, and in the case of 
Vac14 this association with the membrane is stabilised by its interaction with
Fig4 (Rudge et al., 2004), and more recently it has been suggested that both
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Vac14 and Fig4 are recruited to the vacuole membrane through their 
interaction with Fab1 (Botelho et al., 2008). Vac14 is required for the 
maximal response to hyperosmotic shock, although overexpression of Fab1 
is able to restore basal levels of Ptdlns(3,5)P2 back to near normal levels in 
Vac14 mutant cells, it does not restore the response to hyperosmotic stress 
(Bonangelino et al., 2002). This and the fact that Fab1 retains partial activity 
in the absence of Vac14 suggest that Vac14 activates Fab1 kinase activity 
for maximal Ptdlns(3,5)P2 production under certain stimuli. Indeed, 
subsequent studies showed that both Vac14 in a complex with the 
phosphatase Fig4, and Vac7, were all required for this response, and the 
subsequent turnover of Ptdlns(3,5)P2 (Duex et al., 2006a; Duex et al., 
2006b). Although no direct interaction has been demonstrated between 
Vac14 and Fab1 (Dove et al., 2002), a recent study has shown that Fab1 
does most likely bind to both Vac14 and Fig4 through its chaperonin domain 
to form a common lipid kinase complex (Botelho et al., 2008). S. cerevisiae 
Vac14 possesses a putative transmembrane domain and motifs that suggest 
involvement in membrane trafficking such as the FIEAT repeats found in 
many membrane trafficking proteins including Vps15, which regulates its 
interaction with the Pl(3)-kinase Vps34 (Bonangelino et al., 2002). The 
domain structure is shown in figure 1.9.
1.7.3 Mammalian Vac14
Vac7 homologues have yet to be discovered in any other organisms, 
however Vac14 has homologues in the genome of every eukaryote
sequenced to date. In mammalian cells Vac14 is a widespread but relatively
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low abundance protein. Its role in mammalian cells mimics that in S. 
cerevisiae, it acts as an upstream activator of the kinase PIKfyve, and 
mammalian Vac14 and PIKfyve have been shown to coimmunoprecipitate 
with one another and partially colocalise on MVB/late endosome 
membranes. In fact, Vac14 coimmunoprecipitates can catalyse the formation 
of Ptdlns(3,5)P2 and Ptdlns(5)P, further demonstrating that the two proteins 
have a strong and stable interaction in mammalian cells.
Knockdown of Vac14, in mammalian cells does not cause the 
vacuolation seen in PIKfyve knockdown cells; instead it renders cells prone 
to vacuolation following treatment with ammonium chloride. The same is true 
of knockdown of Fig4 in mammalian cells (Sbrissa et al., 2007). Knockdown 
of Vac14 also leads to a marked decrease in PIKfyve kinase activity, but not 
in the levels of the protein itself, and also to a reduction in both Ptdlns(3,5)P2 
and Ptdlns(5)P levels (Sbrissa et al., 2004).
1.7.4 Neurodegeneration
In a whole animal context, mutations in Fig4 and loss of Vac14 have 
recently been found to be a cause of neurodegeneration. A mutation in Fig4 
has been found in the pale tremor mouse and human patients with the 
Charcot Marie Tooth disorder CMT4J. Cultured fibroblast from pale tremor 
mice were found to have a 3-fold reduction in Ptdlns(3,5)P2 and enlarged 
cytoplasmic vacuoles in approximately 40% of cells. Recent studies in 
Vac14 knockout mice found that homozygotes died 1-2 days after birth. 
Cells cultured from these mice developed cytoplasmic vacuoles, had normal
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levels of PIKfyve, but reduced Ptdlns(3,5)P2 levels, indicating that Vac14 
acts as an activator of PIKfyve in vivo (Zhang et a!., 2007).
Recent evidence from mammalian cells suggests that Ptdlns(3,5)P2 
can also be hydrolysed by the Ptdlns(3)-phosphatases known as the 
myotubularins, mutations in several of which also cause variations of the 
neurodegenerative disorder Charcot Marie Tooth disease, as with Fig4 
(Wishart and Dixon, 2002; Pendaries e ta i, 2003). There are 12 mammalian 
myotubularins, only some of which are catalytically active. These are 
proposed to hydrolyse Ptdlns(3,5)P2 at the D-3 position of its inositol ring to 
form Ptdlns(5)P, although this remains somewhat controversial.
1.8 Ptdlns(3,5)P2 effectors
Limited knowledge of the binding domains that specifically target this 
lipid have lead to limited identification of Ptdlns(3,5)P2 effectors. Various 
groups have reportedly elucidated novel binding partners with different levels 
of specificity for this lipid and these are described in the following sections.
1.8.1 PROPPINs
Probably the best characterised Ptdlns(3,5)P2 effector in S. cerevisiae 
is the protein Svp1 (swollen vacuole phenotype), which was identified in a 
screen for mutants that phenocopy the enlarged vacuole of Fab1 mutant 
cells (Dove etal., 2004). Svp1 has also been identified as Aut10, Atg18 and 
Cvt18 reflecting its roles in the autophagy and cytoplasm-to-vacuole (cvt) 
targeting pathways (Barth etal., 2001; Guan etal., 2001), this is discussed in 
further detail in section 1.9.4.
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Interestingly, Svp1 is separated from Fab1 on chromosome VII by only 
one open-reading frame. In a similar manner to Fab1, Fig4 and Vac14, Svp1 
also localises to the yeast vacuole membrane, in a Fab1 kinase-dependent 
manner, but in addition it also localises to an as yet uncharacterised punctate 
compartment. Overexpression of Fab1 does not rescue the Svp1 mutant 
phenotype, however overexpression of low levels of GFP-Svp1 does, 
suggesting that the defect is caused by a loss of Svp1 and not an indirect 
loss of Fab1, and that Svp1 is downstream of Ptdlns(3,5)P2 production. The 
S. cerevisiae genome encodes two other Svp1-like proteins, HSV1 (also 
called Mail or Atg21) and HSV2, which do not cause vacuole enlargement, 
localise to a non-vacuolar compartment and do not require Fab1 for their 
localisation. GST-Svp1 has been shown through several different methods 
to bind to Ptdlns(3,5)P2 with high specificity (an apparent Kd of approximately 
180nM), 10-fold greater than the binding of the FYVE domain of Hrs to 
Ptdlns(3)P. It also weakly binds to Ptdlns(3)P and requires Magnesium for 
the specificity of binding. Svp1 mutant cells produce 5-10 times more 
Ptdlns(3,5)P2 than normal but still have an aberrant vacuole morphology, 
suggesting that these cells must not be correctly responding to Ptdlns(3,5)P2 
(Dove et al., 2004). Svp1 has also been shown to bind Fab1 by yeast two- 
hybrid analysis, suggesting that it may also negatively regulate the kinase 
activity of Fab1 (Georgakopoulos et al., 2001). Whilst the vacuole 
morphology phenotype of Fab1 mutant cells is reiterated by Svp1 mutant 
cells, they do not display the heat tolerance, vacuole acidification or MVB 
sorting defects of Fab1 mutants, thus Svp1 is clearly not involved in all 
Ptdlns(3,5)P2 cellular functions (Dove et al., 2004).
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Svp1-like proteins are widespread in all eukaryotes. According to Dove and 
Colleagues, the most Svp1-like human homologue is encoded by the 
DKFZp434J154 gene, which they term hSvpIa and which corresponds to 
WIPI-2 (Dove et al., 2004). In fact, there are four human Svp1-like 
homologues, which have become known as the WIPI family, for WD-repeat 
containing proteins that interact with phosphoinositides (Jeffries et al., 2004; 
Proikas-Cezanne et al., 2004). As illustrated in figure 1.12, the mammalian 
proteins are phylogenetically divided into two distinct groups: WIPI-1AA/IPI-2 
and WIPI-3/WIPI-4. There is some suggestion in the literature that WIPI-1 
represents the yeast protein Atg18 and WIPI-2 represents Atg21. However, 
a reciprocal blast analysis tells us that both WIPI proteins are actually both 
slightly more Atg 18-like than Atg21 -like, which is reflected in the relative 
identities of the different proteins, see Table 1.1 below. This is further 
supported by genome exploration studies, which have shown that Atg 18 is 
always present but that Atg21 is restricted to yeast (personal communication 
Daniel Ridgen, University of Liverpool). What is clear from phylogenetic 
analyses is that WIPI-3 and WIPI-4 group more closely with the yeast protein 
HSV2.
Table 1.1 Shared identity of WIPI family with yeast Svp1-like proteins
Identity/similarity Atg18 Atg21 HSV2
WIPI-1 21.76/20.23% 14.65/17.82% 17.32/18.14%
WIPI-2 22.89/16.7% 14.72/18.15% 18.18/18.39%
WIPI-3 19.44/13.49% 16.67/13.29% 22.77/14.73%
WIPI-4 21.17/17.28% 15.87/17.06% 23.79/17.4%
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Figure 1.12. Phylogenetic analysis of the PROPPIN’s
Parsimonious tree illustrating the relationships between the mammalian 
and yeast PROPPIN’s, created by PHYLIP phylogenetic analysis software 
(Felsenstein, J. 1993. PHYLIP (Phytogeny Inference Package) version 
3.5c. Distributed by the author. Department of Genetics, University of 
Washington, Seattle). The mammalian WIPI family forms two groups. 
WIPI-1 and WIPI-2 are more closely related to the yeast protein Atg18, 
whereas WIPI-3 and WIPI-4 are more closely related to the yeast protein 
HSV2. Numbers in red indicate bootstrap values.
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The term PROPPIN has also been proposed to encompass this entire 
family of proteins in all organisms, for beta-propeller proteins that interact 
with phosphoinositide (Michell et al., 2006). This is in reference to the fact 
that the key feature of all these proteins is that they are predicted to fold into 
beta-propellers. Beta-propellers are a diverse group of proteins built of 
between 4 and 8 blades packed in a circular array. Each blade consists of a 
4-stranded antiparallel beta sheet (Neer et al., 1994; Yu et al., 2000). The 
PROPPIN’s are part of a superfamily of proteins within the beta-propeller 
fold, that are characterised by the possession of highly conserved repeating 
units composed of around 40 amino acids and typically ending with Try-Asp 
residues (hence WD repeat proteins). The domain structure of WIPI-2 is 
shown in figure 1.9. Their common function is to regulate the assembly of 
multiprotein complexes by presenting a stable attachment platform (Fong et 
al., 1986; Garcia-Higuera etal., 1996).
Svp1 possesses a widely conserved basic region between blades 5 
and 6. Mutation of a pair of arginine residues within this region reduced the 
binding to Ptdlns(3,5)P2 40-fold, and an overexpression construct with these 
residues mutated does not rescue the enlarged vacuole phenotype, 
suggesting that Svp1 binds Ptdlns(3,5)P2 through these residues and that it 
requires this binding to perform its vacuole functions (Dove et al., 2004). 
These basic residues are conserved in higher eukaryotes, suggesting that 
phospholipid binding is likely to be an ancestral, evolutionarily conserved 
property.
All of the human WIPI genes are ubiquitously expressed, with
particularly high expression in skeletal and heart muscle and testis. WIPI-1
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and WIPI-2 give rise to alternative splice variants, WIPI-1 a and |3 and WIPI-2 
a , |3, 6 and y. To date only WIPI-1 a and p (WIPI-49) have been examined in 
the literature. In this study WIPI-2 a  is characterised. WIPI-1 p/WIPI-49 has 
been shown to bind phosphoinositides with higher specificity for Ptdlns(3)P 
than for Ptdlns(3,5)P2 through a liposome binding assay (Jeffries et al., 
2004), thus it remains unclear which lipid the mammalian proteins bind. A 
summary of the four key Ptdlns(3,5)P2 proteins and their proposed functions 
is shown in figure 1.13.
1.8.2 Other effectors
Other effectors that have been identified include the ENTH domain 
containing Epsins, Ent3 and Ent5. Some groups report specific binding to 
Ptdlns(3,5)P2 by qualitative lipid overlay assays (Friant et al., 2003; Eugster 
et al., 2004), whilst others report no specific binding to any phosphoinositides 
through surface plasma resonance (SPR) analysis on phosphoinositide- 
doped phospholip ids i^Mfiaoclee 11 , et 2fl06)The ESCRT III 
complex protein Vps24/CHMP3 was identified from phage-display based 
screen for proteins that bind Ptdlns(3,5)P2 (Whitley et al., 2003). However, 
this protein displays no recognised phosphoinositide-binding domain, and 
subsequent SPR studies again demonstrated no specificity for any 
phosphoinositide (Michell etal., 2006). The ability of these proteins to bind 
Ptdlns(3,5)P2 and act as effectors remains to be clarified, but they are 
proposed to act in MVB sorting.
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Other proteins that have been reported to bind Ptdlns(3,5)P2, but for 
which a function has yet to be ascribed are a-tocopherol-binding protein 
(ATTP) (Krugmann eta!., 2002), two Sec14 domain-containing proteins in 
plants (Kearns et al., 1998), the sorting nexin SNX1 (Cozier et ai, 2002) and 
trafficking protein Ivylp (Lazar et al., 2002).
1.9 Cellular role of Ptdlns(3,5)P2
Given the diverse nature of functional outputs of PIKfyve activity it is 
possible that Ptdlns(3,5)P2 controls a range of cellular processes, several of 
these are discussed in the following sections.
1.9.1 Endomembrane homeostasis and terminal maturation of the lysosome
In Ptdlns(3,5)P2 deficient yeast cells the terminal compartment of the
endocytic pathway, the vacuole, is grossly enlarged (Yamamoto etal., 1995;
Gary et al., 1998; Odorizzi et al., 1998). There is also a failure in the
trafficking of certain cargoes to the vacuole (Odorizzi et al., 1998).
Importantly, a variety of different studies have documented remarkably
similar enlargement of endosomal compartments in Drosophila, C. elegans
and ail mammalian cell lines tested, suggesting that Ptdlns(3,5)P2 is
important in the homeostasis of endosomal membranes and that this is an
evolutionary conserved function (Sbrissa et al., 1999; Nicot et al., 2006;
Rusten et al., 2006; Rutherford et al., 2006). This was shown to be
dependent on Ptdlns(3,5)P2 synthesis by Shisheva and colleagues, who
demonstrated that a point mutant defective in Ptdlns(5)-P, but synthesising
near normal levels of Ptdlns(3,5)P2, did not cause vacuolation (Ikonomov et
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a/., 2002a). Furthermore, it is not only loss of the kinase PIKfyve/Fab1 that 
elicits these effects, but other Ptdlns(3,5)P2-associated proteins as well 
(Chow et al., 2007; Zhang et al., 2007). The precise molecular mechanisms 
underlying the role of Ptdlns(3,5)P2 in endomembrane homeostasis have yet 
to be elucidated. It has previously been hypothesised that Ptdlns(3,5)P2 
regulates ILV formation, fission of transport intermediates from early 
endosomes (Ikonomov et al., 2006), or the retrieval of membrane to the TGN 
(Rutherford et al., 2006).
Studies from a variety of different organisms show that the swollen 
compartment labels with late endosomal/lysosomal markers and is not 
acidified (Nicot et al., 2006; Rutherford et al., 2006). Although S. cerevisiae 
show a defect in the trafficking of certain cargoes to the vacuole, in 
mammalian cells and C. elegans there is no defect in receptor internalisation, 
recycling or transport to the lysosome or subsequent protein degradation 
(Ikonomov et al., 2003a; Nicot et al., 2006; Rutherford et al., 2006). It was 
suggested that Ptdlns(3,5)P2 therefore controls the maturation of the 
lysosome. However, studies in Drosophila demonstrated a role for 
Ptdlns(3,5)P2 in downregulation of wingless and notch receptors (Rusten et 
al., 2006). Thus, the literature from different organisms remains to be 
consolidated and the precise nature of the role of Ptdlns(3,5)P2 in 
endolysosomal trafficking pathways is yet to be defined.
1.9.2 Endosóme to TGN trafficking
Ptdlns(3,5)P2 has been implicated in retrograde transport pathways to
the TGN through a number of different lines of evidence, and a failure in
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retrieval of membrane from endosomal compartments in Ptdlns(3,5)P2 
deficient cells is proposed to contribute to the membrane swelling. In S. 
cerevisiae the Fab1 activator Vac7 and the Ptdlns(3,5)P2 downstream 
effector Svp1/Atg18 have been shown to be involved in retrograde transport 
of cargo from the yeast vacuole to the TGN (Bonangelino et al., 1997; Dove 
et al., 2004). Vac14 binds to the yeast orthologue of the y-adaptin subunit of 
the AP-1 complex (Alp4). This complex is thought to be involved in both 
anterograde and retrograde TGN transport pathways, as detailed in section 
1.2.7. Furthermore, AP-1 was subsequently shown to be required for the 
activation of Fab1 in Ptdlns(3,5)P2 dependent processes at the vacuole 
(Phelan et al., 2006). Vac14 has also been shown to bind to the yeast 
protein Vps5, the yeast equivalent of the retromer component SNX-2 (Gavin 
et al., 2006).
In mammalian cells siRNA mediated ablation of PIKfyve lead to a 
change in the steady state distribution of ciM6PR to more early endosomal 
structures, partial degradation of ciM6PR, and a delay in the retrieval of 
chimeric CD8-ciM6PR and sortilin constructs, suggesting that retrieval of 
cargo to the TGN was perturbed and increasingly diverted towards the 
lysosome (Rutherford et ai, 2006). It was proposed that Ptdlns(3,5)P2 may 
regulate retromer-dependent retrieval of ciM6PR, a hypothesis that is 
consistent with evidence that shows that Ptdlns(3,5)P2 may bind to the 
retromer component SNX-1 (Cozier et ai, 2002). In addition, overexpression 
of the mammalian Ptdlns(3,5)P2 binding protein WIPI-1 affects the 
distribution of both AP-1 and ciM6PR (Jeffries et ai, 2004).
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However, as mentioned previously, PIKfyve has also been shown to 
bind to the Rab9 effector p40 and to play a role in the trafficking of cargo 
from the late endosome to the TGN through regulation of the membrane 
association of the Rab9/p40/TIP47 complex (Ikonomov et at, 2003b; Sbrissa 
et al., 2005). Given that retromer-dependent retrieval is proposed to occur at 
the early endosome and yet the nature of the swollen compartment appears 
to be late endosomal or lysosomal, it seems likely that Ptdlns(3,5)P2 may 
regulate membrane retrieval from both of these compartments.
1.9.3 Autophagy
Autophagy, literally self-eating, is a ubiquitous process of cellular 
protein degradation in eukaryotic cells. Its main function is to restore the 
levels of amino acids and eliminate damaged organelles in response to 
stress conditions, allowing the cell to adapt to environmental and/or 
developmental changes. It differs from apoptosis in that it forms a normal 
part of a cell’s physiological processes, however under abnormal 
circumstances it can initiate autophagic cell death or type II programmed cell 
death (Schweichel and Merker, 1973). The amount of research in the 
autophagy field has seen a rapid expansion in recent years (Klionsky, 2007), 
and it has been implicated in a range of different cellular processes such as 
cancer (a number of genes required for autophagy are also tumour 
suppressors) (Gozuacik and Kimchi, 2004), ageing (involved in the clearance 
of protein aggregates that accumulate during neurodegenerative diseases 
such as Huntington’s and Parkinson’s) (Rajawat and Bossis, 2008) and the 
immune response (pathogens are encapsulated into autophagosomes during
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infection, and autophagy has been linked to the toll-like receptor (TLR) 
response to infection) (Seay and Dinesh-Kumar, 2007; Xu et al., 2007).
Although Christian de Duve first described autophagy more than 40 
years ago, our molecular understanding of this process has only just begun. 
There are three types of autophagy: chaperone-mediated autophagy is a 
mechanism that allows the degradation of cytosolic proteins that possess a 
particular consensus pentapeptide motif (Majeski and Dice, 2004), 
microautophagy is the direct engulfment of the cytoplasm by protrusions from 
the surface of the degradative organelle (Kunz et al., 2004), and 
macroautophagy (Klionsky, 2005; Yorimitsu and Klionsky, 2005) (henceforth 
referred to as autophagy).
Autophagy begins with the formation of a phagophore or limiting 
membrane, the source of which is unknown, and continues with the 
extension of the phagophore to surround a portion of the cytosol. The ends 
of the phagophore fuse, forming a double membrane bound organelle called 
the autophagosome. This fuses with endocytic organelles to form either an 
amphisome (through fusion with early endosomes) or an autolysosome 
(through fusion directly with the lysosome). The contents are subsequently 
degraded and the resulting amino acids are exported into the cytosol and 
recycled (Arstila and Trump, 1968; Gordon and Seglen, 1988; Stromhaug 
and Seglen, 1993).
1.9.3.1 Induction of autophagy
Autophagy is conducted by a complex array of so-called Atg
(autophagy related) genes that function at different stages of this process.
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To date 30 Atg genes have been identified in yeast involved in various forms 
of autophagy. The autophagic machinery in other model eukaryotic 
organisms such as Dictyostellium discoideum, Arabiodopsis thaliana, D . 
melanogaster and C. elegans overlap considerably with that in yeast, but non 
display the complete convergence of yeast and mammals (Klionsky, 2007).
Autophagy occurs at a basal rate in normal growing cells, but is 
dramatically induced in response to certain types of environmental stress, 
such as nutrient starvation and inhibition of the target of rapamycin (TOR) 
protein (Schworerand Mortimore, 1979; Mortimore and Poso, 1987). Under 
nutrient rich conditions autophagy is inhibited by the serine/threonine protein 
kinase TOR, which either directly or indirectly phosphorylates Atg 13. Atg 13 
forms part of the autophagy-inducing complex, also composed of Atg 17 and 
the serine/threonine kinase Atg1. Following nutrient deprivation or following 
treatment with rapamycin (an inhibitor of TOR), Atg13 is rapidly and partially 
dephosphorylated and has an increased affinity for binding to Atg1. These 
changes correlate with an increase in autophagic activity (Kamada et ai,
2000).
Autophagy is also activated by nutrient deprivation in mammalian 
cells, which may act through repression of the mammalian TOR protein 
(mTOR) or other as yet undefined mechanisms, thus far the only component 
of the autophagy-inducing complex to have been identified in mammalian 
cells is the Atg1 orthologue ULK-1 (Chan et at, 2007). In mammalian cells, 
the negative regulatory cascade upstream of mTOR includes a class I Pl(3)- 
kinase, PDK1, and Akt/PKB (O'Reilly et al., 2006). Concordantly, the
phosphatase PTEN acts antagonistically to the Pl(3)-kinase to induce
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autophagy (Arico et a/., 2001; Ueno et at, 2008). Autophagy can also be 
induced by deprivation of insulin and other growth factors which signal 
through the PI(3)-kinase/AKT pathway (Wagner, 2005). Figure 1.14 outlines 
the stages of autophagy and the Atg genes required in yeast and mammalian 
cells.
1.9.3.2 Role of Ptdlns(3)P in autophagy
Following induction of autophagy, the initial stages of vesicle 
nucléation occur. This has been shown to be dependent, both in yeast and 
mammals, on the activation of the class III Pl(3)-kinase Vps34 and 
generation of Ptdlns(3)P. This activation depends on the formation of a 
multiprotein complex that includes, in yeast, Atg6/Beclin 1, Vps15, and 
Atg14, and in mammals, Atg6/Beclin 1, Vps15, UVRAG, Bif-1 (also known as 
endophillin B1) and Ambra 1 (Kametaka et al., 1998; Kihara et at, 2001). In 
mammals, Beclin 1 interacts with Bcl-2 or its close homologue BcI-Xl, and 
the activation of the complex requires the dissociation of these two proteins 
(Liang et at, 1998).
1.9.3.3 Vesicle elongation
The process of elongation and completion of the autophagosome are 
conducted by two evolutionarily conserved ubiquitin-like conjugation systems 
in both yeast and mammals (Ohsumi and Mizushima, 2004). Ubiquitin is 
conjugated to target proteins via the action of a cascade of enzymes known 
as E1 activating enzymes, E2 conjugating enzymes and E3 ligases (Hershko
and Ciechanover, 1992; Jentsch, 1992; Varshavsky, 1992). The first system
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in autophagy involves the conjugation of Atg12 to Atg5, via an E1 -like 
enzyme Atg7 and an E2-like enzyme Atg10. The resulting conjugate is 
organised into a complex by associating with Atg16, to form the Atg16-Atg5- 
Atg12 complex.
The second pathway involves the conjugation of the lipid 
phosphatidlyethanolamine (PE) to a glycine residue of Atg8 (Ohsumi and 
Mizushima, 2004). The mammalian homologue of Atg8 is LC3, originally 
identified as microtubule associated protein 1 light chain 3 (Kabeya eta!., 
2000). This conjugation occurs by the sequential action of the protease 
Atg4, the E1-like enzyme Atg7, and the E2-like enzyme Atg3. It leads to the 
conversion of Atg8/LC3 from a soluble, cytoplasmic form to a membrane- 
associated form; the membranes that it associates with are predominantly 
those of the forming autophagosome. Yeast Atg8 mediates tethering and 
fusion of liposomes containing Atg8-PE in vitro, leading to the suggestion 
that this recruitment of Atg8/LC3 to the autophagosome membrane is 
responsible for the phagophore membrane expansion (Kabeya et al., 2000; 
Xie et al., 2008).
1.9.3.4 Proposed role of Ptdlns(3,5)P2 in autophagy
In yeast the integral membrane protein Atg9 is localised to the PAS 
(pre-autophagosomal structure; the proposed site of initiation of 
autophagosome formation) and an as yet uncharacterised punctate 
localisation, but is excluded from the completed autophagosome (Noda et al., 
2000; Suzuki et al., 2001; Kim et al., 2002). Given that Atg9 is a
transmembrane protein, it must be retrieved from the PAS by vesicular
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transport, prior to autophagosome completion. It has subsequently been 
shown that Atg2, Atg18 and the Pl(3)-kinase complex are all required for the 
retrieval of Atg9 (under these mutant backgrounds Atg9 localises solely to 
the PAS) and Atg9 has been shown to bind Atg18 in a manner dependent on 
Atg1 and Atg2 (Reggiori et al., 2004). Precisely how the Atg1-Atg13 complex 
mediates Atg9 retrieval is still unclear. The current hypothesis is that the 
Atg1-Atg13 complex (involved in the initiation of autophagy) induces a 
simultaneous interaction between Atg18, Atg9 and Atg2 at the PAS. The 
formation of this complex mediates the retrieval of Atg9 from the PAS once 
its function is completed. An S. cerevisiae Atg18 mutant displayed an 
accumulation of autophagosomes, and was suggested to possess a defect in 
the fusion of autophagosomal structures with the yeast vacuole (Barth et al.,
2001).
Atg18 is also known as Svp1 and has been shown to bind both 
Ptdlns(3)P and Ptdlns(3,5)P2 (see section 1.8). The nature of the proposed 
role of Atg18 as part of an Atg9 retrieval complex is somewhat reminiscent of 
its role in retrieval from the yeast vacuole to the TGN under vegetative 
conditions, suggesting that Ptdlns(3,5)P2 may have a dual role in this 
process under different cellular conditions. However, some data has shown 
that the role of Atg18/Svp1 in autophagy is independent of its capacity to 
bind Ptdlns(3,5)P2 (Dove etal., 2004).
A second member of the Svp-1 like protein family in yeast, 
Atg21/HSV2, plays a role in the Cvt pathway, in the recruitment of Atg8 to the 
PAS (pre-autophagosomal structure) or expanding phagophore under
vegetative conditions (Meiling-Wesse et al., 2004). Although a mammalian
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Svp1 homologue WIPI-1 has been shown to be involved in autophagy, it’s 
relationship with Atg9 and the importance of its lipid-binding capabilities in 
autophagy have yet to be determined.
The role of the kinase Fab1/PIKfyve in autophagy has also been 
recently assessed. In Fab1 mutant Drosophila, there was an accumulation of 
amphisomes (Rusten et al., 2007), in C. eiegans pkk-3 mutants an 
accumulation of LC3 was observed (Nicot et al., 2006), and in mammalian 
cells treated with a specific inhibitor of PIKfyve (YM201636) there was a 
decrease in protein degradation (Jefferies et al., 2008), following starvation 
induced autophagy. These data suggest that Fab1/PIKfyve and possibly the 
effector protein Atg18 play a role in the later stages of the autophagy 
pathway. However, the precise role of Ptdlns(3,5)P2 in autophagy, and how 
this relates to Atg18 as an effector protein, remains to be clarified.
1.10 Current work
A number of key questions remain to be resolved in respect to 
Ptdlns(3,5)P2 metabolism in mammalian cells, that may provide further 
insight into the role of this lipid in endocytic membrane trafficking pathways. 
The aim of the current work was to examine four mammalian proteins 
associated with Ptdlns(3,5)P2 metabolism: PIKfyve, Vac14, Fig4 and WIPI-2, 
and to:
1) produce and characterise various tools to permit further study of these 
proteins
2) analyse their cellular localisation
3) produce purified protein
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4) examine the interactions between these proteins (in particular, focusing on 
the Vac14-Fig4 interaction)
5) assess the knockdown phenotypes of each protein in mammalian cells to 
assess the roles of each protein in common endocytic trafficking pathways, 
and in starvation-induced autophagy
6) directly compare the phenotypes associated with both PIKfyve siRNA 
treatment and pharmacological inhibition
72
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CHAPTER TWO
Materials and Methods
2.1 Molecular biology
2.1.1 Reagents
Mouse full-length PIKfyve and human full-length Fig4 cDNA were 
obtained from the Kazuso Institute, Japan (clone names mib04069 and 
ha06690). Mouse full-length Vac14 was obtained from the Mammalian Gene 
Collection I.M.A.G.E Consortium (clone # IRAKp961N24109Q). Human full- 
length WIPI-2 was obtained from the RZPD German Resource Centre for 
Genome Research (clone # DKFZp434J154Q). XL1-Blue supercompetent 
cells (#200236), Pfi/Ultra™ and PfuTurbo™ DNA Polymerase were all 
obtained from Stratagene (La Jolla, CA, USA). DH5a subcloning efficiency 
chemically competent cells (#18265-017), One Shot BL21 (DE3)pLysE 
competent cells (#C6060-03), electrophoresis grade agarose and all custom 
made primers for PCR were obtained from Invitrogen (Paisley, UK). Luria- 
Bertani broth (#LAB191) was obtained from Lab M (Bury, UK). TAE (#EC- 
872) was obtained from National Diagnostics (Hull, UK). Quick-load 1 kb 
DNA ladder (#N0468S), T4 DNA polymerase (#M0252S), T4 DNA ligase 
(#M0205S), Calf Intestinal Alkaline Phosphatase (#M0209S) and all 
restriction endonucleases were obtained from New England Biolabs 
(Hertfordshire, UK). Mini-prep (#27106), HiSpeed Maxi-prep (#12633), gel 
extraction (#28604) and PCR purification (#28704) kits were all obtained 
from QIAgen (Crawley, UK). A complete list of plasmids used is outlined in
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Table 2.4. All other chemicals were from Sigma Aldrich (Poole, UK) unless 
otherwise stated.
2.1.2 Preparation of competent E. Coli for transformation
Luria-Bertani (LB) broth and agar were made up with distilled water and 
used for all culture of E. coli. 100ml LB broth was inoculated with 5ml of log­
phase E. coli and incubated at 37°C with shaking at 250rpm in a Lab-Therm 
shaker (Kühner, Switzerland). Once cells had reached an optical density 
(OD)55o of 0.48 they were chilled on ice for 15 minutes. Cells were pelleted 
(5min, 2500rpm, 4°C) and pellets resuspended in 30ml ice-cold TfBI buffer 
(100mM RbCI2, 50mM MnCI2, 30mM KOAc, 10mM CaCI2, 15% (v/v) glycerol, 
pH adjusted to 5.8 with HOAc, sterile filtered). Cells were then chilled on ice 
for 20-30 minutes, pelleted again, and resuspended in 4ml ice-cold TfBII 
buffer (10mM MOPS pH 7.0, 10mM RbCI2, 75mM CaCI2 and 15% (v/v) 
glycerol, sterile filtered). Cells were dispensed in 50pl aliquots on dry ice and 
stored at -80°C. Competent E. coli DH5a were prepared for DNA production 
and commercially purchased DH5a and XL1-Blue supercompetent cells were 
also used for this purpose.
Larger DNA constructs, which proved more difficult to transform into
bacteria, were often transformed using electrocompetent E. coli. In this case
500ml LB broth was innoculated with a 2.5ml suspension of log-phase E. coli
and incubated at 37°C with shaking at 300rpm to an OD6oo of 0.5-0.6. Cells
were chilled on ice for 15 minutes, pelleted (3000rpm, 10 minutes, 4°C) and
resuspended in 50ml ice-cold 10% glycerol. Cells then underwent a series of
pelleting and resuspension steps in 25ml ice-cold 10% glycerol, followed by
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4ml ice-cold 10% glycerol, followed by 1.5ml ice-cold 10% glycerol, and then 
dispensed in 50pl aliquots on dry ice and stored at -80°C.
2.1.3 Transformation of competent E. coli
Typically 50pl DH5a or XL1-Blue E. coli were thawed on ice. 
Approximately 50ng (plasmid DNA) or 5pl (ligation) was added to the thawed 
cells and incubated for 30 minutes on ice. Cells were heat-shocked (42°C for 
45 seconds for XLIBIue or 37°C for 20 seconds for DH5a) in a water bath 
and then immediately returned to ice for 2 minutes. 250pl LB was added to 
the cells and they were incubated at 37°C for 1 hour with shaking at 250­
300rpm. 200pl of this culture was plated onto pre-warmed LB agar plates 
supplemented with 100pg/ml Ampicillin or 25pg/ml Kanamycin or other 
appropriate antibiotics, determined by the resistance of the plasmid. For 
larger plasmids, a lower ampicilin concentration was used to encourage 
growth.
For electrocompetent transformation of larger plasmids, 40pl 
electrocompetent E. coli were thawed on ice, and 1-2pl DNA was added. 
Cells were incubated on ice for 10 minutes and, subsequently the mixture 
was transferred to an electroporation cuvette. The sides of the cuvette were 
dried, the cuvette was placed in between the contacts of a micropulser (Bio­
Rad), set to Ec2, and pulsed. The cuvette was placed immediately back on 
ice and 250pl LB added. The cell culture was then incubated for 1 hour at 
37°C with shaking at 235rpm and then 50pl of this culture was plated onto an 
LB agar plate supplemented with the appropriate antibiotic.
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For subsequent purification of DNA from transformants, a single colony 
was picked and incubated overnight in LB broth (5ml for mini-preps and 
protein purification cultures, 150ml for maxi-preps) supplemented with 
appropriate antibiotic. Bacteria were then pelleted by centrifugation 
(4500rpm, 15 minutes, 4°C), the supernatant removed and DNA purified 
using mini or maxi-prep kits according to the manufacturer’s protocol. The 
concentration of maxi-prep DNA was estimated by measurement of the 
OD26o of the DNA and also by agarose gel electrophoresis and comparison 
to a 1 kb DNA ladder. The purity of DNA for transfection purposes was also 
assessed by measurement of the ratio of OD26o to the OD2so of the DNA.
2.1.4 Agarose gel electrophoresis
An agarose gel (between 0.8 and 1.2%) was prepared by adding 
electrophoresis grade agarose to TAE buffer. The mixture was heated in a 
microwave until the agarose had completely dissolved and then cooled at 
room temperature. Ethidium bromide was then added to a final 
concentration of 0.5pg/ml, the gel was poured and then left at room 
temperature to set. DNA samples were made up in sample buffer (5% w/v 
glycerol, 0.1 mM EDTA, 0.04% bromophenol blue) and resolved in TAE in a 
Fisherbrand horizontal midi electrophoresis tank (Fisher Scientific, 
Loughborough, UK) along with 10pl (per lane) of 1kb Quickload DNA ladder, 
at 100V. DNA bands were then visualised using an ultraviolet light source.
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2.1.5 Restriction endonuclease analysis
Restriction digests were set up using enzymes and buffers from New 
England Biolabs and using reaction conditions specified by the manufacturer. 
Typically digests were performed for 1 hour, using 1pg DNA in a total volume 
of 10pl. For subcloning, approximately 4-6pg of DNA were digested in a total 
volume of 50pl for at least 4 hours (see Table 2.1). For each digest an 
excess of enzyme was added with the volume not exceeding 10% of the total 
mixture.
Products were analysed by agarose gel electrophoresis. For sub­
cloning, gel fragments were excised using a sterile knife and DNA purified 
using a gel extraction kit. To ensure optimal activity of enzymes and 
production of DNA, double digests were sometimes carried out sequentially. 
After the first digest, 10% of the incubation mixture was run on an agarose 
gel to determine its success, whilst the remainder was run through a PCR 
purification column prior to the second digest.
Table 2.1. Reaction mixture for a typical restriction digest
Reagent Volume
Nuclease-free Variable
water
10x restriction 1pl
enzyme buffer
DNA sample 1|jg
Restriction 1pl
enzyme
Final volume 10pl
Reagent Volume
Nuclease-free Variable
water
10x restriction 5pl
enzyme buffer
DNA sample 4-6pg
Restriction 2-3pl
enzyme
Final volume 50pl
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2.1.6 Polymerase chain reaction (PCR)
Each of the plasmids made as part of this study underwent a PCR 
amplification using primers designed to add restriction sites, to enable sub­
cloning into a range of different vectors. DNA was PCR amplified using 
PfuUltra™ or Turbo™ enzymes. PCR reactions were set up at 4°C. A 
typical PCR reaction mixture is shown in table 2.2. The first step in the 
reaction consisted of a single cycle of 2 minutes at 95°C. This was followed 
by thermal cycling which typically consisted of a dénaturation period of 30 
seconds at 95°C, followed by 30 seconds at the annealing temperature 
(dependent on primer size and base content; typically the highest Tm of both 
primers - 5°C) and an extension time of 1-2 minutes per kilobase (kb) of the 
target DNA sequence. 25 cycles were performed, culminating in a polishing 
stage of 10 minutes at 72°C. PCR products were analysed by gel 
electrophoresis and the correct size gel fragment excised and run through a 
QIAquick PCR purification column. A ‘no template’ control was always run 
alongside each PCR reaction. PCR conditions were occasionally altered to 
increase PCR product yield, for example, the number of cycles was 
increased to 30 or the extension time was increased to 2kb/minute.
78
Chapter Two: Materials and Methods
Table 2.2. Reaction mixture for a typical PCR amplification
Reagent Volume
Nuclease free water Variable
10x Pfu buffer 5pl
dNTPs (25mM each) 0.5pl
Primer 1 (lOOng/pl) 2.5pl
Primer 2 (100ng/pl) 2.5pl
Template DNA 50ng
Pfu Turbo 1 pi
Total 50pl
Table 2.3 Primers used for PCR and site-directed mutagenesis
Name Use Sequence (5’ to 3’)
JW-WIPI-2 F PCR aaggatccccatgaacctgg eg ag cc
JW-WIPI-2 R PCR ccgtcgactcagtcagcagtcgaagaatc
JW-Fig4 F PCR aatgatcatgcccacggccgccgccccca
JW-Fig4 R PCR ggctcgagtcacaggtagcggttcctgatg
JW-Fig4-F2* PCR aattgg atccaaatg cccacggccg ccg
JW-Fig4 R2* PCR gcctcgagcccgaggaacctttctgtc
JW-Fig4sf Seq tcatgggttctgtgggcagt
JW-Fig4sr Seq ctctggtgtccaccagtaag
JW-Vac14 F PCR ccagatctccatgaacccagagaaggattttg
JW-Vac14 R PCR aactcgagtcagaggataactctgcggtc
JW-Vac14sf Seq cagctggcgggccgggtaat
JW-Vac14sr Seq agctggaagagctcggtgga
WIPI-2 KDRES F PCR ctcacgacagccccttggcagcgctggcctttg
WIPI-2 KDRES R PCR caaaggccagcgctgccaaggggctgtcgtgag
WIPI-2 RR mutant F SDM ctctttgaattcacgacaggagtaaagagg
WIPI-2 RR mutant R SDM cctctttactcctgtcgtgaattcaaagag
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Note: Initial pCRTOPO-Fig4 construct 5’ end incorrect when sequenced. F2 
and R2 (*) primers designed to address this. SDM -  site directed 
mutagenesis, seq -  sequencing.
For sub-cloning, PCR products were purified using a PCR purification 
kit and ligated into pCR4Blunt-TOPO according to the manufacturer’s 
protocol, as outlined in table 2.4.
Table 2.4. pCR4Blunt-TOPO cloning reaction
Reagant Volume
Fresh PCR product 1pl
Salt solution 1 |jl
Sterile Water Add to a final volume of 5pl
TOPO® vector 1pl
Final volume 6pl
2pl of this cloning reaction was then used to transform chemically 
competent MACH1™-T1® E. coli cells and grown overnight on LB agar plates 
supplemented with 100pg/ml ampicillin. DNA was purified from 
transformants by mini and maxi-prep and DNA was subsequently analysed 
by restriction endonuclease digest and agarose gel electrophoresis, to check 
for full-length and correctly orientated insert. Correct pCR4Blunt-TOPO 
constructs were sent for automated fluorescent DNA sequencing at the DNA 
Sequencing Service (University of Dundee) using the internal M13F and 
M13R priming sites within the pCR4Blunt-TOPO vector and specifically 
designed insert specific primers if needed.
80
Chapter Two: Materials and Methods
2.1.7 Ligations and sub-cloning
DNA was sub-cloned into a variety of different expression vectors:
Table 2.5. Plasmids generated for this project
Plasmid name Origin Use
pSPORT1-hSvp1a RZPD Subcloning
pCRTOPO-WIPI-2 JW Subcloning
pEGFPC2-WIPI2 JW Overexpressed protein IF, WB
pCMVmyc-WIPI2 JW Overexpressed protein IF, WB
pTrcHisC-WIPI2 JW Bacterial protein production (His tag)
pAcHis-WIPI2 JW Baculovirus protein production
pACT2-WIPI2 JW Y2H (prey)
pFBT9-WIPI2 JW Y2H (bait)
pCRTOPO-WIPI-2 KDRES JW Subcloning (RNAi resistant clone)
pCMVmyc-WIPI-2 KDRES JW Overexpressed protein RNAi resistant. Rescue experiments
pSPORT6.1 -mVac14 I.M.A.G.Econsortium Subcloning
pCRTOPO-mVac14 JW Subcloning
pTrcHisC-mVac14 JW Bacterial protein production
pAcG2T-mVac14 JW Baculovirus protein production
pCMVFIA-mVac14 JW Overexpressed protein WB, IF, IP
pEGFPC2-mVac14 JW Overexpressed protein WB, IF, IP
pACT2-mVac14 JW Y2H (prey)
pFBT9-mVac14 JW Y2H (bait)
pSPORT1-hFig4 Kl Subcloning
pCRTOPO-hFig4 JW Subcloning
pAcFlis-hFig4 JW Baculovirus protein production
pEGFPC2-hFig4 JW Overexpressed protein WB, IF, IP
pCMVmyc-hFig4 JW Overexpressed protein WB, IF, IP
pACT2/pFBT9-hFig4 JW Y2FI bait and prey
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Note: hSvpIa = WIPI2. Abbreviations: Kl -  Kazuso Institute, Japan; RZPD 
- German Resource Center for Genome Research, I.M.A.G.E -  The 
I.M.A.G.E Consortium; FC -  Frank Cooke, UCL; HS -  Harald Stenmark, 
Oslo, HP -  Hannah Poison, CRUK; IF-immunofluorescence; WB -  Western 
blotting.
Vector and insert were prepared by restriction digest agarose gel 
electrophoresis. The correct sized bands were extracted from the agarose 
using a gel extraction kit. Vector and insert were then combined in a ligation 
reaction (see Table 2.6 below). Typically 50-1 OOng of vector DNA was used 
and an equimolar ratio of insert DNA calculated using the following formula:
Insert DNA (ng) = Vector DNA (nq) x size insert (kb)
size vector (kb)
A vector to insert ratio of 1:1, 1:3 or 1:5 was used depending on the 
type of ligation (blunt or sticky end) and the possibility of multiple inserts 
being ligated into vector DNA., The mixture was incubated either at room 
temperature for 3 hours or overnight at 4°C. Between 2 and 5pl ligation 
reaction was used to transform chemically or electrocompetent E. coli and 
then plated on selective agar plates. DNA was purified from transformants 
using miniprep kits. Mini-prep DNA was verified using restriction 
endonuclease digest and agarose gel electrophoresis. Once the correct 
ligated product was obtained a DNA maxi-prep and glycerol stock of each 
construct were also made and stored appropriately.
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Table 2.6. Subcloning ligation reaction using T4 DNA ligase
1:1 1:3 Insert alone Vector
alone
Vector Calculated Calculated - Calculated
volume volume volume
Insert Calculated Calculated Calculated -
volume volume x 3 volume
10 x T4 1 |jl 1 pi 1pl 1 Ml
T4 Ligase 1 |jl 1 pi 1pl 1 Ml
Sterile water Make up to Make up to Make up to Make up to
final volume final volume final volume final volume
Total 10pl 10pl 10pl 10pl
It was occasionally necessary to design a cloning strategy 
incorporating blunt ended ligation if, for example, vector and insert were in 
different frames. For blunt end ligations 3’ overhangs were removed or 5’ 
overhangs filled in using a T4 DNA polymerase enzyme (see table 2.7 
below).
Table 2.7. T4 polymerase reaction
Reagent Volume
DNA Variable
T4 buffer 5pl
dNTPs 4pl of 5mM mix
(100mM each final)
T4 polymerase 3pl (1-311/pg)
Water Variable
Abbreviations: dNTPs (deoxynucleotide triphosphates -  four derivatives: 
adenosine, guanine, cytosine and thymine)
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The mixture was incubated at 12°C for 15 minutes and then the 
enzyme was heat inactivated for 10 minutes at 75°C in the presence of 
EDTA to a final volume of 10mM.
In many cases vectors were dephosphorylated using Calf Intestinal 
Alkaline Phosphatase to prevent vector self-ligation and reduce background; 
this was done by adding 0.5pl CIP to the 50pl digest volume and incubating 
the mixture at 37°C for 20 minutes.
pCR4Blunt-TOPO and pTrcHisC vectors were obtained from 
Invitrogen (Paisley, UK). pEGFPC2, pCMV-HA and pCMV-myc were from 
Clontech (Saint-Germain-en-Laye, France). pAcG2T was from 
BDBiosciences (Oxford, UK) and pCMVFIag2c from Stratagene (La Jolla, 
USA). pACT2, pFBT9 (derived from pGBT9) and pAcHis (derived from 
pAcSG2) were from Francis Barr (University of Liverpool, UK).
2.1.8 Site-directed mutagenesis
In order to generate RNAi resistant WIPI-2 constructs, specific amino 
acids were mutated using an overlapping PCR method (see Figure 2.1), 
using pCRTOPO-WIPI-2 as a template. The final product was transformed 
into pCR4BluntTOPO and sequenced as described previously to ensure the 
correct amino acid changes.
2.1.9 RNA extraction, reverse transcription and quantitative PCR
Due to the unavailability of a Fig4 antibody, it was necessary to
assess the knockdown of Fig4 by RT-PCR. HeLa cells were seeded onto 6-
well plates and transfected twice with 40nM Fig4 siRNA oligos over a 72 hour
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Tube 1 Tube 2
PCR 1
Position of intended 
mutation(s)
L_ _I
Products 
PCR 2
I___
Mutated product
Non-mutant primer
Mutant primer 
Template DNA
Figure 2.1. Overlapping PCR to create siRNA resistant WIPI-2.
pCRT0P0-WIPI-2 template was incubated in two separate PCR reactions 
with complimentary forward and reverse primers containing the necessary 
mutations , and a forward or reverse primer complimentary to the beginning 
or end of the template sequence. The products from the first PCR reaction 
were then incubated in a second PCR reaction with the same non-mutant 
primers complimentary to the beginning and end of the sequence. In this 
reaction a full-length product is created that incorporates mutated forward and 
reverse strands.
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period, as described in section 2.3.7. Cells were subsequently trypsinised 
from the dish and centrifuged in an eppendorf tube. RNA was extracted from 
the resultant cell pellet using the RNAeasy® mini kit (Qiagen) and the 
QIAshredder for homogenisation, according to the manufacturer’s 
instructions. RNA was quantified in a spectrophotometer at AbS26o and the 
purity of RNA assessed by measuring the ratio of absorbance at 260 and 
280. 1pg of RNA was reverse transcribed into cDNA using the QuantiTect 
Reverse Transcription kit (Qiagen) according to the manufacturer’s 
instructions. Genomic DNA contamination was minimised by first treating 
with the gDNA wipeout buffer provided with the kit. cDNA was quantified by 
qPCR using the DyNAmo™ HS SYBR® Green qPCR kit (Finnzymes, Finland) 
according to the manufacturer’s instructions. Both a no template control and 
an actin housekeeping gene control were used. A typical qPCR reaction is 
shown below in table 2.8.
Table 2.8. Typical qPCR reaction
Template NTC
Mastermix* 7.5pl 7.5pl
F primer (1pg/pl) 0.3pl 0.3pl
R primer (1pg/pl) 0.3pl 0.3pl
RNAase free H20 6.4pl 6.4pl
cDNA 1.5pl -
*Mastermix contains hot start version of modified Thermus brokianus DNA 
polymerase, SYBR® Green I, optimised PCR buffer, 5mM MgCfe, and dNTP 
mix.
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The qPCR reaction was cycled in an ¡Q5 Multicolor Real-Time PCR 
Detection System (Biorad, Hemel Hempstead, UK) for the following times 
and temperatures.
95°C for 2 minutes 
95°C for 30 seconds
60°C for 30 seconds ^  35 cycles
72°C for 30 seconds J  
72°C for 10 minutes
cDNA levels were quantified using the accompanying BioRad software.
2.2 Protein Biochemistry
2.2.1 Reagents
Chemicals were obtained from Sigma unless otherwise stated.
ProtoGel-30% Acrylamide/Bisacrylamide solution (37.5:1 w/v ratio) (#EC-
890), AccuGel_ 30% Acrylamide/Bisacrylamide solution (19:1 w/v ratio)
(#EC-849), ProtoGel resolving buffer (#EC-892), ProtoGel stacking buffer
(#EC-893), N,N,N’,N’-Tetramethylethylenediamine (TEMED) (#EC-503) and
Tris-Glycine-SDS PAGE buffer (#EC-870) were all obtained from National
Diagnostics. Ammonium persulphate (APS) (#A3678), 2-mercaptoethanol
(#M6250) and Ponceau S (#P7170) were obtained from Sigma. Pre-stained
broad range (#P7708S) and unstained broad range (#P7702S) SDS-PAGE
molecular weight standards were from New England Biolabs (NEB).
PROTRAN nitrocellulose 0.45pm pore-size (BA 83, #10401465) was
purchased from Schleicher & Schuell, GmbH, Dassel, Germany. Marvel
skimmed milk powder was from Premier Brands, UK and bovine serum
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albumin (BSA) (#40-00-410) was from First Link UK Ltd. SuperSignal West 
Pico enhanced chemiluminescence (ECL) substrate was obtained from 
Pierce, Rockford, IL, USA (#34080). Isopropyl-S-thiogalactopyranoside 
(IPTG) was obtained from Melford Laboratories Ltd. Suffolk, UK (#MB1008). 
Mammalian protease inhibitors (#P8340) and bacterial protease inhibitors 
(#P8465) were obtained from Sigma. NuPAGE Antioxidant (#NP0005) and 
MOPS SDS running buffer (#NP0002-02) were from Invitrogen.
2.2.2 SDS polyacrylamide gel electrophoresis (SDS-PA GE)
The resolution of proteins in polyacrylamide gels was performed using 
the denaturing, discontinuous system described by Laemmli (Laemmli, 
1970). Gels were set up in BioRad Mini-Protean® 3 cell apparatus according 
to the manufacturer’s instructions. Samples were resuspended in 5 x SDS- 
PAGE sample buffer containing B-mercaptoethanol. Recipes for gels and 
sample buffer are given in tables 2.9 and 2.10. Samples were boiled for 5 
minutes at 98°C prior to loading onto a gel alongside standard molecular 
weight markers. Typically, gels were run for 15mins at 90V and 80mins at 
135V in 1x electrophoresis running buffer (containing 50mM Tris, 0.1% SDS 
and 380mM glycine). Gels were then incubated for 1 hour with Coomassie 
Blue Stain (1mg/ml Coomassie Brilliant Blue (Gibco), 10% acetic acid, 50% 
methanol) or processed for Western blotting (see section 2.2.3). Gels were 
destained at room temperature for 1 hour (5% acetic acid, 35% methanol) 
and dried at 80°C for 2 hours under a vacuum with a BioRad gel drier. 
Alternatively, pre-cast NuPAGE Bis-Tris SDS-PAGE 4-12% gradient gels
were used for greater resolution of a range of different molecular weight
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proteins (#NP0321, Invitrogen). Gels were run in the XCell SureLock Mini­
Cell system (Invitrogen). Typically gels were run in NuPAGE MOPS SDS 
buffer containing NuPAGE Antioxidant at 200V for 60 minutes.
Table 2.9. Recipes for SDS-PAGE gels
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Ingredient Resolving gel
6% 8% 10% 12%
30% acrylamide (ml) 4 5.34 6.66 8
4X Resolving Buffer (ml) 5.2 5 5 5
Distilled water (ml) 10.58 9.24 7.92 6.58
TEMED (pi) 20 20 20 20
10% APS (pi) 200 200 200 200
Total volume (ml) 20 20 20 20
Ingredient Stacking gel
4%
30% acrylamide (ml) 1.35
4X Resolving Buffer (ml) 2.5
Distilled water (ml) 6.1
TEMED (pi) 10
10% APS (pi) 50
Total volume (ml) 10
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Table 2.10 Recipe for sample buffer
Sample buffer (100mi) 5x 1x Final concentration
0.5mM Tris-CI pH 8.0 31.25ml 12.5ml 62.5mM
SDS 3g 15g 3%
10% Glycerol 50g 10g 10%
3.3% 2-mecaptoethanol* 6.25ml 1.25ml 3.3%
Bromophenol blue 0.05g 0.01g 0.01%
‘Alternatively DTT was added to sample buffer at a inai concentration of
1mM before use.
2.2.3 Western Blotting
Following SDS-PAGE proteins were transferred to nitrocellulose for 60 
minutes at 24V in a Genie blotter (Research Products International Corp., Ill, 
USA). Membranes were stained with Ponceau S in order to monitor the 
efficiency of transfer, then incubated in 5% milk in phosphate-buffered saline 
(PBS) for at least 1 hour (at room temperature) or overnight (at 4°C) in order 
to block non-specific binding. Membranes were then incubated in blocking 
buffer containing specific primary antibodies for at least 1 hour (at room 
temperature) or overnight (at 4°C). Unbound antibodies were removed by 
repeated rinsing in PBS and then membranes incubated for 1 hour at room 
temperature in solutions containing fluorescent or horseradish peroxidase 
(HRP)-conjugated secondary antibodies. Proteins were detected either via 
enhanced chemiluminescence (ECL) or using a LI-COR Odyssey® infrared 
imaging system according to the manufacturer’s protocol.
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Table 2.11 Primary and secondary antibodies used in this study
Antibody Species Source Use
Anti-Beclin Mouse BD Trans. Labs WB
Anti-ULK-1 Mouse Santa Cruz WB
Anti-CIMPR Rabbit Paul Luzio IF
Anti-CIMPR (ST052) Rabbit Sharon Tooze WB
Anti-SNX1 Rabbit Matthew Seaman/ AbCam
IF
WB
Anti-Vps26 Rabbit Matthew Seaman/ AbCam
IF
WB
Anti-WIPI2 Rabbit JW WB/IF
Anti-Vac14 Rabbit JW WB/IF
Anti-PIKfyve Rabbit Lois Weisman WB/IF
Anti-WIPI1 Rabbit Sharon Tooze WB
Anti-EGFR-R1 Mouse CRUK IF
Anti-EGFR (1005) sc-03 Goat Santa Cruz WB
Anti-LAMP1 Mouse NIHCD IF
Anti-EEA1 Rabbit Ian Mills IF
Anti-EEA1 Mouse BD Trans. Labs IF
Anti-LC3 Mouse Nanotools WB/IF
Anti-TGN46 Sheep Vas Ponnambalam IF
Anti-GM130 Sheep Francis Barr IF
Anti-Golgin 245 Mouse Santa Cruz IF
Anti-Met Mouse Cell Signalling WB
Anti-CD8 Mouse Matthew Seaman IF/WB
Anti-HA Mouse Clontech IF/WB
Anti-His Mouse Qiagen WB
Anti-myc Mouse Upstate WB
Anti-GFP Sheep Ian Prior IF/WB
Anti-phospho-Akt Rabbit Cell Signalling WB
Anti-phospho-MAPK Mouse Cell Signalling WB
Anti-a tubulin Mouse Sigma IF
Anti-Transferrin receptor Mouse Boehringer IF
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Antibody Source CatalogueNumber Use
Anti-mouse IgG-HRP Sigma A4416 WB
Anti-mouse IgM-HRP Sigma A8786 WB
Anti-rabbit IgG-HRP Sigma A9169 WB
Donkey anti-mouse IRDye® 
800CW
Licor
Biosciences 926-32212 WB
Donkey anti-mouse IRDye® 680 LicorBiosciences 926-32222 WB
Donkey anti-rabbit IRDye® 
800CW
Licor
Biosciences 926-32213 WB
Donkey anti-rabbit IRDye® 680 LicorBiosciences 926-32223 WB
Donkey anti-goat IRDye® 
800CW
Licor
Biosciences 926-32214 WB
Anti-mouse IgG-AF 594 MolecularProbes A11005 IF
Anti-mouse IgM-AF 594 MolecularProbes A21044 IF
Anti-rabbit IgG-AF 594 MolecularProbes A11012 IF
Anti-mouse IgG-OG 488 MolecularProbes 06380 IF
Anti-rabbit-IgG-OG 488 MolecularProbes 06381 IF
Table 2.11 gives details of all primary and secondary antibodies used for 
both western blotting and immunofluorescence.
2.2.4 Stripping Western Blots
Western blots were briefly washed in PBS to remove residual ECL 
reagent and then incubated in stripping buffer (62.5mM Tris-HCI pH6.7, 2% 
SDS (w/v), 100mM 2-mercaptoethanol) at 50°C for 30 minutes with 
occasional agitation. Membranes were then given two 10 minute washes in
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PBS containing 0.1% (w/v) Tween-20. The membranes were then blocked 
and re-probed as described in section 2.2.3.
2.2.5 Protein Assay
The protein concentration of cell lysates was determined by the 
Bradford method using the BIO-RAD protein assay kit (#500-0006). Bovine 
immunoglobulin (#19640, Sigma) was used to create a standard curve each 
time the assay was performed. Cells lysates prepared in buffers containing 
SDS were quantified using the BCA protein assay kit (Pierce, UK) according 
to the manufacturer’s instructions.
2.2.6 Recombinant protein production from E.coli
Constructs to be expressed were sub-cloned into pTrcHisC bacterial 
expression vectors. One Shot BL21(DE3)pLysE competent cells were 
transformed with the relevant constructs according to manufacturer’s 
instructions. Transformed cells were grown overnight, then diluted 1:20 into 
500ml LB to an OD550 of 0.8. Protein production was induced with the 
addition of IPTG and grown for 4 hours at 37°C. Bacteria were harvested by 
centrifugation for 15 minutes at 4°C in a Jouan centrifuge (CR412, 
#29404191, Jouan, Saint Herblain, France) at 3,500 x g followed by 
resuspension in PBS, another round of centrifugation and the pellet snap 
frozen in liquid nitrogen.
2.2.7 Purification of HiS6-tagged recombinant proteins
Bacterial pellets were resuspended in 15ml IMAC 5 buffer (20MM Tris-
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HCI pH 8.0, 300mM NaCI, 5mM imidazole) supplemented with lysozyme 
(0.5mg/ml) and bacterial protease inhibitors. The resultant supernatant was 
rotated end-over-end at 4°C for 30 minutes followed by sonication on ice 6x 
30 seconds with the MICROSON XL2000 ultrasonic sell disrupter. This 
lysate was pelleted by centrifugation in a Beckman Coulter Optima MAX 
ultracentrifuge (MLA-80 rotor) at 100, 000 x g for 30 minutes. The recovered 
supernatant was rotated end-over-end for 2 hours at 4°C with 0.5ml pre­
washed nickel-nitrilotriacetic acid (Ni-NTA) beads. Beads were spun for 5 
minutes at 700 x g and washed 4x in IMAC 20 buffer (20MM Tris-HCI pH 8.0, 
300mM NaCI, 20mM imidazole). Purified His6-tagged proteins were eluted 
from Ni-NTA beads with IMAC 200 buffer (20mM Tris-HCI pH 8.0, 300mM 
NaCI, 200mM imidazole) and dialysed against 50mM Tris/HCI pH 7.2, 
100mM NaCI, 1mM DTT. Purified proteins were aliquotted, snap frozen and 
stored at -80°C.
2.2.8 Generation of recombinant baculovirus
Sf9 cells were cultured in IPL-41 medium (Sigma) supplemented with 
10% foetal bovine serum (FBS), 2% yeastolate, 1% fungizone (250pg/ml), 
and 50mg/ml Gentamicin (all from Invitrogen). Cells were maintained in 
175cm2 flasks at 27°C, and split 1:3 when confluent. The BD BaculoGold™ 
Baculovirus Expression Vector System was purchased from BD Biosciences 
(Oxford,UK). Recombinant baculovirus was obtained by cotransfection of 
Sf9 cells with the protein of interest (in a His-tagged baculovirus vector) and 
BaculoGold DNA. 60mm diameter dishes were seeded with 2 x 106 cells,
which were then allowed to adhere for 5 minutes. In an eppendorf tube
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0.5pg of BaculoGold DNA was combined with 4.5pg of maxiprep DNA of 
interest, mixed gently and incubated at room temperature for 5 minutes. 
Subsequently 1ml Transfection Buffer B was added to the DNA mixture and 
1ml Transfection Buffer A was added to the cells to replace the growth 
medium. The DNA/buffer mix was then added dropwise to the plates with 
gentle rocking. The plates were incubated at 27°C for 4 hours and the 
medium was then replaced with fresh growth medium. The level of infection 
was assessed after 4 days and the supernatant harvested after 5 days. The 
viral stock was then amplified by seeding 2 x 107 Sf9 cells in a 175cm2 flask, 
adding 200pl viral stock and incubating the cells at 27°C for 4-5 days. The 
supernatant was then harvested into 50ml tubes and the amplified viral stock 
was titrated to assess protein production and determine the amount of virus 
required for optimal protein production. For titration of the virus, 5 x 104 cells 
were seeded per well of a 96 well plate. The cells were allowed to adhere for 
15 minutes. 100pl of amplified stock was added to the first well, and then 
serially diluted over the next 11 wells to create a titration of the viral stock. 
The dish was then sealed with parafilm and incubated for 2.5 to 3 days at 
27°C. Subsequently cells were washed with 1 x PBS and then lysed in 50pl 
sample buffer. Samples were boiled for 10min prior to loading 30pl of each 
sample onto a coomassie gel alongside 15pl control uninfected sample.
2.2.9 Production of recombinant protein from baculovirus
6 175cm2 flasks were each seeded with 2 x 107 cells. Cells were 
allowed to adhere for 5-10 minutes prior to the addition of 170pl (optimum
amount as determined by titration -  see chapter 3) of amplified baculovirus
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protein. Cells were incubated at 27°C for 2 days and the supernatant was 
harvested into 50ml tubes (one 50ml tube per 2 flasks). 500pl of supernatant 
was removed to a 1.5ml eppendorf tube, spun for 3 minutes at full 4,500rpm, 
rinsed in PBS, spun again and then resuspended in 100pl sample buffer for 
analysis on Coomassie gel. The remaining supernatant was then spun for 
10 minutes at 2,000rpm at room temperature. The supernatant was 
discarded and the pellet was snap frozen in liquid nitrogen and stored at - 
80°C until purification. All baculovirus waste was mixed with 2% Trigene and 
then discarded after 24 hours, whilst plasticware was autoclaved immediately 
after use.
2.2.10 Purification of His-tagged proteins from baculovirus infected cells
Each cell pellet prepared as described in section 2.2.9 was 
resuspended in 3ml lysis buffer (10mM Tris pH 7.5, 100mM NaCI, 1mM DTT, 
protease inhibitor cocktail). Cells were then lysed by sonication with a large 
sonicator probe in short bursts. Lysed material was pelleted at 45, 000 rpm 
at 4°C for 15 minutes. Nickel-NTA beads were washed 3 times in IMAC5 
buffer (see section 2.2.7 for details of IMAC buffers) and Sf9 supenatant was 
subsequently incubated with the beads at 4°C for 2 hours. 50pl samples of 
sonicated material and supernatant were removed for analysis on a 
coomassie gel. The pellet was resuspended in 2ml 1X sample buffer and 
50pl removed for analysis on a gel. Beads were pelleted at 1500rpm for 2 
minutes, 50pl of unbound material kept for analysis and then beads were 
washed 4 times with IMAC20 and then eluted in 3 times in 1ml IMAC200
each time. 50pl samples of the eluate and beads were removed and then
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the eluate was dialysed overnight at 4°C against 50mM Tris/HCI pH 7.2, 
100mM NaCI, 1mM DTT. The various stages of the prep were analysed by 
SDS-PAGE gel electrophoresis and coomassie stain and the dialysed protein 
stock was aliquotted, snap frozen and stored at -80°C.
2.3 Cell Biology
2.3.1 Reagents
All cell culture reagents were obtained from Invitrogen unless 
otherwise stated. All plasticware used was from Corning Inc, Corning, NY, 
USA. All chemicals were from Sigma unless otherwise stated. Purified 
active heterodimeric human hepatocyte growth factor (HGF) was obtained 
from Genentech Inc. (San Francisco, CA, USA). Purified mouse EGF was 
obtained from J. Smith, Liverpool, UK.
The protease inhibitor Leupeptin was obtained from Sigma Aldrich and 
the vacuolar ATPase proton pump inhibitor Concanamycin (#344085) was 
obtained from Merck Biosciences, Whitehouse Station, NJ, USA. PIKfyve 
inhibitor was a kind gift of Kevin Shokat (UCSF, USA). GST-2xFYVE (Hrs) 
vector was a gift from Harald Stenmark (Gillooly et at., 2000) and was 
produced in bacteria and isolated with Glutathione Sepharose then 
biotinylated with Sulfo-NHS-LC-Biotin (Pierce, UK).
2.3.2 Cell culture
HeLa, HEK293A, and HEK293T were cultured in a humidified 5% CO2
atmosphere at 37°C in Dulbecco’s Modified Eagle’s Medium (DMEM),
supplemented with 10% FBS, 1% non-essential amino acids, and 1%
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penicillin/streptomycin sulphate. Cells were maintained by growing to 
confluence in 100mm dishes before being split at 1:5 dilution every 2-3 days 
as appropriate.
For most biochemical assays and transfections, cells were seeded in 
either 100mm or 60mm diameter dishes, or in 6-well plates at a density such 
that they would be approximately 80% confluent at the onset of the 
experiment. For immunofluorescence studies cells were seeded at a lower 
density in 6-well plates on 22mm x 22mm coverslips or in 12-well plates on 
19mm diameter coverslips (Scientific Laboratory Supplies, Nottingham, UK).
2.3.3 Culture of HeLaM CD8-ciM6PR and CD8-Furin cell lines
CD8-ciM6PR-HeLaM and CD8-Furin HeLaM cells (a generous gift of 
Dr Matthew Seaman, Cambridge Research Institute) are a stably transfected 
cell line expressing chimeras of the luminal domain of CD8 fused to the with 
the cytoplasmic tail of the CIMPR and Furin (Seaman, 2004). For 
maintenance, cells were grown in HeLa medium supplemented with 
0.5mg/ml G418.
2.3.4 Transfection of tissue culture cells
Cells were usually seeded at a density such that they would be 
approximately 50% confluent at the time of transfection. Cells were routinely 
transfected with GeneJuice (#70967, Merck Biosciences) at a ratio of 3pl 
transfection reagent to 1pg DNA according to the manufacturer’s instructions.
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2.3.5 Immunofluorescence
Cells grown on coverslips were fixed immediately after each 
experiment (or following a 5 minute incubation in 0.05% Saponin in PBS to 
remove cytosolic staining) by a 15-minute incubation in 3% 
paraformaldehyde (PFA) (TAAB, UK) in PBS. Residual PFA was quenched 
by a 20 minute incubation in 50mM NH4CI in PBS and then cells were 
permeabilised by a 5 minute incubation in 0.2% Triton-X-100 in PBS (except 
where cells were treated with saponin prior to fixation). Alternatively, cells 
were fixed in 100% methanol for 10 minutes at -20°C. Cells were then 
blocked by incubation in 10% goat serum/PBS or 0.2% fish skin gelatin/PBS 
for at least 30 minutes. Coverslips were incubated for 20 minutes with 
specific primary antibodies diluted in 5% goat serum/PBS or 0.2% 
gelatin/PBS. Following extensive washing, coverslips were then incubated for 
20 minutes with secondary antibodies diluted in 5% goat serum/PBS or 0.2% 
gelatin/PBS. After further washing coverslips were mounted on glass 
microscope slides (Scientific laboratory supplies, Nottingham, UK) using a 
mounting medium containing Mowiol® 4-88 (#475904, Merck Biosciences) 
and where necessary a DAPI stain. Cells were then observed on a SP2 
AOBS (Leica; HCX PL APO CS 63.0 x 1.4 oil objective) confocal microscope. 
For experiments using Biotinylated GST-2xFYVE protein, cells were 
permeabilised in 20pM digitonin in 80mM Pipes pH 6.7, 1mM MgCI2, 5mM 
EGTA, and blocked in 10% BSA/20pM digitonin-Pipes. Subsequent antibody 
incubations were in 5% BSA/20pM digitonin-Pipes, and washes in Pipes 
buffer.
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2.3.6 Growth factor stimulation and cell lysis
Cells were serum-starved for 16 hours in serum-free DMEM and 
subsequently stimulated for the required time periods with approximately 
100ng/ml HGF/SF or 100ng/ml EGF. Where used, PIKfÿve inhibitor was also 
present throughout the period of growth factor stimulation. Following this, the 
cells underwent three washes with ice-cold PBS and were then lysed for 10 
minutes on ice in lysis buffer (0.5% Nonidet P40 (NP-40, Merck Biosciences), 
25mM Tris-HCI pH7.5, 100mM NaCI, 50mM NaF) supplemented with 
mammalian protease inhibitor cocktail (#P8340, Sigma) and phosphatase 
inhibitor cocktail II (#P8340, Sigma). Lysates were pre-cleared by 
centrifugation at 21000 x g and the protein yield determined as described in 
section 2.2.5. Alternatively, cells were lysed in 1X sample buffer containing 
2-mecaptoethanol or DTT, or in hot SDS lysis buffer (1% SDS, 50mM NaF, 
1mM EDTA) at 110°C for 10 minutes with intermittent vortexing.
2.3.7 RNA interference
Cells were seeded at 5.88 x 105 per 60mm diameter dish in full HeLa
medium and allowed to adhere overnight. Immediately before transfection,
the HeLa medium was replaced with DMEM containing no serum and no
antibiotics. Cells were then transfected with short interfering RNA (siRNA)
oligonucleotides using the oligofectamine transfection reagent (#12252-01,
Invitrogen) according to the manufacturer’s protocol. On-Target Plus
SMARTpool and deconvoluted duplex siRNA oligonucleotides (oligos) were
obtained from Dharmacon Inc., Lafayette, CO, USA. For each knockdown
40nM oligos were used. Initially, pooled oligos were used for knockdown, but
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once knockdown efficiency had been determined oligo pools were 
deconvoluted and individual specific oligos were used for each protein. For 
details of the specific siRNA oligos used for each protein see table 2.12. A 
non-specific control VII (# D-0012G6-07020) RNA duplex was also purchased 
from Dharmacon (sense 5’-ACUCUAUCGCCAGCGUGACUU-3’; a n t i s e n 
s e 5 ’ -PGUCACGCUGGCGAUAGAGUUU-3’). Four hours after transfection 
serum was added to the medium to a final concentration of 10%. A two-hit 
protocol was used in each case, in which, after 24h transfection, cells were 
trypsinised and reseeded, allowed to adhere overnight and then transfected 
for a further 24h with a second hit of RdEhiMOaitigdsarneter 
dishes and 6-well plates the number of cells and amount of siRNA used was 
scaled up or down appropriately.
Table 2.12. Pooled and individual deconvoluted oligos used in this 
study
Protein target Accession number Pooled oligo number
PIKfyve NM_015040 #L-005058-00-0005
Vac14 NM_018052 #L-015729-00-0005
WIPI-2 NM015610 #L-020521 -01-0005
WIPI-1 NM 017983 #L-018205-01-0005
Fig4 NM_014845 #L-019141-00-0005
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Protein target 
(Oligo number)
Sense Antisense
PIKfyve
(J-005058-13)
5’-GGCACAAGCUAUAGCAAUUUU-3’ 5'-PAAUUGCUAUAGCUUGUGCCUU-3 '
Vac 14
(J-015729-08)
5’-GGUCAGAGGCCCUUUCAUCUU-3 ' 5’-PGAUGAAAGG GCCUCUGACCUU-3’
W IPI-1 siGenome  
(D -0 1 8205-03-0005)
5-CCUAUAAUCUUGUG CCG UG-3’
W IP I-2
(J-020521-09)
5’-CGACAGUCCUUUAG CGGCAUU-3’ 5’-PUGCCGCUAAAGGACUGUCGUU-3’
W IP I-2
(J-020521-12)
5’-G GACCGGGUACUUCGGGAAUU-3’ 5’-PUUCCCG AAGUACCCG GUCCUU-3 '
ULK-1 siGenome  
(D -005049-01 -0005)
5’-CCUAAAACGUGUCUUAUUU-3’
Beclin
(specially designed)
5’-G ACGUGGAAAAGAACCGCAUU-3’ 5’-UGCGGUUCUUUUCCACGUCUU-3’
2.3.8 Immunoprécipitation
Immunoprécipitation was performed by incubating 750pg lysed protein 
with end-over-end rotation with 5pl GFP or HA antibody and 30pl protein G- 
agarose (#P4691, Sigma) for 2 hours at 4°C. Resultant immunoprecipitates 
were washed three times in wash buffer containing 0.1% NP-40, 25mM Tris- 
HCI pH7.5 and 150mM NaCI and then once in 10mM Tris pH7.5 to remove 
detergent, before preparation for SDS-PAGE by adding 30pl 1.5x sample 
buffer.
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2.3.9 Transmission Electron Microscopy
Cells were washed three times with ice-cold PBS++ (supplemented 
with 0.1M CaCI2 and MgCI2) and then fixed in 4% PFA/2.5% glutaraldehyde 
for 30 minutes on ice. Cells were then washed again in PBS and then post­
fixed in 1% Osmium tetroxide (0s04) in distilled water on ice in the dark for 1 
hour. Subsequently, the cells were washed three times in PBS, and then 
twice in distilled water for 30 minutes each time, followed by incubation in 5% 
Uranly acetate in 30% ethanol for 1 hour. Samples were dehydrated by 
sequential 10 minute ethanol washes in 30%, 60%, 70%, 80% and then twice 
in 100% ethanol, then infiltrated with a 1:1 ratio of resin to 100% ethanol for 
30 minutes. The infiltration resin was completely removed and 100% resin 
added to the samples. 100% resin was added to several resin moulds, which 
were placed face down on top the cell sample. Samples were polymerised at 
60°C for 2-3 days.
2.3.10 HRP uptake experiments
Cells were incubated in 10mg/ml HRP (#P8375 Biozyme, South 
Wales, UK) in serum-free medium at 37°C for 10 minutes, 1 hour or 4 hours. 
Subsequently, cells were washed 3 times in ice-cold PBS++ and then fixed in 
0.5% glutaraldehyde for 30 minutes. At room temperature cells were then 
washed 3 times in 0.1M Tris-CI pH 7.6. Following this cells were incubated 
for 10 minutes in 0.1% diaminobenzidine (DAB, Sigma) in Tris buffer and 
then for 10 minutes in 0.1% DAB and 0.01% H202 in Tris buffer at room 
temperature in the dark. The reaction was terminated by washing 3 times,
for 5 minutes each, in Tris buffer, and then 2 times, for 5 minutes each, in
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PBS. Cells were post-fixed in 1% 0s04 in 0.1 M phosphate buffer pH 7.4 for 
1 hour in the dark on ice and then processed for EPON embedding and EM 
as described from the post-fixation stage in section 2.3.9.
2.3.11 CD8 uptake assay
CD8-CIMPR or CD8-Furin cells were seeded onto coverslips and 
treated with siRNA as described in section 2.3.7 or with 800nM PIKfyve 
inhibitor for 4 hours. Subsequently coverslips were transferred to a well 
containing 3ml ice-cold DHB (serum-free DMEM containing 25mM Hepes 
and 0.2% fatty-acid free BSA (Fraction V, Sigma) for 15 minutes on ice. 
They were then incubated face down on a 100pl spot of DHB containing 
1pg/pl monoclonal anti-CD8 antibody (courtesy of Matthew Seaman, 
Cambridge Research Institute) for 1 hour on ice in the dark. Following this 
the coverslips were washed twice in ice cold PBS and transferred back into 
pre-warmed growth medium for the required time period. Cells were then 
fixed and processed for immunofluorescence as described in section 2.3.5.
2.3.12 Shiga toxin assay
Cy3-STxB was a kind gift from Francis Barr, University of Liverpool. 
HeLa cells were seeded onto coverslips and treated with siRNA as described 
in section 2.3.7 or with 800nM PIKfyve inhibitor for 4 hours. Subsequently 
coverslips were incubated on ice for 30 minutes with 2pg/ml Cy3-STxB in 
uptake medium (DHB - as described in section 2.3.11). Coverslips were then 
washed in 1X PBS and transferred to normal growth medium for the required
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timepoints at 37°C, 5% CO2. Subsequently, cells were fixed and processed 
for immunofluorescence as described in section 2.3.5.
2.3.13 Acidification assays
Acridine Orange was added to cells in full growth medium at a 
concentration of 5pg/pl for 10 minutes. Cells were subsequently washed in 
1X PBS and mounted onto slides in PBS for live imaging. As a control cells 
were treated with 100nM concanamycin for 1 hour prior to treatment with 
Acridine Orange. Lysotracker red was added to medium at 100nM for 120 
minutes prior to fixation and processing for immunofluorescence.
2.4 Yeast two-hybrid assay
2.4.1 Reagents
pACT2 and pFBT9 vectors were kind gifts from Francis Barr 
(University of Liverpool, UK). The yeast two-hybrid host strain PJ69-4A 
(MATa trp1 -901 leu2-3, 112 ura3-52, his3-200 gal4A gal80A LYS2::GAL1- 
HIS3 GAL2-ADE2 met2::GAL7-lacZ) was used as the bait strain for all Y2H 
experiments (provided by Phil James, University of Wisconsin, USA). PJ69- 
4A carries three independent GAL4-responsive reporter genes (GAL1-HIS3, 
GAL2-ADE2 and GAL7-lacZ). The PJ69-4A strain was developed to provide 
a suitable mating partner with identical genotype to PJ69-4A resulting in the 
yeast strain PJ69-4_ (provided by Phil James). PJ69-4_ was used as the 
prey strain for all Y2H experiments. Taq polymerase, Yeast Extract and 
Peptone 140 (#30392-021) were from Invitrogen/Gibco (Paisley, UK).
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Lithium acetate (LiOAc), PEG3350, Sodium hydroxide, salmon testes DNA 
and all amino acids were from Sigma Aldrich (Poole, UK). Glucose 
(#GLU03) and yeast nitrogen base (#CYN0410 without amino acids) were 
from Formedium (Hunstanton, UK). Agar (#400-050) was from Biogene 
(Cambridge, UK). Casamino acids (#228-830) were from DIFCO (Voigt 
Global Distribution, Kansas, USA).
2.4.2 Yeast transformations
Vac14, WIPI-2 and Fig4 were subcloned into pACT2 (prey vector -  
DNA activation domain) and pFBT9 (bait vector - DNA binding domain). 2ml 
YPAD medium (for recipes see Table 2.15) was inoculated with PJ69-4A 
Mat-a (bait) or complimentary mating-type switched Mat-a (prey) yeast cells 
and grown overnight at 30°C with shaking at 200rpm. The following morning 
8ml of YPAD medium was added to the cells and they continued to be 
incubated for a further 5 hours. The cell culture was spun at 2,300 rpm for 5 
minutes and the supernatant discarded. The cell pellet was resuspended in 
5ml 100mM LiOAc. 1.5ml of this resuspension was removed and centrifuged 
at 2,300rpm for 5 minutes. The supernatant was discarded once again and 
then the pellet was resuspended in the mixture in table 2.13.
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Table 2.13. Typical reaction for transformation of yeast with miniprep 
DNA
Ingredient Volume
50% (v/v) PEG3350 185pl
1M LiOAc 28pl
Distilled H2O 36pl
Denatured salmon testes DNA 7pl
Miniprep DNA of interest 1 pi
Total 350pl
The samples were cycled in a PCR machine as follows:
30°C for 30 minutes 
42°C for 25 minutes 
30°C for 1 minute
The resulting mixture was plated onto SD (synthetic defined) agar plates 
lacking in tryptophan and low in adenine (for bait constructs) and in leucine 
(for prey constructs) and grown for 3 days at 30°C. Colonies were checked 
by PCR using primers specific to the insert. A typical yeast colony PCR is 
outlined in table 2.14.
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Table 2.14. Yeast colony PCR (reaction mixture per colony)
Ingrédient Volume
F primer (10mM) 0.75pl
R primer (10mM) 0.75pl
dNTPs 0.45pl
Taq polymerase buffer 1.5pl
MgCI2 0.75pl
Taq polymerase 0.15pl
DMSO 0.3pl
H20 7.35pl
Total 12pl
Yeast colonies were resuspended in 3pl 0.02M sodium hydroxide for 
lysis and then added to 12pl of PCR mastermix. PCR reactions were cycled 
as follows:
95°C for 5 minutes 
95°C for 1 minute
Annealing temperature of primer -5°C for 1 minute I  35 cycles 
72°C for 3 minutes 30 seconds J
72°C for 5 minutes
The same yeast colony was also added to 20pl of water and 
subsequently spotted onto selective agar plates and grown at 30°C for 5 
days to test the autoactivation of the constructs. A pool of glycerol stocks of 
colonies that do not autoactivate was made
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Table 2.15. Recipes for yeast media
YPAD (500ml) SD-X (500ml)
10g Glucose 10g Glucose
10g Peptone 3.35g Yeast Nitrogen Base
5g Yeast Extract Appropriate amount of amino
0.05g Adenine acid X
10g Agar (For solid medium) 10g Agar (For solid medium)
SD + Casamino acids + ura + high ade
10g Glucose
3.35g Yeast Nitrogen Base 
7g Casamino acids 
0.01g Uracil 
0.05g Adenine
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Table 2.16. Selective media/agar
Name Description Use
YPAD Nutrient rich yeast 
medium/agar
Growth of yeast
SD-W Synthetic defined medium 
deficient in Tryptophan
Bait selection
SD-L Deficient in Leucine Prey selection
SD-WH
Deficient in Tryptophan and 
Histidine
Testing for autoactivation of bait 
constructs (Increased stringency)
SD-LH Deficient in Leucine and 
Histidine
Testing for autoactivation of prey 
constructs (Increased stringency)
SD-
WHAT
Deficient in Tryptophan and 
Histidine 3-amino-1,2,4-triazole 
(3-AT)
Testing for autoactivation of bait 
constructs (increased stringency)
SD-LHAT
Deficient in Leucine and 
Histidine 3-AT
Testing for autoactivation of prey 
constructs (Increased stringency)
SD-WA Deficient in Tryptophan and Testing for autoactivation of bait
Adenine constructs (most stringent)
SD-LA Deficient in Leucine and Testing for autoactivation of prey
Adenine constructs (most stringent)
SD-WL Deficient in Tryptophan and Double selection, used to select
Leucine diploids after mating
SD-
WLHAT
Deficient in Tryptophan and 
Leucine and Histidine 3-AT
Triple selection (less stringent), 
used for selecting interacting 
partners
SD-WAL
Deficient in Tryptophan, 
Adenine and Leucine
Triple selection, used for selecting 
interacting partners (most 
stringent)
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2.4.3 Yeast mating
Yeast glycerol stocks were spotted onto appropriate selective media 
and allowed to grow for 3 days at 30°C. Colonies were then resuspended in 
20pl water and 2pl of both bait and prey were spotted onto a YPAD plate on 
top of one another and allowed to grow overnight at 30°C. The following day 
growth was transferred onto selective media (-WL followed by -WLHAT and 
-WAL) using a sterilised velvet cloth. Plates were incubated at 30°C for 5 
days.
2.4.4 Beta-gal assay
As an alternative assay for interacting partners, this assay was used 
to assay the level of reporter construct transcription. To transfer diploid yeast 
growth onto filter paper it was laid on top of the growth and rubbed gently. 
The filter paper was then submerged in liquid nitrogen for 10 seconds to lyse 
the cells. After thawing the filter paper for 30 seconds, it was covered with B- 
gal reagent (6mls Z buffer (60mM Na2HP04, 40mM Na2H2PC>4, 10mM KCI, 
1mM MgS04) 1.6mg/ml X-Gal reagent, 11 pi B-mercaptoethanol), and 
checked for air bubbles. This was covered over and left at 37°C for 
approximately 5 hours; with colour change (white to blue indicating 
production of B-Gal) monitored and recorded every hour.
The theory underlying yeast two-hybrid assays is outlined in figure 2.2.
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Figure 2.2. Yeast two-hybrid assay.
The yeast two hybrid method developed by Fields and Song to detect 
protein-protein interactions. Genes of interest are cloned into bait and prey 
vectors which possess either a DNA binding domain or an activating 
domain, and the yeast genes for Tryptophan and Leucine, to confer growth 
on drop out medium. These are then transformed into living haploid yeast 
of two different mating types. The yeast are then mated and diploids are 
selected by growth on medium deficient in both Leucine and Tryptophan. If 
bait and prey proteins interact then the DNA and activating domain wil be 
brought into close proximity and bind the promoter of a reporter gene, thus 
driving its transcription. Interacting partners are selected by growth on a 
triple drop out medium also deficient in Adenine.
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2.5 Autophagy assays
2.5.1 LC3 lipidation assay
2GL9 cells (HEK293A cells stably transfected with GFP-LC3) were 
treated with siRNA as described in section 2.3.7 (except that 80nM oligos 
were used for each transfection), or with 800nM PIKfyve inhibitor for 4 hours. 
Cells were subsequently either ‘fed’ in normal growth medium, or starved in 
Earl’s Buffered Saline Solution (EBSS) for 2 hours. Cells were then lysed in 
80pl (for each well of a 12-well dish) 1X sample buffer. Prior to running on a 
gel 1mM DTT and 0.01% bromophenol blue was added to the samples. 
10pg each sample was run on a 12% 1.5mm Bis-Tris gel by SDS-PAGE. 
Proteins were transferred to nitrocellulose. Following transfer the membrane 
was incubated in Ponceau S for 5 minutes to monitor protein transfer, and 
then processed by Western blotting as described in section 2.2.3. GFP-LC3 
lipidation was examined using a polyclonal sheep GFP antibody (Ian Prior, 
University of Liverpool), and protein loading monitored using polyclonal anti­
tubulin antibody (Sigma, Poole, UK). The extent of lipidation was quantified 
using Odyssey software or Image J (Rasband, W.S., ImageJ, U. S. National 
Institutes of Health, Bethesda, _Maryland, USA, http://rsb.info.nih.gov/ij/, 
1997-2007) and a ratio of GFP-LC3II to total GFP-LC3 levels was 
determined.
2.5.2 LC3 II spot formation assay
2GL9 cells were seeded onto coverslips pre-treated with 0.1mg/ml 
poly-D-Lysine, and at the end of an experiment, cells were fed in normal
growth medium or starved in EBSS for 2 hours prior to fixation in 3%
113
Chapter Two: Materials and Methods
PFA/PBS and processing for immunofluorescence as described in section 
2.3.5. For detection of endogenous LC3 cells were fixed in ice-cold methanol 
for 10 minutes at -20°C and incubated with a monoclonal anti-LC3 antibody 
(Nanotools, Germany). Where used Wortmannin (Sigma, #W1628) was 
added to medium for 30 minutes at 100nM and Leupeptin (Millipore, UK) was 
added to cells with starvation medium at a concentration of 0.25mg/ml.
2.6 Antibody production
2.6.1 Antibody production
A custom antibody service provided by Covance was used to produce 
rabbit polyclonal antibodies against mVac14, hFig4 and hWIPI-2. mVac14 
(762 -782), hFig4 (891-907) and hWIPI-2 (430-454) (see Figure 3.1 for more 
details) were conjugated to Keyhole Limpet Haemocyanin (KLH) using M- 
Maleimideobenzoic acid N-hydroxy succinimide ester (MBS). MBS 
conjugates the amine group within lysine residues in KLH to the sulfhydryl 
group within cysteine residues of the target peptide. These were then used 
as antigens to immunise two New Zealand White Rabbits per peptide 
(UL 003 to UL 008) to account for biological variation. Immunogen was 
emulsified with Freund’s Complete Adjuvant (FCA) for initial injections. 
Freund’s Incomplete Adjuvant (FIA) was used for all subsequent injections 
(boosts). The immunisation schedule is shown in table 2.17, it followed a 
three-week cycle of boosts with test bleeds taken approximately 10 days 
after the boosts. The schedule was concluded with a terminal bleed yielding 
55-65ml. Upon arrival antibody bleeds were aliquotted under sterile 
conditions and stored at -20°C until required.
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Table 2.17. Covance immunisation schedule
Day Procedure
Day 0 Pre-bleed (PI) and 1st immunisation (ID/SC) (500^g with FCA)
Day 21 Boost (SC) (500|ag with FIA)
Day 42 Boost (SC) (250fxg with FIA)
Day 52 Test bleed (TB)
Day 63 Boost (SC) (250^g with FIA)
Day 73 Production bleed 1 (PB1)
Day 84 Boost (SC) (250|j,g with FIA)
Day 94 Production bleed 2 (PB2)
Day 105 Boost (SC) (250|utg with FIA)
Day 115 Production bleed 3 (PB3)
Day 118 Terminal bleed (EX)
2.6.2 SDS-PA GE modifications
HeLa cells were either transfected with GFP-hFig4, GFP-mVac14 or 
GFP-hWIPI-2, or were left untransfected, and then lysed 24 hours later. In 
order to test a single sample with different antisera, a single 8% gel was 
prepared with transfected protein and untransfected protein from the same 
samples loaded in alternate lanes. The concentration of the lysates was 
determined by protein assay as described in materials and methods, and 
then 30[xg was loaded onto an 8% SDS-PAGE gel. The material was
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subsequently transferred to nitrocellulose blot, cut into strips and each strip 
was probed with pre-immune serum and bleeds from each rabbit. The 
predicted molecular weight of each over-expressed and endogenous protein 
is shown in table 2.18.
Table 2.18. Predicted molecular weights of over-expressed and 
endogenous proteins (determined by ExPasy (http://us.expasv.org/cqi- 
bin/peptide-mass.pl).
Protein Over-expressed Endogenous
hFig4 130kDa 106.3kDa
hWIPI-2 76kDa 50kDa
mVac14 115kDa 88kDa
2.6.3 Affinity purification of Vac14 and WIPI-2 antibodies
Antibodies were affinity purified using a SulfoLink® Immobilization Kit 
for Peptides (Thermo Scientific, USA) according to the manufacturer’s 
instructions. 1mg peptide was used, and 2ml of the final bleeds of rabbits 
UL 003 and UL 008 were used.
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CHAPTER THREE
Characterisation of proteins associated with Ptdins(3,5)P2
metabolism
3.1 Introduction
Proteins that bind or synthesise phosphoinositides are key regulators 
of membrane traffic and signalling in eukaryotic cells. The precise function 
and localisation of one of the most recently discovered phosphoinositides, 
Ptdlns(3,5)P2, in mammalian cells is still poorly understood. Studies in S. 
cerevisiae identified four proteins associated with the metabolism of this lipid, 
for which mammalian homologues have been identified. As discussed in 
chapter one, these are the Ptdlns(3)P 5-kinase PIKfyve/Fab1 (Yamamoto et 
al., 1995; Shisheva etal., 1999), the PIKfyve activator Vac14 (Bonangelino et 
al., 2002; Sbrissa et al., 2004), the 5-phosphatase Fig4/Sac3 (Rudge etal., 
2004; Sbrissa et al., 2007), and a family of downstream effectors, dubbed the 
WIPI family (Atg18/Svp1 in yeast) (Dove etal., 2004; Jeffries et al., 2004; 
Proikas-Cezanne et al., 2004).
The vast majority of the mammalian literature has focused on the 
kinase PIKfyve, as its loss produces a similar dramatic phenotype to the 
yeast mutant; swollen cytoplasmic vacuoles (Rutherford et al., 2006). Much 
remains to be discovered about the other proteins Vac14, Fig4 and the WIPI 
family, in mammalian cells; their precise function, regulation, and relationship 
with one another and with the lipid. Previous studies have focused on a 
specific member of the mammalian WIPI family, WIPI-49 (also known as 
WIPI-1). For the purposes of this study WIPI-2 was chosen to complement
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the pre-existing literature on WIPI-1 (Jeffries et al., 2004; Proikas-Cezanne et 
at., 2004). As illustrated in section 1.8.1 the mammalian WIPI family is 
phylogenetically divided into two similar groups composed of WIPI-1 with 
WIPI-2, and WIPI-3 with WIPI-4 (Proikas-Cezanne etal., 2004). Both WIPI-1 
and WIPI-2 are equally closely related to the yeast protein Atg18/Svp1, 
whereas WIPI-3 and WIPI-4 are more closely related to the yeast protein 
HSV2. Thus, the development of tools and reagents to study WIPI-2 are 
particularly important, to assess any functional redundancy of these two 
proteins.
The aim of the work laid out in this chapter was to prepare an 
extensive range of tools and reagents in order to better study these proteins 
in the following ways: 1) To clone the open-reading frame for each protein 
into a range of different expression vectors. 2) To develop antibodies against 
each protein. 3) To determine the cellular localisation of each protein 
through examination of both overexpressed and endogenous protein. 4) To 
produce recombinant protein for ail three proteins. 5) To examine any 
interactions between the mammalian proteins and determine novel 
interacting partners.
3.2 Results
3.2.1 Generation of expression constructs
cDNA constructs for Vac14, WIPI-2 and Fig4 were generated as 
described in the materials and methods chapter. Each ORF was cloned into 
a range of expression constructs to enable study of these proteins in a
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variety of different contexts. Table 3.1 provides a summary of the constructs 
that were made and for what purpose.
Table 3.1 Summary of the cDNA constructs made from this study.
Plasmid name Use Expression tested by WB Comments
pEGFPC2-WIPI2 GFP tag WB, IF Yes (76kDa) 30-40%(t-e)*
pCMVmyc-WIPI2 myc tag WB, IF Yes (52.6kDa) 10%
pTrcHisC-WIPI2 Bacterialrecombinant protein Yes (52.6kDa)
Not
expressed
pAcHis-WIPI2 Baculovirus recombinant protein Yes (51.4kDa) Insoluble
pACT2-WIPI2 Directed Y2H screen (prey) No
pFBT9-WIPI2 Directed Y2FI screen (bait) No
pCMVmyc-WIPI-2
KDRES
Rescue siRNA 
phenotype Yes (52.6kDa)
Not affected 
by siRNA
pTrcHisC-
mVac14
Bacterial
recombinant protein Yes (91.6kDa)
Produces
protein
pAcG3X-mVac14 Baculovirus recombinant protein Yes (114kDa)
Not
expressed
pCMVHA-
mVac14 HA tag WB, IF, IP Yes (90.3kDa) 40-50%
PEGFPC2-
mVac14 GFP tag WB, IF Yes (115kDa) 40-50%
pACT2-mVac14 Directed Y2H screen No
pFBT9-mVac14 Directed Y2H screen No
pAcHis-hFig4 Baculovirus recombinant protein Yes (105kDa)
Not
expressed
pEGFPC2-hFig4 GFP tag WB, IF, IP Yes (130kDa) 5-10%
pCMVmyc-hFig4 myc tag WB, IF Yes(106.2kDa) 5%
pACT2-hFig4 Directed Y2H screen No
pFBT9-hFig4 Directed Y2H screen No
* t.e - transfection efficiency (assessed by immunofluorescence)
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3.2.2 Characterisation of antibodies against Fig4 by Western blotting
Antibodies were produced from two New Zealand White rabbits (as 
described in Materials and Methods) from the peptides shown in Figure 3.1, 
conjugated to KLH. In order for these antibodies to become useful tools they 
needed to be characterised for use in various methods and for their 
specificity against the target protein. Each bleed from the two rabbits for all 
three antibodies was characterised first by Western blotting, at a dilution of 
1:100 and compared to the pre-immune serum which should not contain any 
specific antibodies. A frozen aliquot of antibody was also tested to determine 
if freeze-thawing affected serum activity.
Fig4 serum from both rabbits was unable to detect overexpressed 
GFP-Fig4, which has a predicted molecular weight of approximately 130kDa 
(Figure 3.2; solid arrow), the expression of which was previously tested by 
Western blotting. Table 3.1 lists the overexpression constructs generated for 
this study; Western blotting and immunofluorescence were used to test the 
correct expression of full-length proteins and assess their transfection 
efficiency.
HEK293T cells were used to test Fig4 antibodies, to eliminate the 
possibility that transfection efficiency of overexpressed Fig4 or levels of 
endogenous protein were below the detection sensitivity of the antibody in 
HeLa cells. Some proteins are detected by this serum (Figure 3.2), and it is 
possible that one of these represents a low level of endogenous protein, as 
there are proteins at the correct molecular weight (106kDa; dashed arrow),
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Figure 3.1. Peptides used in the production of antisera.
Diagram illustrating the domain structures of hWIPI-2, hFig4 and 
mVac14 and the relative position of the peptide used for the 
production of antibodies. Each peptide is C terminal in location. 
The sequences are less than 30 amino acids in length; hence their 
conjugation to KLH facilitates immunisation.
Rabbit UL_006 . + . + - + - + - ♦ - +  GFP-hFig4
Figure 3.2. Determining the utility of an anti-Fig4 antibody by 
Western blotting.
HEK293T cells were either transfected with pEGFPC2-hFig4 (+) or left 
untransfected (-), lysed with hot lysis buffer after 24h, and 30pg lysates 
resolved on an 8% SDS-PAGE gel. Material was transferred to a 
nitrocellulose blot and probed with each bleed (PI = Pre-immune, TB = 
Test bleed, PB = Production bleed) from both rabbits (UL_005 and 
UL_006). An aliquot was snap frozen in liquid nitrogen and then thawed 
before use to ensure this did not adversely affect the activity of the serum. 
Serum from both rabbits does not detect overexpressed Fig4 (130kDa; 
solid arrow). It is unclear whether endogenous protein is detected or not 
(103.6kDa; dashed arrow)
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detected by several bleeds and not by the pre-immune serum.
In order to test the ability of this antibody to detect endogenous 
protein, pooled siRNA oligos designed to target Fig4 were used, to determine 
if any of these bands were ablated by knockdown of the protein. None of the 
proteins detected by Fig4 serum is suppressed by the siRNA oligos (figure 
3.3). It is possible, however, that the Fig4 oligos are ineffective in 
suppressing Fig4 protein. As such, RT-PCR was performed on HeLa cell 
lysates treated with Fig4 siRNA oligos, to establish that the messenger RNA 
levels were depleted. It is clear that these oligos are able to suppress Fig4 
messenger RNA levels (figure 3.4). Although this does not always 
correspond to a loss in protein, the evidence suggests that this antibody is 
unable to detect Fig4 protein.
3.2.3 Characterisation of antibodies against Vac14 by Western blotting
All bleeds for both rabbits of Vac14 serum were able to detect 
overexpressed Vac14 protein (GFP-Vac14; 115kDa; solid arrow) and the 
serum is still active following snap freezing (Figure 3.5). Rabbit UL 008 
appears to be more sensitive and detects several bands at approximately the 
correct molecular weight (88kDa; dashed arrow) for endogenous Vac14. To 
be certain that these proteins correspond to endogenous Vac14, pooled 
Vac14 siRNA oligos were used (Figure 3.6). A protein of the correct 
molecular weight is substantially suppressed by Vac14 siRNA oligos at both 
48 and 72 hours of transfection and a range of oligo concentrations.
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Scr7 Mock No Fig4 Scr7 Mock No Fig4 
adds, oligo adds, oligo
48h hour knockdown 72h hour knockdown
Figure 3.3. Fig4 serum is unable to detect endogenous Fig4 protein.
HeLa cells were seeded onto 6-well plates and transfected with 100nM 
Dharmacon On-Target Plus SMARTpool™ Fig4 oligos for 48 and 72h. 
Cells were lysed in NP40 lysis buffer and 60pg lysates resolved on an 8% 
SDS-PAGE gel. Both no treatment (mock), no oligo (no adds.) and 
scrambled oligo (100nM) (Scr7) controls were also performed. Protein 
was transferred to nitrocellulose and probed with anti-Fig4 serum (PB3, 
UL_006, 1:100) and anti-tubulin to control for protein loading. Fig4 oligos 
do not affect any of the proteins detected by Fig4 serum.
1.2
> 0.8OJ
E 0.6
.14—»-2 a; cc 0.4
0.2  -
0
£#|M» « #§ 1
Mock Oligo 1 Oligo2 Oligo3 Oligo 4 Pool
Figure 3.4. Fig4 siRNA oligos effectively reduce mRNA levels of Fig4 .
HeLa cells were treated with 40nM individual and pooled siRNA oligos 
against Fig4 for 72 hours. Cells were then trypsinised, pelleted and RNA 
was extracted from the cell pellet. The RNA was reverse transcribed into 
cDNA and this was quantified by qPCR to determine the relative levels of 
mRNA in each sample compared to control cells. See materials and 
methods for details. Every oligo affects Fig4 mRNA levels to some extent, 
both the pooled oligo (used in this study) and oligo 2 give the most 
significant reduction in mRNA levels.
Rabbit UL.007 + - + -  + -  + - + - +  GFP-mVae14
Rabbit UL_008 - + -  + . +  . +  - + .  + GFP-mVac14
Figure 3.5. Determining the utility of anti-Vac14 antibody by Western 
blotting.
HeLa cells were either transfected with pEGFPC2-mVac14 (+) or left 
untransfected (-), lysed with hot lysis buffer after 24h, and 30|ig lysates 
loaded onto an 8% SDS-PAGE gel. Material was transferred to a 
nitrocellulose blot and probed with each bleed (PI = Pre-immune, TB = 
Test bleed, PB = Production bleed) from 2 rabbits (UL_007 and UL_008). 
An aliquot was snap frozen in liquid nitrogen and thawed before use to 
ensure this did not adversely affect the activity of the serum.
There is a clear band corresponding to the overexpressed protein in each 
bleed (GFP-Vac14; 115kDa; solid arrow). Rabbit 008 may also detect 
endogenous protein (88kDa; dashed arrow).
AFigure 3.6. Vac14 serum detects endogenous protein by Western 
blotting.
HeLa cells were seeded onto 6-well plates and transfected with 
Dharmacon On-Target Plus SMARTpool™ Vac14 oligos for 48 or 72h. 
Cells were lysed in NP40 lysis buffer and 60pg lysates resolved on a 10% 
SDS-PAGE gel. Both no treatment (Mock), no oligo (no adds.) and 
scrambled oligo (Scr7) controls were also performed. Proteins were 
transferred to nitrocellulose and probed with anti-Vac14 serum (PB3, 
UL_008, 1:100) and anti-tubulin to control for protein loading.
A) Cells were transfected with 100nM oligos for both 48h and 72h.
B) Cells were transfected with 100nM scrambled and an increasing 
amount of Vac14 oligo (as indicated) for 72h.
A clear band at the level of endogenous Vac14 (88kDa; solid arrows) is 
knocked down even after 48h, and to an even greater extent after 72h. 
Knockdown occurs even at the lowest concentration of oligo.
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3.2.4 Characterisation of antibodies against WIPI-2 by Western blotting
For WIPI-2 sera, rabbit UL_003 was able to detect overexpressed 
protein (GFP-WIPI-2; 76kDa; solid arrow) with increasing sensitivity across 
the bleeds, and still functioned after freeze-thawing. Rabbit UL 004 appears 
to detect a much weaker band at the correct molecular weight for 
overexpressed protein, suggesting that it has much lower sensitivity to rabbit 
UL 003. Conversely, rabbit UL_004 did detect some proteins at the correct 
molecular weight for endogenous protein (49kDa; dashed arrow) while rabbit 
UL 003 did not (Figure 3.7).
The terminal bleeds of each antibody were also tested at two different 
concentrations (Figure 3.8). These tests demonstrated that for WIPI-2 the 
terminal bleed of both rabbits were in fact able to detect overexpressed 
protein (solid arrow) and proteins at the correct molecular weight for 
endogenous WIPI-2 (dashed arrow), with rabbit UL 003 demonstrating 
higher sensitivity.
WIPI-2 serum is able to detect endogenous protein (Figure 3.9). A 
band corresponding to the correct molecular weight for endogenous WIPI-2 
is substantially knocked down after both 48 and 72 hours of transfection, and 
with a range of different oligo concentrations. The molecular weight of this 
band is slightly higher than expected, with an electrophoretic mobility of 
55kDa compared to the predicted 49kDa.
3.2.5 Affinity purification of Vac 14 and WIPI-2 antibodies
Although both Vac14 and WIPI-2 antibodies were able to detect 
endogenous proteins, there were numerous other proteins also detected by
128
Rabbit UL 003 + + + + GFP-hWIPI2
Rabbit UL_004 . + . + . +  . +  . + . + GFP-HWIPI2
Figure 3.7. Determining the utility of an anti-WIPI-2 antibody by 
Western blotting.
HeLa cells were either transfected with pEGFPC2-hWIPI2 (+) or left 
untransfected (-), lysed with hot lysis buffer after 24h, and 30pg lysates 
were loaded onto an 8% SDS-PAGE gel. Material was transferred to a 
nitrocellulose blot and probed with each bleed (PI = Pre-immune, TB = 
Test bleed, PB = Production bleed) from 2 rabbits (UL_003 and 
UL_004). An aliquot was snap frozen in liquid nitrogen then thawed 
before use ensure this did not adversely affect the activity of the serum. 
A band of the correct molecular weight is clearly visible for 
overexpressed WIPI2 in all bleeds of rabbit 003 (GFP-WIPI-2; 76kDa; 
solid arrow). Rabbit 004 detects many more non-specific bands and 
poorly detects overexpressed WIPI-2. It is unclear if either serum 
detects endogenous protein (49kDa; dashed arrow).
Rabbit UL 003 Rabbit UL 004
PI
1:100
EX
1:100
EX PI 
1:1000 1:100
EX EX
1:100 1:1000 anti-GFP
Rabbit UL 005 Rabbit UL 006
PI EX EX PI EX  EX
1:100 1:100 1:1000 1:100 1:100 1:1000 anti-GFP
Rabbit UL_007 Rabbit UL_008
PI EX EX PI EX EX
1:100 1:100 1:1000 1:100 1:100 1:1000 anfl-GFP
+ GFP-mVac14
Figure 3.8. Characterisation of the final bleed of each antibody by 
Western Blotting.
HeLa or HEK293T cells were either transfected with GFP-Vac14, Fig4 or 
WIPI2 (+) or left untransfected (-), lysed with hot lysis buffer after 24h, and 
30|ig lysates resolved on an 8% SDS-PAGE gel. Material was transferred to 
a nitrocellulose blot and probed with final exanguination bleed (EX) and 
pre-immune (PI) serum from both rabbits. The final lane was probed with an 
anti-GFP antibody to show the correct molecular weight of overexpressed 
proteins. All bleeds from both rabbits of WIPI-2 and Vac14 serum detect 
overexpressed protein (97kDa and 115kDa; solid arrows), and possibly pick 
up endogenous protein also (49kDa and 88kDa; dashed arrows). Anti-Fig4 
serum does not detect either overexpressed (solid arrow) or endogenous 
(dashed arrow) protein. GFP-Fig4 is correctly expressed as determined by 
anti-GFP blot (130kDa).
A 168 —  116 —  
97 —
66
66
42
34
66
'*WM> ' MW ’
IB: WIPI-2
IB: Tubulin
No WIPI-2
Scr7 Mock adds, oligo Scr7 
48h hour knockdown
Veh.
No WIPI-2 
adds, oligo
72h hour knockdown
Figure 3.9. WIPI-2 antibodies detect endogenous protein by Western 
blotting.
HeLa cells were seeded onto 6-well plates and transfected with 100nM 
Dharmacon On-Target Plus SMARTpool™ WIPI-2 oligos for 48 or 72h. 
Cells were lysed in NP40 lysis buffer and 60pg lysates loaded onto an 10% 
SDS-PAGE gel. Both no treatment (Mock), no oligo (no adds.) and 
scrambled oligo (Scr7) controls were also performed. Protein was 
transferred to nitrocellulose and probed with anti-WIPI-2 serum (EX, 
UL_003, 1:100) and anti-tubulin to control for protein loading.
A) Cells were transfected with 100nM oligos for both 48h and 72h.
B) Cells were transfected with 100nM scrambled oligo and an increasing 
amount of WIPI-2 oligo for 72h.
A band is visible just above the 55kDa marker (solid arrows), which 
corresponds to endogenous WIPI-2, that is partially knocked down after 48h, 
but more substantially knocked down after 72h. This band is knocked down 
to some degree by all oligo concentrations.
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these sera. By reducing the concentration of the final bleed, it was possible 
to reduce the amount of background bands, but it was then difficult to 
visualise the endogenous protein. To increase the specificity of these 
antibodies they were affinity purified against the peptides used for 
immunisation and the resulting affinity purified antibodies were subsequently 
retested by Western blotting. Both antibodies retain the ability to detect both 
overexpressed and endogenous protein by Western blotting, and both have a 
far reduced number of non-specific bands (Figure 3.10). In the case of WIPI- 
2, the predominant protein detected is now that which is suppressed by 
treatement with siRNA oligos.
In order to optimise these antibodies for use, and minimise the 
background to signal ratio, the affinity purified antibodies were tested at a 
range of different concentrations, to find an optimal working dilution. Affinity 
purified WIPI-2 is able to detect endogenous WIPI-2 at each concentration to 
some extent, but with the highest sensitivity at 1:100 and 1:250. Vac14 
antibody is able to detect endogenous protein down to a dilution of 1:500 
(Figure 3.11). In order to reduce the amount of non-specific background and 
to conserve antibody stocks WIPI-2 and Vac14 antibodies were typically 
used at a dilution between 1:250 and 1:500 (see table 3.2 for a summary).
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Figure 3.10. Specificity of affinity purified Vac14 and WIPI-2 antibodies 
for Western blotting.
HeLa cells were transfected with GFP-Vac14 and myc-WIPI-2 and lysates 
run next to untransfected controls on an SDS-PAGE gel. Proteins were 
transferred to nitrocellulose and probed with affinity purified antibodies to 
test their efficacy at specifically detecting endogenous and overexpressed 
Vac14 and WIPI-2. Both antibodies are still able to detect overexpressed 
and endogenous protein and detect far fewer non-specific proteins following 
affinity purification. Arrows mark the position of endogenous (dashed arrow) 
and overexpressed (solid arrow) proteins.
1:100 1:250 1:500 1:1000 
IB: WIPI-2
Figure 3.11. Determining the optimal working dilution of affinity 
purified antibodies for Western blotting.
HeLa cell lysates were resolved on a 10% SDS-PAGE gel. Proteins were 
transferred to nitrocellulose, and the blot was subsequently cut into one lane 
strips and probed with different concentrations of WIPI-2 and Vac14 
antibodies, to determine the optimal working concentration for Western 
blotting. Solid arrows mark the position of endogenous protein.
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Table 3.2. Summary of conditions for use of characterised antibodies
Antibody Bleed Dilution
Rabbit anti-Vac14 Production Bleed 3 1:100
UL_008
Affinity purified 1:250-1:500 (WB and IF)
Rabbit anti-WIPI-2 Final bleed UL_003 1:100
Affinity purified 1:250-1:500 (WB and IF)
3.2.6 Localisation of overexpressed proteins
In order to better understand the function of proteins associated with 
Ptdlns(3,5)P2 metabolism, it is essential to determine their intracellular 
localisation and thus their most likely sites of action. Each protein was 
cloned into a GFP tagged vector in order to determine the cellular localisation 
of the overexpressed protein in hPdLathr®Ellsoverexpressed 
proteins localise predominantly to the cytoplasm (Figure 3.12). However, for 
both GFP-mVac14 and GFP-hWIPI-2 an underlying punctate stain can be 
observed in a proportion of cells (approximately 20%). This punctate stain is 
more clearly revealed upon permeabilisation with saponin prior to fixation.
It has been suggested that Vac14, Fig4 and PIKfyve may all form part 
of a single protein complex (Sbrissa et a/., 2007). In fact Vac14 and Fig4 
(Rudge et al., 2004) have been shown to interact with one another, as have 
Vac14 and PIKfyve (Sbrissa et al., 2004). More recently, an interaction 
between Vac14 and Svp1/Atg18 has been demonstrated (Tarassov et al., 
2008). It is therefore interesting to examine the colocalisation of each of 
these proteins, to see if they are found at a similar cellular localisation.
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Partial colocalisation of HA-mVac14 with both GFP-hWIPI-2 and GFP-hFig4 
was observed (figure 3.13). Although this is somewhat unsurprising given 
the cytosolic nature of the proteins, the majority of colocalisation between 
GFP-Vac14 and GFP-Fig4 concentrates at seemingly reticular areas of the 
cell.
3.2.7 Localisation of endogenous proteins
Due to the caveats of examining overexpressed protein it would also 
be prudent to examine the localisation of endogenous protein if possible, 
thus the immunofluorescent staining of WIPI-2 and Vac14 antibodies was 
studied (Figure 3.14 and 3.15). By examining the colocalisation between 
overexpressed protein and the staining obtained with the terminal bleed of 
the two rabbits for each serum, it is clear that both antibodies are able to 
detect overexpressed protein in HeLa cells by immunofluoresence. Leica 
image analysis software was used to produce an intensity-scatter plot of the 
amount of colocalisation in each field of cells. The greater the colocalisation 
between the two channels the less scatter on both axis. Both sera work well 
for immunofluorescence at a dilution of 1:100 and 1:1000 and when cells are 
fixed with paraformaldehyde and permeabilised with Triton X-100. The pre­
immune serum generates a much more random scatter plot than the 
antibodies, showing that it is not specifically detecting the overexpressed 
protein.
In order to improve the specificity of Vac14 and WIPI-2 antibodies, the 
sera were affinity purified. The affinity-purified serum was tested by 
immunofluorescence in HeLa cells, in both control cells and those treated
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GFP + 
HA-Vac14
GFP-Fig4
HA-Vac14
GFP-WIPI-2
HA-Vac14
GFP HA Merge
Figure 3.13. Overexpressed GFP-Fig4 and GFP-WIPI-2 partially 
colocalise with HA-Vac14.
HeLa cells were transfected with combinations of GFP-Fig4, GFP-WIPI-2 
and HA-Vac14 for 24h and then fixed in 3% PFA/PBS and permeabilised 
with 0.2% TX-100. Empty GFP vector was used as a control. Both 
GFP-WIPI-2 and GFP-Fig4 partially colocalise with HA-Vac14. The 
colocalisation between GFP-Fig4 and HA-Vac14 is concentrated around 
areas of reticular stain (as marked with an arrow). Scale bars represent 
20pm.
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Figure 3.14. Determining the utility of anti-Vac14 antibody for 
immunofluorescence.
HeLa cells were transfected with a pEGFPC2-mVac14 construct. 24h after 
transfection cells were fixed with 3%PFA/PBS, permeabilised with 0.2% 
Triton/PBS and stained with the terminal bleed of anti-Vac14 serum at 1:100 
and 1:1000. Secondary antibodies used were AlexaFluor594 donkey 
anti-rabbit. Cells were visualised on a Leica confocal microscope and a 
colocalisation scatter plot of each field of cells was produced using leica 
based software.
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Figure 3.15. Determining the utility of anti-WIPI-2 antibody by 
immunofluorescence.
HeLa cells were transfected with pEGFPC2-hWIPI-2. 24h after 
transfection cells were fixed with 3%PFA/PBS, permeabilised with 0.2% 
Triton/PBS and stained with the terminal bleed of anti-WIPI-2 serum at 
1:100 and 1:1000. Secondary antibodies used were AlexaFluor594 
donkey anti-rabbit. Cells were visualised on a Leica confocal microscope 
and a colocalisation scatter plot of each field of cells was produced using 
leica based software.
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with siRNA oligos. The cytosolic staining detected by both Vac14 and WIPI- 
2 antibodies is lost following siRNA knockdown of these proteins, suggesting 
that the endogenous protein is being detected, and that the cytosolic stain 
represents a pool of endogenous protein (Figure 3.16). The punctate 
structures observed with overexpressed proteins may be an artefact of 
overexpression, or the sensitivity of the antibodies may not be high enough 
to detect the endogenous protein on these structures.
3.2.8 Production of purified recombinant Vac14 protein
Another key tool for studying aspects of these proteins is to produce 
recombinant protein. Both bacterial and baculovirus expression systems 
were used to attempt to purify His-tagged Vac14, WIPI-2 and Fig4 (see 
materials and methods for details of expression and purification). Vac14 was 
purified in bacterial cells. One-shot BL21(DE3)pLysE chemically competent 
E. coli were transformed with pTrcHis-mVac14. Protein production was 
induced with 0.1 mM IPTG for 4 hours at 37°C (the optimum conditions for 
protein production were determined by testing a variety of temperatures, 
times and concentrations of IPTG). 50pl samples were taken from each 
stage of the purification procedure, and 5 or 10pl of each sample resolved on 
a 10% SDS-PAGE gel. This has been represented as the percentage input 
from the original sample in a Western blot of the various stages of protein 
purification, probed with anti-Vac14 antibody (Figure 3.17). It is clear that 
Vac14 protein production is induced, but there is ‘leaky’ expression of the 
protein by the promoter, as it also present in the uninduced sample. Note 
that less of the induced than uninduced input was loaded on the gel. This
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Figure 3.16. Specificity of WIPI-2 and Vac14 antibodies for 
immunofluorescence.
HeLa cells were fixed, permeabilised and stained with affinity purified 
antibodies against Vac14 and WIPI-2 in control cells and in cells treated 
with siRNA against the respective protein, to determine the specificity of 
immunofluoresent staining of the two antibodies. The majority of 
immunofluorescent stain is depleted following knockdown of the 
respective protein, suggesting the cytosolic staining is specific.
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Figure 3.17. Western blot analysis of the expression of HiS6-mVac14 
in BL21 bacterial cells.
His6-Vac14 protein production was induced with 0.1 mM IPTG at 37°C for 4 
hours and purified on Nickel-NTA beads.
A) Purification samples were analysed by 10% SDS-PAGE, transferred to 
nitrocellulose and stained with anti-Vac14 antibodies. Molecular weight of 
His-Vac14is 91.6kDa.
B) Hise-mVac14 protein and a gradient of BSA were run on a 10% 
SDS-PAGE gel and stained with Coomasie blue. The concentration of 
full-length HiS6-mVac14 is between 1 and 1.5pg/pJ.
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explains why there appears to be no induction of the protein. Protein is lost 
throughout the course of the purification procedure, with the bulk of protein 
being insoluble and thus left behind in the pellet fraction. A significant 
amount also remains bound to the Ni-NTA beads and there are some 
degradation products detectable after dialysis.
Purified Vac14 protein was compared to a BSA gradient and this 
shows that the concentration of full-length useable protein was between 1 
and 1.5pg/pl. It is interesting to note that degradation/truncation products are 
present in the final purified protein preparation when examined by 
Coomassie stain (3.17 B) but not by Western blot (3.17 A). As the antibody 
used for Western blotting (anti-Vac14) is directed against the C terminus of 
the protein, it is possible that it does not detect these products as they 
originate from the His-tagged N terminus, likewise if they represent truncation 
products. Alternatively, these bands could represent bacterial proteins that 
have adhered to the beads and are therefore not detected by a Vac14 
antibody.
3.2.9 Production of purified recombinant WIPI-2 protein
One of the key goals of obtaining purified proteins would be to 
examine all three proteins and their interactions with one another. The 
baculovirus system was used to produce both WIPI-2 and Fig4. Insect cells 
(Sf9) were transfected with pAcHis-hFig4 or pAcHis-hWIPI-2 along with 
baculovirus DNA (see materials and methods for details). For optimal 
production of protein the ratio of virus particles per cell, termed the 
multiplicity of infection (MOI), must also be optimal. Too low and
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asynchronous replication and premature cell lysis can lead to reduced and 
delayed protein production. Too high and the virus propagates too rapidly, 
leading to depletion of cellular metabolites before optimum protein production 
is achieved. It is therefore important to titrate the virus that is produced, to 
achieve the correct balance. For His6-WIPI-2 virus, this titration is shown in 
figure 3.18 A. The virus can be amplified by reinfection of Sf9 cells if 
necessary, to achieve a higher viral titre.
By coomassie stain the protein of interest was undetectable, thus I 
transferred the protein to nitrocellulose and probed with the anti-WIPI-2 
antibody to determine if protein was produced. From the viral titration it is 
clear that the lysis or recovery of lysed material was somewhat uneven as 
the protein levels fluctuate. Previous experience in the lab established that 
typically between 0.39 and 0.78pl per 5 x 104 cells usually resulted in a high 
level of protein production. Given that protein levels began to reduce from 
0.78pl and above, and that past experience had shown that lower amounts of 
virus did not produce optimal amounts of protein when scaled up despite 
indications from the titration, I chose to use 170pl of virus for 2 x 107 cells. 
This corresponds to 0.425pl of virus per 5 x 104 cells, a range in between the 
two optimum values.
Protein was purified in a similar manner to bacterial protein. The 
resultant purification steps for WIPI-2 are shown by Western blot in figure 
3.18 B. Although WIPI-2 protein was produced, the majority of protein was 
insoluble, potentially forming inclusion bodies. And the protein that was not 
insoluble subsequently dropped out of solution during the dialysis stage. 
Thus, no useable WIPI-2 protein was produced. Fig4 protein was also not
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Figure 3.18. HiS6-WIPI-2 recombinant protein production using the 
baculovirus system.
HiS6-WIPI-2 protein was produced using the baculovirus system from Sf9 
insect cells.
A) Titration of the amplified pAcHis-WIPI-2 virus (see materials and 
methods for details). The protein was undetectable by Coomasie stain, 
but once transferred to nitrocellulose and probed with anti-WIPI-2 antibody 
it could be clearly seen. The titration was used to determine the optimal 
viral concentration for protein production. Predicted molecular weight of 
HiS6-WIPI-2 is 51.4kDa.
B) Western blot analysis of the stages of HiS6-WIPI-2 protein production 
probed with anti-WIPI-2 antibody. Percentage input represents the 
amount of total material loaded onto gel. A substantial amount of protein 
is insoluble. The rest drops out of solution during dialysis.
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successfully produced using this system. In this case the initial titration of 
the virus, showed that recombinant Fig4 virus was not produced, this was 
judged by Coomassie stain and Western blotting with an anti-His antibody 
(not shown).
3.2.10 Interaction between Fig4 and Vac14 demonstrated by 
coimmunoprecipitation of overexpressed proteins
The final stage in characterisation of the three proteins was to 
examine any possible interactions between them. It had previously been 
reported that the yeast Vac14 and Fig4 interact with one another (Rudge et 
al., 2004), and I was able to confirm this finding in mammalian cells, both by 
coimmunoprecipitation (Figure 3.19), as also described recently in the 
literature (Sbrissa et al., 2007), and by yeast two-hybrid directed screen 
(Figure 3.21). It would be useful to also examine the coimmunoprecipitation 
of the endogenous proteins, however, this was not possible due to the 
unsuitability of the Fig4 antibody.
3.2.11 Overexpression of Vac 14 stabilises Fig4
It was also noted by examining coexpression of HA-Vac14 and GFP- 
Fig4 by Western blotting, that expression of HA-Vac14 stabilises the 
expression of GFP-Fig4 (Figure 3.20). Typically, the expression of GFP-Fig4 
in HeLa cells is very low, however, upon cotransfection with HA-Vac14 we 
see a clear band appear that corresponds to the correct molecular weight for 
GFP-Fig4. Equal protein loading in these two lanes was confirmed by
blotting with anti-tubulin antibodies. A similar observation was made in the
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Figure 3.19. Overexpressed GFP-Fig4 and HA-Vac14 
coimmunoprecipitate with one another.
HeLa cells were transfected with combinations of GFP-Fig4 and 
HA-Vac14 for 24h and then lysed in NP40 lysis buffer. 750ug protein 
was immunoprecipitated with the opposing primary antibody (either 
sheep polyclonal GFP or mouse monoclonal HA). IP and non-IP 
lysates were loaded onto an 8% SDS-PAGE gel, proteins were 
transferred to nitrocellulose and this was subsequently probed with 
anti-GFP or anti-HA antibodies. GFP-Fig4 is detected by an anti-HA 
antibody in the IP samples, and vice versa for HA-Vac14, indicating the 
two overexpressed proteins coimmunoprecipitate with one another.
Figure 3.20. HA-Vac14 stabilises GFP-Fig4.
HeLa cells were transfected with the constructs indicated and lysed 24 
hours later using NP40 lysis buffer. Cell lysates (60|jg) were resolved 
on an 8% SDS-PAGE gel and electrophoresed material was 
subsequently transferred to a nitrocellulose blot. The membrane was 
probed with monoclonal anti-GFP and monoclonal anti-HA antibodies. 
The final two lanes were separated from the rest of the blot and 
probed with anti-Fig4 polyclonal serum. Clear bands at the correct 
molecular weight for each over-expressed protein can be identified, 
except for GFP-Fig4 where no band is detected. However, upon 
coexpression with HA-mVac14 a distinct band corresponding to 
GFP-Fig4 is visible (arrow). This is not the case when the same 
material is probed with anti-Fig4 serum, no band is detected in either 
lane.
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literature by immunofluorescence of overexpressed Fig4 and Vac14 in Cos-7 
cells, the abundance of Fig4 vesicular structures increased when Fig4 and 
Vac14 were expressed together (Sbrissa et al., 2007). It was hoped that if 
coexpression with Vac14 could increase the stability of Fig4, then I might be 
able to see at least overexpressed protein with the anti-Fig4 antibody, and 
possibly even endogenous protein. This was found not to be the case. 
Perhaps the levels of overexpressed Fig4 produced are still below the 
detection threshold of the Fig4 antibody, or the C terminus of the protein, to 
which the antibody is directed, is degraded.
3.2.12 Interactions demonstrated by directed yeast-two hybrid screen
A directed yeast two-hybrid screen (Figure 3.21) reinforces the 
interaction between mammalian Fig4 and Vac14. This interaction is found 
when the proteins are in both bait and prey vectors, although it is stronger 
when Vac14 is in the prey vector and Fig4 in the bait vector. Interestingly, 
we also see an interaction between WIPI-1 and WIPI-2. Due to unavailability 
of the pACT2-WIPI-1 construct, I was unable to test this interaction in both 
directions. Interestingly, Vac14 is shown to interact with itself, suggesting 
that this protein may dimerise.
Yeast two-hybrid interactions were confirmed using a beta- 
galactosidase assay, to examine production of this enzyme. Interacting 
partners should reconstitute the DNA binding and activation domain of the 
lacZ gene and expression of beta-galactosidase. If this enzyme is produced 
then the reagent used in the assay should be turned blue. The interaction 
between Vac14 and Fig4 is confirmed by beta-galactosidase assay when the
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Figure 3.21. Directed yeast two-hybrid screen confirms interaction 
between mammalian Vac14 and Fig4.
A directed screen employing each protein in both bait and prey vectors 
was carried out through mating of mat-a and mat-oc PJ69-4A yeast. 
Mated yeast were plated on selection media of increasing stringency and 
growth was used to score the strength of interaction. Vac14 and Fig4 
interact with one another, WIPI-1 and WIPI-2 also interact, and Vac14 
interacts with itself.
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Figure 3.22. Beta-galactosidase assay confirms two-hybrid 
interactions.
Diploid yeast from the yeast two-hybrid screen were tested for 
beta-galactosidase enzyme activity. Strong development of blue colour 
confirms the interaction between Vac14 and Fig4 and Vac14 with itself. 
There is also weak enzyme activity for WIPI-2 and WIPI-1, and Vac14 
with WPI-1 and WIPI-2.
Chapter Three
interaction is strong, but not for the weaker interaction when the bait and prey 
constructs are swapped (Figure 3.22). The interactions between WIPI-1 and 
WIPI-2 and Vac14 and itself are also confirmed. There is also weak 
production of this enzyme in the interactions between Vac14 and both WIPI 
proteins, although this was not detected in the yeast-two hybrid assay itself.
3.3 Discussion
The work presented in this chapter set out to develop key tools to 
facilitate the study of mammalian Ptdlns(3,5)P2 through analysis of four 
proteins that regulate its metabolism and cellular functions. A range of 
mammalian expression vectors and yeast two-hybrid constructs were 
generated and used in recombinant protein production, localisation studies, 
and interaction analysis. Functional antibodies against WIPI-2 and Vac14 
were generated, that were able to detect both overexpressed and 
endogenous protein by Western blotting and immunofluorescence, to some 
extent. Given that there are no antibodies to these proteins commercially 
available, these are invaluable resources. They were utilised to great extent 
in this study in order to validate siRNA suppression of proteins (see chapter 
four), to examine protein localisation (this chapter), and in autophagy studies 
(see chapter six).
In this chapter I demonstrated that all three overexpressed proteins 
display a predominantly cytosolic stain, with a reticular pattern in the case of 
overexpressed Vac14, similar to that seen in Cos-7 cells (Sbrissa et al., 
2004), and an underlying punctate stain to some extent in all three. The
punctate staining of Fig4 is also reminiscent of that seen in Cos-7 cells
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(Sbrissa et al., 2007). None of these proteins are predicted to possess any 
transmembrane domains, thus the cytosolic staining is unsurprising. 
However, saponin permeabilisation revealed a weak underlying punctate 
stain in the case of Vac14 and WIPI-2, which may indicate that these 
proteins also have a transient association to membranes, potentially to the 
early endosomes where PIKfyve is found (Rutherford et al., 2006). The 
nature of the punctate compartments remains somewhat elusive, as the low 
levels of expression made colocalisation with other markers difficult. The 
yeast proteins have also been shown to display only weak membrane 
association (Guan et al., 2001). In the case of Fig4, this membrane 
association could be through binding of Vac14, as expression of Vac14 has 
been shown to increase the level of punctate staining of Fig4 (Sbrissa et al., 
2007). However, this was not found to be the case in this study when HA- 
Vac14 and GFP-Fig4 were coexpressed (Figure 3.11), although an 
accumulation of both proteins was found in areas of reticular staining.
The second important use of the tools generated in this chapter was 
analysis of direct interaction between Vac14, WIPI-2 and Fig4, producing 
some confirmatory and some novel data. Table 3.3 and figure 3.23 both 
illustrate the interactions demonstrated in this study in the context of the 
current literature. Using both biochemical means, in examining the 
coimmunoprecipitation of overexpressed Vac14 and Fig4, and the Yeast two- 
hybrid method, an interaction between Vac14 and Fig4 was confirmed. Our 
data, along with recently published data (Sbrissa et al., 2007) show clearly 
that the yeast interaction is conserved in higher organisms, suggesting that 
this is an important relationship between Vac14 and Fig4.
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Data from this study also show that overexpression of Vac14 
stabilises Fig4 in HeLa cells, further suggesting that the interaction between 
these two proteins may be important in a cellular context for the regulation of 
Fig4 activity. This interaction is particularly interesting because Vac14 has 
been shown to regulate the activity of the kinase (Rudge et al., 2004), as well 
as interacting with its counterpart phosphatase Fig4, suggesting that these 
three proteins may in fact form a single multiprotein complex to tightly 
regulate the levels of Ptdlns(3,5)P2. Recent data suggests that the yeast 
proteins may also form part of a common lipid kinase complex, and that Fab1 
interacts with both Vac14 and Fig4 through its chaperonin domain and the 
complex is recruited to the vacuole membrane through the Fab1 FYVE 
domain, where it regulates both synthesis and turnover of Ptdlns(3,5)P2 
(Botelho et al., 2008). It would therefore be interesting to dissect the 
interaction between the mammalian proteins to determine if the chaperonin 
domain is also important for this function.
The strongest interaction observed in the screen was between Vac14 
and itself. Interestingly, this was also found to be the case for the yeast 
proteins (Dove et al., 2002), strongly suggesting that this protein may 
dimerise, and that this has an evolutionarily conserved function for this 
protein.
Yeast two-hybrid analysis also identified an interaction between WIPI- 
1 and WIPI-2. Although this may indicate that the WIPI proteins dimerise, 
and that the similarity between the two proteins allows for heterodimerisation, 
at least for WIPI-2 no self-interaction was observed. Alternatively, the WIPI
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Figure 3.23. Interactions demonstrated in this study in the context of 
the literature on these proteins.
This diagram illustrates the interactions that have were demonstrated in 
this study in the context of other previously established data in the 
literature.
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proteins may have some as yet uncharacterised function that requires them 
to interact with one another. The similarity between the two proteins, and 
their relationship with the yeast proteins, suggests that there may be some 
redundancy in the function of these two proteins.
Table 3.3 Summary of known interactions and those demonstrated in
this study
Interaction Protein species Method Reference
Vac14 -  Fig4
Yeast and 
mammalian
ColP
Yeast two-hybrid
(Rudge et al., 
2004; Sbrissa et 
al., 2004; Sbrissa 
et al., 2007) 
This study
Vac14 -  PIKfyve Mammalian ColP
(Sbrissa et al., 
2004)
Fab1 -  
Atg18/Svp1
Yeast Yeast two-hybrid
(Georgakopoulos 
et al., 2001)
Vac14 -  
Atg18/Svp1
Yeast
Protein fragment 
complementation 
assay*
(Tarassov et al., 
2008)
WIPI-1 — WIPI-2 Mammalian Yeast two-hybrid This study
Vac14 -  Vac14
Yeast and 
mammalian
Yeast-two hybrid
This study 
(Dove et al., 
2002)
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* Note: In this assay two proteins of interest are fused to complementary 
fragments of a reporter protein. If the two proteins of interest interact, the 
reporter fragments are brought together and fold into their native structure, 
reconstituting the reporter activity of the PCA.
Production of recombinant proteins met with limited success. A 
useable amount of Vac14 protein was generated, which could therefore be 
used in future studies to examine the enzymatic activity of Vac14. The 
production of WIPI-2 could also be reassessed in the future to attempt to 
increase the solubility of this protein. However, I was unable to obtain any 
expression of Fig4 protein. Optimising protein production was not prioritised, 
as I was unable to do the enzymatic studies I had initially set out to do, to 
address the question of how Vac14 interacts with Fig4 and regulates its 
function in the cell, and assess the substrate specificity of Fig4.
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CHAPTER FOUR
The Role of PIKfyve in Regulating Retrograde Transport
Pathways
4.1 Introduction
Despite the fact that much of the machinery that regulates production, 
turnover and binding of Ptdlns(3,5)P2 has been uncovered, a complete 
understanding of its precise cellular function remains elusive. Its precursor 
Ptdlns(3)P is localised to the membranes of early endosomes and MVBs 
(Gillooly et ai, 2000), where it plays a role in early endosome fusion by 
recruitment of EEA-1 (Jones and Clague, 1995; Li etal., 1995; Mills et a/., 
1998; Simonsen etal., 1998), internalisation of ubiquitinated membrane 
receptors by recruitment of the ESCRT 0 protein Hrs (Urbe et al.t 2000; 
Raiborg et al., 2001; Raiborg et al., 2002), and formation of intralumenal 
vesicles (Fernandez-Borja etal., 1999; Futter etal., 2001).
Due to a lack of antibodies or bioreporters for Ptdlns(3,5)P2, its 
localisation has been inferred from that of the kinase PIKfyve/Fab1. Thus, it 
is proposed to localise predominantly to the membranes of early endosomes 
at steady state (Cabezas etal., 2006; Ikonomov etal., 2006; Rutherford et 
al., 2006), where it has been implicated in a number of endosomal functions. 
In S. cerevisiae, Fab1 mutants, devoid of Ptdlns(3,5)P2, display a range of 
different phenotypes, including a dramatically swollen vacuole that is 
improperly acidified (Rudge et al., 2004). Like Fab1, the mammalian kinase 
PIKfyve, is also essential for endosomal membrane homeostasis, and loss of 
this enzyme results in the progressive accumulation of cytoplasmic vacuoles
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(Ikonomov etal., 2001; Rutherford et al., 2006). One key question that 
remains to be answered is the origin of these vacuoles.
Given that MVBs in Ptdlns(3,5)P2 depleted cells contain fewer 
intralumenal vesicles, it has been argued that enlarged vacuoles may result 
from a defect in inward invagination of the limiting membrane of the MVB 
(Ikonomov etal., 2003a; Rudge et al., 2004). However, in S. cerevisiae Fab1 
mutant cells sorting of endocytosed cargo into MVBs is unaffected, and 
although sorting of biosynthetic cargo to the vacuole is blocked, this can be 
overcome by irreversible ubiquitination of the cargo (Odorizzi etal., 1998; 
Dove etal., 2002; Katzmann etal., 2004), suggesting that Fab1 more likely 
controls the sorting of certain proteins, rather than regulating the process of 
inward invagination. Likewise, in mammalian cells overexpressing a 
catalytically inactive mutant PIKfyve, swollen cytoplasmic vacuoles have 
been described as MVB-like structures with fewer internal vesicles. Although 
fluid phase endocytosis is perturbed, there is no defect in internalisation or 
degradation of epidermal growth factor receptor (EGFR) (Ikonomov et al., 
2003a). These data suggest that if there is in fact a defect in invagination in 
MVBs, this is most likely not the predominant mechanism contributing to 
vacuolation.
A second mechanism has been proposed that implicates PIKfyve in 
retrograde transport pathways from endosomes to the TGN, such that a 
defect in membrane retrieval on these pathways could also contribute to 
endomembrane enlargement (Rutherford etal., 2006). As discussed in detail 
in section 1.9, knockdown of PIKfyve causes a delay in retrieval of receptors 
such as ciM6PR and sortilin to the TGN from early endosomes (Rutherford et
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al., 2006). Furthermore, proteins associated with Ptdlns(3,5)P2 metabolism, 
such as the yeast protein Atg18/Svp1, one of its mammalian counterparts, 
WIPI-1, and the PIKfyve activator Vac14, have also been implicated in these 
trafficking pathways (Dove et al., 2004; Jeffries et al., 2004; Zhang étal., 
2007).
In the last chapter, tools for the further analysis of three proteins 
associated with Ptdlns(3,5)P2 metabolism were generated, and initial 
characterisation of the proteins performed. Other key methods of cell biology 
for characterisation of protein function are siRNA-mediated knockdown of the 
protein of interest, and use of specific small molecule inhibitors. In this 
chapter we chose to revisit the characterisation of cytoplasmic vacuoles 
following loss of PIKfyve, and examine the contribution of defective 
membrane retrieval to the TGN, with the specific aims being to:
1) Characterise the phenotypes induced by knockdown of Vac14, Fig4 and 
WIPI-2 by fluorescence and electron microscopy.
2) Contrast and compare the effects of PIKfyve knockdown (chronic loss) 
and loss of PIKfyve activity caused by treatment with PIKfyve inhibitor (acute 
loss).
3) Examine the effects of knockdown of Vac14, WIPI-2 and Fig4 and 
inhibition of PIKfyve acitivity on a variety of trafficking pathways between the 
TGN and the endocytic pathway.
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4.2 Results
4.2.1 Demonstrating effective suppression of endogenous proteins
A key aim of this chapter was to assess the knockdown phenotypes of 
each protein. Therefore, it was important to demonstrate effective 
knockdown by a range of oligos against each protein. Using previously 
characterised Vac14 and WIPI-2 antibodies (chapter three), and a 
generously gifted PIKfyve antibody, pooled oligos were deconvoluted to 
determine which individual oligos induced a significant level of protein 
suppression.
Pooled oligos against Vac14 and WIPI-2 were effective in substantially 
reducing the levels of endogenous protein (Figures 3.6 and 3.9), as were 
pooled PIKfyve oligos (Figure 4.1). For PIKfyve, oligos 3 and 4 produce 
substantial knockdown, and this was found to correspond to the oligos that 
produced cytoplasmic vacuoles. For Vac14, all four oligos gave effective 
knockdown, and in the case of WIPI-2, oligos 1 and 4 both effectively 
knocked down endogenous protein.
For all experiments pooled oligos were initially used. Observed 
phenotypes were then reconfirmed with oligo 4 for WIPI-2 and Vac14 and 
oligo 3 for PIKfyve. Although Fig4 oligos were deconvoluted by RT-PCR 
(Figure 3.4), Fig4 pooled oligos were used for all experiments, as the effects 
on protein levels could not be determined and the pool of oligos gave a 
substantial reduction in messenger RNA levels.
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Figure 4.1. Knockdown efficiency of pooled and individual oligos.
HeLa cells were treated with 40nM pooled and individual oligos against 
the indicated proteins for 72h. Cells were lysed in NP40 lysis buffer and 
run on SDS-PAGE gels, transferred to nitrocellulose and then probed with 
the indicated antibodies.
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4.2.2 Vacuole formation
In yeast, Fab1 mutants display a dramatically swollen vacuole (Rudge 
et al., 2004). It was previously shown that in mammalian cells, 
overexpression of a kinase-dead mutant or knockdown of PIKfyve 
reconstitutes this phenotype, causing an accumulation of swollen 
cytoplasmic vacuoles of unknown origin (Ikonomov et al., 2002a; Rutherford 
et al., 2006). This effect was confirmed in HeLa cells with the siRNA oligos 
used in this study (Figure 4.2 A). It was found that upon treatment of cells 
with PIKfyve siRNA, approximately 30% of cells developed swollen vacuoles.
When cells were treated with Vac14 siRNA only 3% of cells displayed 
swollen vacuoles. This is despite its role as an allosteric activator of PIKfyve, 
and in contrast to the S. cerevisiae Vac14 mutant phenotype that mimics that 
of Fab1, whilst the knockdown of the protein was clearly efficient (Figure 4.1). 
Interestingly, neither WIPI-2 nor Fig4 displayed any vacuolar phenotype, 
despite a high degree of knockdown in the case of WIPI-2. A combination of 
PIKfyve knockdown with knockdown of either Vac14 or Fig4 did not 
significantly alter the number of cells displaying a vacuolar phenotype. 
Inhibition of PIKfyve using MF4 also produced the same vacuolar phenotype, 
in nearly 100% of cells.
4.2.3 Vacuole characterisation
Loss of PIKfyve activity (by both siRNA treatment and inhibition) also 
caused formation of swollen endosomal compartments (Figure 4.2 B). This 
is examined in more detail in Figure 4.3. EEA-1 labelled early endosomes
164
Treatment % vacuoles
P IK fyve RNAi 30%
Vac 14 R N A i 3%
W IPI-2 R N A i 0%
F ig4  R N A i 0%
P IK fyve +  Vac 14 RN A i 28%
P IK fyve +  F ig4  R N A i 27%
V acl4  +  F ig4  RN A i 0%
P IK fyve inhibitor 90-100%
EEA-1 L A M P -2
Figure 4.2. PIKfyve knockdown and inhibition induces accumulation 
of swollen endosomal compartments and large cytoplasmic 
vacuoles.
HeLa cells were treated with 40nM PIKfyve siRNA oligos for 72h or 800nM 
MF4 or an inactive analogue for 4h prior to fixation in 3% PFA/PBS, 
permeabilisation with 0.2% TX-100 and staining with the respective 
antibodies. A) As with PIKfyve knockdown, its inhibition induces the 
accumulation of a heterogenous population of swollen cytoplasmic 
vacuoles. Table of penetrance of vacuole phenotype with different 
treatments. B) Loss of PIKfyve activity also causes an accumulation of 
swollen endosomal compartments. Enlgarged images of the boxed areas 
are displayed underneath the main panel. Scale bars represent 20pm.
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are dramatically swollen in comparison to control cells, and often aggregate 
around the larger cytoplasmic vacuoles from which the early endosomal 
marker is predominantly excluded. Late endosome/lysosome marker LAMP- 
2, on the other hand, is associated with the larger cytoplasmic vacuoles, as 
demonstrated by phase overlay, though it does not appear to uniformly label 
the limiting membrane, if at all. Initial images suggested that LAMP-2 veicles 
might be contained within the lumen of the large vacuoles. However, A Z- 
series taken through individual cells and projected into a 3D image using 
Leica imaging software demonstrate that LAMP-2 covers the surface of these 
large vacuoles but is predominantly excluded from the lumen. In fact, the 
lumen of the large vacuoles is empty for the most part (Figure 4.3 A). Early 
and late endosome compartments still remain distinct from one another, with 
very limited colocalisation, mostly at points surrounding the large vacuoles. 
Staining with anti-tubulin antibodies demonstrated that the microtubule 
network was intact following loss of PIKfyve activity, and that cytoplasmic 
vacuoles were sheathed in microtubules (Figure 4.3 B).
Vacuoles were examined by electron microscopy following treatment 
with PIKfyve inhibitor (Figure 4.3 C). The larger vacuoles are largely unable 
to take up fluid phase marker HRP even after 4 hours of internalisation, and 
are mostly empty, although occasionally contain one or two internal vesicles 
in a cross-section, which most likely correspond to LAMP-2 labelled vesicles 
observed by immunofluorescence. The vacuoles are surrounded by smaller 
HRP-labelled swollen compartments, which most likely correspond to the 
EEA-1 labelled structures observed by IF. Normal MVB compartments and 
lysosomes were also observed in these cells.
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A EEA-1 + LAMP-2EEA-1 /Phase overlay LAMP-2/Phase overlay projection
Figure 4.3. Cytoplasmic vacuoles are inaccessible to HRP and 
endosomal markers.
HeLa cells were treated with 800nM MF4 prior to A) fixation in 3% 
PFA/PBS, permeabilisation with 0.2% TX-100 and staining with the EEA-1 
and LAMP-2 (A) and a-tubulin (B) and C) uptake of HRP for 4 hours and 
fixation and processing for EM as described in materials and methods. 
The large vacuoles do not readily take up HRP. Smaller cytoplasmic 
vacuoles that are positive for HRP and contain some intralumenal vesicles 
are often found in close proximity to the large vacuoles, as can be seen in 
both EM and IF pictures. Large swollen vacuoles contain few, if any, 
internal vesicles. Scale bars represent 10pm.
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By inhibiting PIKfyve one mechanism of turnover of Ptdlns(3)P is 
prevented, therefore, we might expect to see an increase in the cellular 
levels of this lipid. However, this was found not to be the case (Jefferies et 
al., 2008). In order to be certain that MF4 was not also affecting the activity 
of the 3-kinase Vps34, the localisation of the tandem FYVE domain of Hrs, 
which binds to Ptdlns(3)P with high affinity, was examined. As expected, 
treatment with the PI3-kinase inhibitor wortmannin caused the loss of 
Ptdlns(3)P and EEA-1 positive punctae, however, treatment with PIKfyve 
inhibitor had no effect on either, except that both localised to more swollen 
compartments as previously demonstrated with EEA-1 (Figure 4.4).
siRNA treated cells were also examined by EM to compare cells 
treated with PIKfyve siRNA and inhibitor, and to determine if there were any 
ultrastructural changes following knockdown of WIPI-2, Vac14 and Fig4. In 
PIKfyve siRNA and to a much lesser extent, some Vac14 siRNA treated cells 
we can find cytoplasmic vacuoles, that display similar morphology to those 
seen upon PIKfyve inhibition (Figure 4.5). Once again, normal MVB and 
lysosome compartments were also observed in the same cells as 
cytoplasmic vacuoles. Neither Fig4 nor WIPI-2 knockdown produced any 
significant ultrastructural changes or perturbation in HRP uptake.
4.2.4 Loss of PIKfyve activity affects several endosome to TGN pathways
Previous work has indicated that Ptdlns(3,5)P2 may regulate 
endosome to TGN trafficking pathways (Ikonomov et ai, 2003b; Dove et ai, 
2004; Jeffries et ai, 2004; Rutherford et ai, 2006). Therefore, various
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Mock
Wortmannin
MF4
2x FYVE EEA-1 Merge
Figure 4.4. PIKfyve inhibitor treatment does not affect the localisation 
of Ptdlns(3)P or its subsequent recruitment of EEA-1.
HeLa cells were treated with 800nM MF4 for 4h or 100nM Wortmannin for 
30mins prior to fixation in 3% PFA/PBS, permeabilisation with Digitonin in 
PIPES-MTSB and staining with anti-EEA-1 antibodies and a biotinylated 
GST-tagged tandem FYVE protein. Unlike wortmannin treatment, 
inhibition of PIKfyve did not affect the localisation of the tandem FYVE 
domain protein, nor its colocalisation with EEA-1, suggesting that there is 
no effect on Ptdlns(3)P or its recruitment of effector proteins. Scale bars 
represent 20pm.
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Chapter Four
methods were employed to examine this pathway following knockdown of 
each protein or treatment with the PIKfyve inhibitor.
HeLa cells were treated with siRNA against each protein, and stained 
for both ciM6PR and a trans-Golgi marker TGN46 (Prescott et al., 1997). 
ciM6PR bind lysosomal hydrolases (Kyle et al., 1988; Lobel et al., 1989) 
tagged with mannose-6-phosphate groups at the TGN and assists their 
carriage to the endocytic pathway, whereupon the hydrolases are delivered 
to the lysosome, whilst the ciM6PR are retrieved to the TGN for further 
rounds of transport. I confirmed that siRNA-mediated knockdown of PIKfyve 
causes a redistribution of ciM6PR, as has previously been shown (Rutherford 
et al., 2006). In control HeLa cells ciM6PR is typically found in a perinuclear 
localisation, and displays partial overlap with markers of both the TGN and 
the endosomal system. Following loss of PIKfyve by siRNA treatment, this 
marker localises to more swollen compartments and redistributes around the 
cytoplasmic vacuoles (Figure 4.6). Interestingly, despite a high degree of 
knockdown of WIPI-2 and Vac14 (Figure 4.1) a loss of these proteins did not 
affect the distribution of ciM6PR, nor did knockdown of Fig4. Note also that 
the distribution of the TGN marker TGN46 also appears to be altered 
following PIKfyve knockdown, this is assessed in more detail in separate 
figures.
siRNA treatment does not necessarily indicate a specific role for 
PIKfyve kinase activity, and thus Ptdlns(3,5)P2, on this pathway. As well as 
taking account for non-specific effects of siRNA oligos, it must also be noted 
that protein knockdown represents a chronic loss of the protein over time.
There is a gradual depletion of cellular levels of the protein of interest, and as
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Chapter Four
such compensatory mechanisms can often be employed by the cell, which 
may be responsible for certain observed effects. Furthermore, siRNA 
mediated depletion will remove a protein from all of its potential cellular roles, 
therefore, in the case of PIKfyve, this does not necessarily reflect a loss of 
the lipid kinase activity and depletion of Ptdlns(3,5)P2. For this reason, a 
small molecule inhibitor of PIKfyve lipid kinase activity was used to determine 
the effects of a specific loss of PIKfyve kinase activity. Inhibition of PIKfyve 
kinase activity gives the same effect on ciM6PR as PIKfyve depletion by 
siRNA (Figure 4.7). An inactive analogue of the PIKfyve inhibitor (see Figure 
1.10 for structure) confirms that this is due specifically to a loss of PIKfyve 
activity.
It has been suggested that this altered distribution of ciM6PR following 
loss of PIKfyve is due to failure in their retrieval back to the TGN. One 
mechanism of retrieval involves the retromer complex, a multimeric coat 
protein complex that interacts directly with these receptors and facilitates 
their inclusion into vesicles destined for return to the TGN (Arighi et al., 2004) 
(see section 1.2.7 for more detail). If the ciM6PR fail to be recycled back to 
the TGN they may instead be routed to the lysosome and degraded, and a 
decrease in cellular levels of ciM6PR might be observed. The levels of 
ciM6PR, and two components of the retromer complex, were assessed by 
Western blotting. There was no effect on the cellular levels of any of these 
proteins following either siRNA treatment of any of the proteins investigated, 
or inhibition of PIKfyve (Figure 4.8), suggesting that they are not routed to the 
lysosome. The distribution of two of the retromer components Vps26, (part
of the cargo-binding element of the complex) (Shi et al., 2006), and SNX-1,
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Mock Inactive analogue MF4
ciM6PR
TGN46
Merge
Figure 4.7. Acute inhibition of PIKfyve alters the distribution of 
ciM6PR and TGN46.
HeLa cells were treated with 800nM MF4 or inactive analogue for 4h prior 
to fixation in 3% PFA/PBS, permeabilisation in 0.2% TX-100 and staining 
with ciM6PR and TGN46 antibodies. Inhibition of PIKfyve altered the 
distribution of both markers, with the most severe disruption in cells with 
larger cytoplasmic vacuoles. Scale bars represent 20pm.
O0' c? ^
200—1 
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CIMPR
Tubulin
SNX-1
Tubulin
Vps26
Tubulin
0&  /  c*
^  ^  ‘f ’
X°
CIMPR
SNX-1
Vps26
Tubulin
Figure 4.8. Cellular levels of ciM6PR and retromer components are 
unaffected.
HeLa cells were transfected with siRNA oligos against the indicated 
proteins for 72h or incubated with 800nM MF4 for 4h prior to lysis in NP40 
lysis buffer and Western blotting, or fixation in 3% PFA/PBS and 
permeabilisation in 0.2% TX-100. Both fixed cells and Western blotting 
membranes were stained with antibodies against Vps26 and SNX-1, and 
Western blots were also probed with ciM6PR antibodies. a-Tubulin was 
used as a protein loading control, and scale bars represent 20pm. 
Although SNX-1 and Vps26 label a more swollen endosomal 
compartment, the cellular levels of these proteins, and of CIMPR are 
unaffected by loss of PIKfyve activity.
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(plays a structural role) (Zhong et al., 2002), were examined by 
immunofluorescence. These two proteins localised to swollen endosomal 
compartments upon loss of PIKfyve activity, suggesting that the localisation 
of these components of the retromer complex to the early endosome is 
unaffected.
4.2.5 Loss of PIKfyve activity disrupts TGN46 cycling
The TGN marker TGN46 was used to assess the levels of 
colocalisation of ciM6PR with the TGN, to determine if the cause of the 
redistribution was a failure of ciM6PR to retrieve to the TGN. However, the 
loss of PIKfyve activity also had a notable effect on the distribution of this 
TGN marker itself (Figures 4.6 and 4.7). In both PIKfyve knockdown and 
inhibitor treated cells, there was a marked change in TGN46 staining in 
approximately 20% of cells. This was judged by the blind quantitation of 
each siRNA treatment in 9 fields of cells per coverslip for three separate 
experiments (Figure 4.9). Two categories of TGN46 staining were 
established; tight perinuclear, ribbon-like staining typically observed in most 
control cells (catergory 1) and dispersed punctate staining that often 
surrounds swollen vacuoles (category 2). The proportion of cells not 
accounted for in the quantitation corresponds to an intermediate phenotype, 
where the Golgi staining was not as tight and perinuclear as usual, but did 
not display the vesicular staining. Cells treated with PIKfyve inhibitor also 
demonstrated altered TGN46 staining, in approximately 30% of cells. 
Notably, although PIKfyve inhibitor treatment did not cause category 1
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Figure 4.9. TGN46 cycling is disrupted upon loss of PIKfyve activity.
HeLa cells were transfected with 40nM siRNA ollgos against the indicated 
proteins, or a scrambled control, or incubated with MF4 for 4h prior to 
permeabilisation with 0.05% saponin and fixation in 3% PFA/PBS. Cells 
were stained with TGN46 antibodies and blind quantitation of the TGN 
phenotype in 9 fields of cells per coverslip for 3 independent experiments 
was performed for each condition (A). Loss of PIKfyve activity causes a 
general perturbation in TGN46 staining, and in some cells causes a severe 
redistribution into vesicular structures. cis-Golgi marker GM130 was 
unaffected (B). Scale bars represent 5pm (A) and 20pm (B).
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staining in all cells, there was an increase in the percentage of cells 
displaying a general alteration to TGN46 staining.
As TGN46 itself has been shown to cycle between the TGN and 
plasma membrane, via the endosomal pathway (Ghosh et al., 1998; Mallet 
and Maxfield, 1999), it is possible that loss of PIKfyve activity might also 
influence TGN46 cycling. In order to determine if this effect was due to a 
defect in TGN46 cycling, or a morphological disruption to the Golgi structure 
in general, the distribution of a cis-Golgi marker GM130, was also examined 
(Figure 4.9 B). Loss of PIKfyve activity did not significantly affect the 
distribution of this marker. In some cases it was less tightly perinuclear than 
in control cells, matching the third category of TGN46 staining, but this was 
more often associated with knockdown than treatment with the inhibitor, and 
there was no punctate, vesicular staining.
To further illustrate this point, colocalisation of TGN46 with a second 
trans-Golgi marker Golgin-245 that is not supposed to cycle, was examined 
(Figure 4.10). As with GM130 staining, there is mildly altered staining in 
some cells, this could reflect a slight effect of the presence of the large 
cytoplasmic vacuoles on Golgi morphology, as these occupy a significant 
portion of the cytoplasm in some cells. In cells displaying TGN46 
vesiculation following loss of PIKfyve activity, there is a loss of colocalisation 
with Golgin-245. The cycling itinerary of TGN46 has been proposed to 
incorporate the early stages of the endosomal pathway, including recycling 
endosomes (Ghosh et al., 1998). I examined the colocalisation of TGN46 
with a marker of recycling endosomes, Tf receptor, and found that some of 
the vesicular structures were also positive for Tf receptor.
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Mock Inactiveanalogue MF4
TGN46
Golgln-245
Merge
Figure 4.10. Following loss of PIKfyve activity TGN46 disperses from a 
golgi localisation to recycling/early endosomes.
HeLa cells were treated with 800nM MF4 prior to fixation. Cells were 
stained with antibodies to two classical trans-golgi markers TGN46 and 
Golgin-245, and antibodies to the Transferrin receptor. Following loss of 
PIKfyve activity, in cells where TGN46 is severely perturbed, there is less 
colocalisation with trans-golgi marker Golgin-245 and increased 
colocalisation with Transferrin receptor. Scale bars represent 20pm.
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4.2.6 Loss of PIKfyve activity delays the retrieval proteins on both retromer- 
dependent and independent pathways
Both ciM6PR and TGN46 recycle to the TGN from early endosome or 
recycling compartments in a manner that is, at least in part, mediated by the 
retromer complex (Arighi et al., 2004; Popoff et al., 2007). A perturbation in 
retromer-mediated recycling to the TGN presents one potential explanation 
for the swollen early endosome compartments. However, the large 
cytoplasmic vacuoles do not label with early endosomal markers, and the 
swelling of this compartment must occur through other defects. ciM6PR is 
also retrieved from the late endosome in a manner dependent on Rab9, p40 
and TIP47 (Diaz and Pfeffer, 1998; Carroll et al., 2001), which could 
contribute to membrane swelling of this compartment. If both retromer- 
dependent and retromer-independent pathways are perturbed, this may 
indicate that Ptdlns(3,5)P2 plays a more general role in membrane retrieval 
from the endosomal pathway, contributing to the accumulation of swollen 
compartments. In order to investigate this, a HeLa cell line stably 
expressing the lumenal domain of CD8 fused to the cytosolic tail of ciM6PR 
and Furin was obtained. Furin is a subtilisin-like pro-protein convertase 
proposed to traffic to the TGN via late endosomes, in a retromer-independent 
manner (Mallet and Maxfield, 1999; Seaman, 2004). By following uptake of 
CD8 antibodies, the retrieval of cell surface CD8-ciM6PR and CD8-Furin to 
the TGN can be followed.
Following inhibition of PI Kfyve, there is a delay in retrieval of both 
markers to the TGN (Figure 4.11). Although CD8-ciM6PR can ultimately 
reach the TGN (as judged by colocalisation with the perinuclear portion of
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Figure 4.12. Dynamics of CD8-ciM6PR redistribution following loss of 
PIKfyve activity.
Colocalisation of the terminal timepoint of CD8-ciM6PR uptake (48mins) 
with golgi marker TGN46 and early endosomal marker (EEA-1 ). Following 
loss of PIKfyve activity, CD8-ciM6PR is found in both TGN46 and EEA-1 
labelled compartments. In cells where TGN46 is severely perturbed there 
is no colocalisation between vesicular TGN46 and CD8-ciM6PR. Scale 
bars represent 20pm.
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TGN46 at the final timepoint of CD8 uptake), it shows a slower rate of 
accumulation there. It also localises to swollen EEA-1 labelled 
compartments and around the larger cytoplasmic vacuoles, suggesting it 
may be trapped in both early and possibly late compartments (Figure 4.12). 
Due to technical difficulties I was unable to assess the colocalisation of CD8- 
Furin with these markers.
4.2.7 Loss of PIKfyve activity also affects the retrieval of Shiga toxin
The data presented thus far suggest that loss of PI Kfyve affects both 
retromer-dependent and retromer-independent retrieval pathways to the 
TGN. In order to further reinforce this idea the retrieval of a final marker to 
the TGN was examined. The B subunit of the AB5 type toxin, Shiga toxin, is 
reported to facilitate the entry of this toxin into the cell and its subsequent 
transport to the TGN via the early endocytic pathway (Mallard et al., 1998; 
Bonifacino and Rojas, 2006). Given that this assay had not previously been 
examined in the context of knockdown of PIKfyve or any of the other proteins 
studied here, the effect of siRNA treatment was first examined. PIKfyve 
siRNA treatment leads to a delay in retrieval of Shiga toxin B subunit to the 
TGN, in a similar manner to that seen with the CD8 assay (Figure 4.13). 
Loss of Vac14, WIPI-2 or Fig4 has no effect on the Shiga toxin B subunit 
retrieval pathway (Figure 4.14). In addition, a combination of Vac14 and Fig4 
knockdown had no effect. And, to ensure that WIPI-1 was not able to 
compensate for a loss of WIPI-2, a combination knockdown of both of these 
proteins was also examined, and was found to have no effect. 
Pharmacological inhibition of PIKfyve also affects this pathway in a similar
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PIKfyve
siRNA
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Figure 4.13. Shiga toxin retrieval is delayed following PIKfyve 
knockdown
HeLa cells were treated with 40nM of the indicated siRNA oligos for 72h 
prior to labelling with 2pg/ml Cy3-STxB as described in materials and 
methods and chase with fresh HeLa growth medium for the indicated 
timepoints. PIKfyve knockdown, and combination knockdowns including 
PIKfyve, caused a delay in retrieval of Shiga toxin to a perinuclear 
localisation at the 2h timepoint. Scale bars represent 20pm.
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Chapter Four
manner to PIKfyve knockdown (Figure 4.15). This was further characterised 
(Figure 4.16) and the terminal timepoint of Cy3-STxB uptake was assessed 
for colocalisation with the TGN markers TGN46 and Golgin-245. As with 
CD8-ciM6PR and CD8-Furin, Cy3-STxB is able to reach a TGN 
compartment, illustrated by its colocalisation with Golgin-245. However, its 
accumulation there is impeded. Interestingly, in contrast to CD8-ciMPR and 
CD8-Furin there is significant colocalisation of Cy3-StxB with dispersed 
TGN46-labelled punctae.
4.3 Discussion
The work presented in this chapter serves to elaborate on the current 
literature regarding the proposed role of Ptdlns(3,5)P2 in regulating trafficking 
pathways between the endocytic pathway and the TGN. It is clearly 
demonstrated that a loss of kinase activity, and thus a loss of cellular 
Ptdlns(3,5)P2 is sufficient to disrupt a variety of retrieval pathways to the 
TGN.
4.3.1 Vacuole characterisation
In this study siRNA suppression of endogenous PIKfyve induces 
progressive accumulation of cytoplasmic vacuoles in approximately 30% of 
cells. This is in good agreement with other published work (Rutherford et al., 
2006). Vac14 suppression lead to the same phenotype in a very small 
minority of cells, again in agreement with published literature that suggests 
that knockdown of Vac14 does not induce vacuole formation, but instead 
make cells prone to develop cytoplasmic vacuoles following mild osmotic
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Figure 4.16. Loss of PIKfyve activity affects Shiga toxin and TGN46 
retrieval in a similar manner.
The colocalisation of golgi markers with Cy3-STxB at the terminal 
timepoint of uptake (120mins) was examined in HeLa cells treated with 
800nM MF4 for 4 hours. Following loss of PIKfyve activity, in cells where 
TGN46 is severely perturbed there is substantial colocalisation with 
Cy3-STxB (A). This is not the case for the more stable golgi marker 
Golgin-245 (B). Scale bars represent 20pm.
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shock (Sbrissa et al., 2004; this study). Furthermore, a combined 
knockdown of Vac14 and PIKfyve was found not to increase the number of 
cells displaying cytoplasmic vacuoles more than PIKfyve knockdown alone.
These findings suggest that PIKfyve is able to function in the absence 
of Vac14 activation, but that Vac14 may be required for optimal Ptdlns(3,5)P2 
production under certain conditions. For example, where elevated levels of 
Ptdlns(3,5)P2 are observed, such as under certain cellular stresses, Vac14 
may serve to further activate PIKfyve kinase activity beyond the basal level. 
This has been shown to be the case in yeast, where Vac14 is required for the 
elevation of Ptdlns(3,5)P2 in response to osmotic shock (Bonangelino e ta i,
2002), however, in a number of mammalian cell lines (ie. Cos-7) 
Ptdlns(3,5)P2 levels do not increase in response to osmotic stress (Dove et 
at., 1997).
An alternative explanation for this finding is that, given that Vac14 has 
been shown to interact with and stabilise the mammalian phosphatase Fig4 
(Sbrissa et at., 2007), a loss of Vac14 may result in reduced function of Fig4 
and reduced turnover of Ptdlns(3,5)P2, effectively compensating for the 
reduced PIKfyve activity. In yeast, Vac14 has been shown to recruit Fig4 to 
membranes (Rudge et al., 2004), although the exact purpose of the 
interaction between the mammalian proteins is not understood. In this study 
we were unable to detect any changes in localisation of the overexpressed 
proteins upon coexpression (Figure 3.11), but it has been demonstrated in 
the literature that overexpression of Vac14 increases punctate staining of 
Fig4 in Cos-7 cells (Sbrissa et al., 2007).
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Recently, it was demonstrated that cultured neurons and fibroblasts 
from Vac14 knockout mice have swollen cytoplasmic vacuoles (Zhang et a/., 
2007). Thus, it is possible that the small amount of protein retained in cells 
following Vac14 knockdown is sufficient to carry out Vac14 function, and that 
vacuoles are only present when loss of Vac14 protein is complete as in the 
knockout mice. Alternatively, Vac14 may play an as yet unidentified tissue 
specific critical role. For example, in neurons it has been shown to bind 
neuronal nitric oxide synthase (Lemaire and McPherson, 2006).
Fig4 and WIPI-2 knockdown do not induce formation of cytoplasmic 
vacuoles. This is somewhat surprising for WIPI-2 given that the yeast 
homologue Atg18/Svp1 was initially identified from a screen for mutant 
proteins that produced the same swollen vacuole phenotype (hence Svp1) 
as Fab1 mutants. However, as discussed in section 1.8 (see also figure 
1.12) there are four members of the mammalian WIPI family, WIPI-1 is 53% 
identical to WIPI-2 and both are equally related to the yeast protein. 
Therefore, the question remains as to whether there may be functional 
redundancy between these two proteins, and when WIPI-2 is no longer 
present, WIPI-1 may be able to compensate functionally.
As far as Fig4 is concerned, although no effective protein knockdown 
was demonstrated, from RT-PCR data it is clear that messenger RNA levels 
were reduced, which most likely corresponds to a loss of protein. Mutant 
Fig4 cells in yeast do not display a swollen vacuole phenotype, and show no 
change in Ptdlns(3,5)P2 levels (Rudge ef a/., 2004), suggesting that there 
may be other 5-phosphatases that can dephosphorylate Ptdlns(3,5)P2 and
compensate for a loss of Fig4. In mammalian cells however, ablation of
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mammalian Fig4 (also described as Sac3), has been shown to increase 
levels of Ptdlns(3,5)P2 in vitro but still did not lead to formation of cytoplasmic 
vacuoles. Instead, in a similar manner to Vac14, it renders them more prone 
to developing such vacuoles upon treatment with mild osmotic stress 
(Sbrissa et al., 2007). A combined knockdown of PIKfyve and Fig4 did not 
affect the number of cells displaying the vacuole phenotype, suggesting that 
loss of Fig4 and reduced turnover of Ptdlns(3,5)P2 is insufficient to 
compensate for the PIKfyve knockdown phenotype.
It has previously been shown that the loss of endomembrane integrity 
and subsequent formation of vacuoles is dependent on the lipid kinase 
activity of PIKfyve and not its protein kinase activity or other functions 
(Ikonomov et al., 2002a). The finding that vacuoles are displayed in cells 
treated with PIKfyve inhibitor further indicates that their formation is as a 
direct result of loss of PIKfyve activity, and most likely reduced levels of 
Ptdlns(3,5)P2. It could also be due to a reduction in Ptdlns(5)P or an 
elevation of Ptdlns(3)P levels. However, the latter seems unlikely, because 
the vacuoles appear to be of endosomal origin, and the swelling of 
endosomal compartments is similar to the swollen vacuole phenotype 
observed in S. cerevisiae, which have no detectable levels of Ptdlns(5)P 
(McEwen et al., 1999; Walker et al., 2001). Also, mutations in myotubularins 
that are predicted to lower Ptdlns(5)P levels do not display this phenotype 
(Schaletzky et al., 2003; Tsujita et al., 2004). Furthermore, it is unlikely to be 
due to an increase in Ptdlns(3)P as knockdown of Vps34, the kinase that 
catalyses the formation of Ptdlns(3)P, results in a loss of both Ptdlns(3)Pand 
Ptdlns(3,5)P2, and also displays swollen vacuoles (Johnson et al., 2006).
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However, in order to be certain that these results truly represent a specific 
loss of Ptdlns(3,5)P2 it would be necessary to examine the levels of 
phosphoinositide lipids following treatment with the inhibitor, something that 
is technically demanding and was not feasible in the time limitation of this 
study. This is a limitation that therefore needs to be taken into account.
Characterisation of the cytoplasmic vacuoles in this study revealed 
that they were endosomal in origin, and they most likely represent some form 
of late endosomal/MVB defect. The large vacuoles are surrounded by 
LAMP-2 vesicles, although it is unclear if this marker labels the limiting 
membrane or not. It could be that the LAMP-2 labels microdomains on the 
membrane of the vacuoles, or that the LAMP-2 staining represents LAMP-2 
vesicles fused to the surface of the vacuoles. Immuno-EM studies would 
help to further clarify the nature of this staining and the origin of the vacuoles. 
It is clear however, that early endosomal compartments are also more 
elaborate and swollen, but early endosomal markers are excluded from the 
larger vacuoles, despite the finding that Rab5 positive vesicles fuse to the 
expanding vacuole membrane (Jefferies et al., 2008). This suggests that 
maturation from early endosome to MVB/late endosome/MVB is most likely 
unaffected, but also that EEA-1 and Ptdlns(3)P function is unaffected. And 
indeed localisation of Ptdlns(3)P, as judged by examination of a biotinylated 
GST-tagged tandem FYVE domain, was also unaffected.
Electron microscopy studies reveal that large cytoplasmic vacuoles do 
not readily take up endocytosed HRP, in agreement with a recent study that 
found that they are also inaccessible to the fluid-phase marker Dextran
(Zhang et al., 2007). Large cytoplasmic vacuoles were often found to be
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surrounded by smaller HRP labelled swollen compartments that most likely 
correspond to swollen endosomes, as the early endosomal marker displays a 
similar distribution by immunofluorescence.
Given that these large vacuoles contain fewer internal vesicles, and 
are predominantly empty, it has been suggested that they represent a failure 
in the formation of ILVs. The finding that a member of the ESCRT III 
complex, CHMP3, and other proteins involved in MVB formation, may be 
effectors of Ptdlns(3,5)P2, although the evidence for the specificity of these 
interactions is disputed, adds weight to this hypothesis. However, we 
observed ILVs in both the EEA-1 labelled compartments and also normal 
MVBs and lysosomes by EM following both knockdown and inhibition of 
PIKfyve, suggesting that if Ptdlns(3,5)P2 does function in formation of internal 
vesicles, this may only be in a subset of MVBs. It is widely believed that 
different populations of MVBs may exist with different functions (as discussed 
in section 1.2.4), thus PIKfyve function may be expendable for certain types 
of ILV formation.
Knockdown of the WIPI-2 and Fig4 was also examined by electron 
microscopy. Neither displayed any visible phenotype at neither the light 
microscope nor the electron microscope level, except that it was noted that 
WIPI-2 knockdown caused a substantial amount of cell death. 
Overexpression of WIPI-2 constructs also affected both HeLa and HEK293 
cells in this manner, suggesting that changes in the levels of WIPI-2 is toxic 
to cells and its abundance may be tightly regulated.
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4.3.2 Endosome to TGN trafficking
Previous characterisation of some of these proteins in both S. 
cerevisiae and mammalian cells, indicated that Ptdlns(3,5)P2 may be 
involved in the regulation of trafficking between endosomes and the TGN. I 
chose to revisit this hypothesis and examine the effect of siRNA suppression 
of each protein and inhibition of PIKfyve on a range of different pathways.
Over the past few years the existence of several distinct pathways 
from the endocytic pathway to the TGN has come to light. Each pathway 
seemingly transports different cargos using a range of different protein coats 
and complexes. One such pathway is the retromer-mediated pathway, which 
uses the retromer complex (described in section 1.2.7) to mediate recycling 
of the bulk of the ciM6PR back to the TGN once they have delivered their 
cargo onto the endosomal pathway.
By examining the effect of knockdowns and PIKfyve inhibition on the 
steady state distribution of ciM6PR, and subsequently on the retrieval of cell 
surface CD8-ciM6PR to the TGN, I found that a loss of PIKfyve activity, both 
long-term chronic loss and acute pharmacological inhibition, had the same 
effect. They caused redistribution of ciM6PR at steady state, and a delay in 
retrieval of the chimeric construct to the TGN, such that these markers did 
not display a typical perinuclear staining, but instead surrounded the 
cytoplasmic vacuoles, and labelled swollen endosomal compartments.
However, chimeric CD8-ciM6PR was able to reach a TGN 
compartment to some degree, and there was no alteration in cellular levels of 
ciM6PR, or of retromer proteins Vps26 and SNX-1 (interestingly, SNX-1, is 
proposed to bind Ptdlns(3,5)P2). This suggested that ciM6PR was eventually
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able to retrieve to the TGN, albeit with altered dynamics, and was not 
rerouted to the lysosome, since the protein was not degraded. Alternatively, 
a second defect in lysosomal acidification in mammalian cells, similar to the 
improper acidification of the yeast vacuole, could also explain this finding.
It was also noted that the TGN marker TGN46 displayed a different 
distribution following loss of PIKfyve activity, redistributing into punctate, 
vesicular structures in some cells. TGN46 has been reported to cycle 
between the plasma membrane and the TGN via the endocytic pathway, 
albeit via a partially different route to ciM6PR; through early and recycling 
endosomes, bypassing the late endocytic pathway (Ghosh et al., 1998; 
Mallet and Maxfield, 1999). My further investigation showed that the TGN46 
punctae colocalised with Tf-labelled recycling endosomes, suggesting that 
TGN46 becomes trapped in early/recycling compartments to some degree. 
TGN46 did still display a partially perinuclear distribution and showed overlap 
with ciM6PR in this position. Taken together with an increased colocalisation 
between CD8-ciM6PR and EEA-1, these results imply that there is not a 
complete loss of cycling but more a delay in retrieval and therefore a shift in 
the steady state equilibrium of these proteins.
A second assay for examining the dynamics of retrieval from 
endosomes to the TGN also showed a delay following loss of PIKfyve 
activity. The Shiga toxin B subunit reportedly traffics on the same pathway 
as TGN46 to reach the TGN. Thus, the fact that not only was its retrieval 
perturbed, but that it also colocalised with TGN46 vesicular structures, further 
supports the hypothesis that multiple pathways are perturbed and that
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recycling cargo becomes trapped to some degree in swollen endosomal 
compartments.
Loss of PIKfyve activity not only affected various trafficking itineraries 
from the endocytic pathway to the TGN, but also various retrieval 
mechanisms. There was also a delay in the retrieval of CD8-Furin to the 
TGN, a protein that is thought to utilise a retromer-independent mechanism 
to recycle to the TGN. Although not examined in the current study, previous 
work has determined that recycling of EGF to the plasma membrane is 
unaffected following PIKfyve knockdown (Rutherford et a!., 2006); this 
suggests that this recycling pathway, believed by many to represent a default 
pathway that does not require any specific sorting motifs, may be unaffected, 
and that PIKfyve may specifically coordinate the retrieval of TGN-directed 
membrane from endosomes.
A limitation of the work presented in this chapter is that morphological 
studies are not quantitative, and do not give any indication of the proportion 
of cells affected by the phenotypes observed, except in the case of TGN46. 
In order to increase the impact of the work presented, quantitative 
assessment using programs such as Image J could help to give an indication 
of the statistical significance of the results presented. This was not done due 
to time limitations of the current study.
4.3.3 Conclusion
In conclusion, this chapter establishes a role for Ptdlns(3,5)P2 in 
regulating the dynamics of endosome to TGN trafficking, and suggests that a
defect in membrane retrieval from various stages of the endocytic pathway
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could result in the swollen endocytic compartments and cytoplasmic 
vacuoles observed upon loss of this lipid. Current models for endocytic 
trafficking suggest that material is continually sorted throughout the 
progression of the pathway to the lysosome. Tubulation of early endosomes 
and MVBs permits membrane retrieval from this pathway to various 
intracellular destinations, whereas ILV formation segregates cargo for 
lysosomal degradation. As the pathway progresses the MVB matures or 
cargo is passed onto a more mature compartment that possesses less 
tubules and more ILVs and is capable of fusing with the lysosome. The fact 
that proteins that display delayed trafficking to the TGN are redistributed to 
the limiting membrane of the swollen endocytic compartments, and that 
these swollen compartments display fewer intralumenal vesicles, suggests 
that Ptdlns(3,5)P2 might be involved in coordinating the maturation of the 
MVB and the coordinated sorting of internalised cargo into the correct 
regions of the endosome for retrieval or for delivery to the lysosome.
Indeed Ptdlns(3,5)P2 and PIKfyve have been reported to interact with 
various proteins which coordinate these different functions. For example, 
PIKfyve interacts with p40 (Ikonomov et al., 2003b), a Rab9 effector 
responsible for retrieval of ciM6PR from the late endosome, and 
Ptdlns(3,5)P2 interacts with SNX-1 (Carlton et ai, 2005), a component of the 
mammalian retromer complex. Fab1 has been reported to bind a range of 
different effector proteins from a variety of endosome to TGN pathways, 
including AP-1 components (Phelan et ai, 2006). Another reported 
Ptdlns(3,5)P2 effector is the Epsin-like protein Ent3p (Eugster et ai, 2004). 
Ent3 binds clathrin, AP-1 and the GGA proteins, suggesting it also promotes
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vesicle formation at the endosomal membrane (Duncan et al., 2003). On the 
other hand various components of MVB formation are also reported to bind 
Ptdlns(3,5)P2, such as Vps24/CHMP3 (Whitley et ai, 2003), a member of the 
ESCRTIII complex proposed to facilitate MVB formation. The reduced 
number of intralumenal vesicles in the swollen endocytic compartments 
observed with loss of PIKfyve activity, have lead some to conclude that the 
defect lies in internalisation of intralumenal vesicles. However, MVBs with 
many internal vesicles are present in Drosophila Fab1 mutant cells (Rusten 
et al., 2006), and following siRNA and inhibition of PIKfyve (this study), 
suggesting that PIKfyve is dispensable for at least some types of inward 
veisculation. In support of this hypothesis, a recent study determined that in 
cells overexpressing kinase-deficient PIKfyve, intralumenal vésiculation of 
LBPA containing late endosomes was unaffected (Ikonomov et ai, 2006).
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CHAPTER FIVE
The Role of PIKfyve in Regulating Tyrosine Kinase Receptor
Down regulation
5.1 Introduction
Cells deficient in Ptdlns(3,5)P2 display massively dilated endocytic 
compartments, and perturbed uptake of fluid phase markers into MVBs/late 
endosomes, as characterised in this study and previous literature. A key 
question in Ptdlns(3,5)P2 biology is the origin of these swollen vacuoles. 
There are a number of potential reasons for their appearance. Findings from 
the previous chapter, in the context of the current literature, indicate that one 
contributing factor may be perturbed retrieval of membrane from various 
stages of the endocytic pathway to the TGN. However, the reduced number 
of ILVs in these compartments, observed by EM, also suggests that there 
might be a defect in invagination of membrane into the MVB/late endosome, 
which could further add to the membrane swelling.
Both of these findings could be consolidated by the hypothesis that 
Ptdlns(3,5)P2 acts to recruit a range of effector proteins that coordinate the 
progressive maturation of endosomes, by regulating the dynamics of 
partitioning of endosomes into tubular and vesicular membranes. At the 
early and late endosome Ptdlns(3,5)P2 effectors, such as SNX-1, and 
PIKfyve binding proteins, such as p40, may facilitate the inclusion of 
recycling cargo into tubular elements destined for retrieval to the TGN. 
However, at a later stage of the endocytic pathway, other Ptdlns(3,5)P2
199
Chapter Five
effectors may help to coordinate the maturation of the vesicular MVB/late 
endosóme, such that it is able to fuse with the lysosome.
If this were the case, one might expect to see perturbations in the 
trafficking of endocytosed material to the lysosome. In keeping with this 
hypothesis, Drosophila Fab1 mutants display perturbation in downregulation 
of internalised receptors (Rusten eta!., 2006) and in S. cerevisiae Fab1 
mutants have an improperly acidified vacuole and a defect in trafficking 
biosynthetic material to the vacuole (Odorizzi et a i, 1998; Rudge et al., 
2004). However, conflicting evidence suggests that trafficking of 
endocytosed material in S. cerevisiae is unperturbed and the defects in 
trafficking of biosynthetic material can be overcome by irreversible 
ubiquitination. Furthermore, in mammalian cells, studies with both PIKfyve 
siRNA and overexpression of a kinase-dead mutant, have found no effect on 
the downregulation of EGFR (Ikonomov et al., 2003a; Rutherford et al., 
2006), a well-characterised endocytic cargo, suggesting that endocytosed 
material is still able to reach a functional lysosome.
Given that PIKfyve knockdown is somewhat inefficient, and the 
caveats of analysing overexpressed proteins, I decided to re-examine EGFR 
downregulation in mammalian cells following acute inhibition of PIKfyve with 
MF4. Furthermore, the effects of loss of other proteins associated with 
Ptdlns(3,5)P2 metabolism has not been examined in this context. In 
particular, given that loss of WIPI-2 does not exhibit any effects on 
endosóme to TGN trafficking pathways, this protein may instead act as an 
effector of Ptdlns(3,5)P2 in other cellular processes. The aim of this chapter
was to consolidate the observations made in different organisms and
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conclusively determine what effect loss of PIKfyve activity has on trafficking 
of endocytic cargo to the lysosome in mammalian cells. Furthermore, to 
determine whether knockdown of other Ptdlns(3,5)P2 associated proteins 
may exhibit an effect on this pathway.
5.2 Results
5.2.1 Effect of single knockdowns on EGFR downregulation
The effect of suppression of each protein on the rate of EGFR 
downregulation was examined (Figure 5.1). Following 72-hour transfection 
with siRNA oligos specific to each protein, ligand was added to culture 
medium at a saturating concentration (100ng/ml), following overnight serum 
starvation. Ligand binds to cell surface EGFR causing its internalisation and 
subsequent sorting to and degradation in the lysosome. Cells were lysed at 
various timepoints, and Western blotting used to assess the amount of EGFR 
remaining in the cell. Knockdown efficiency of the oligos used in these 
experiments is outlined in figure 4.1 (PIKfyve oligo 3, WIPI-2 and Vac14 oligo 
4). There is no effect on the rate of EGFR downregulation following 
knockdown of each protein. A sample of control cell lysates was also loaded 
onto each gel (although not shown in the final figure) to serve as a loading 
standard and enable quantitation between blots.
5.2.2 Effect of combined knockdowns on EGFR downregulation
Our initial hypothesis was that knockdown of PIKfyve alone may not 
be sufficient to display an effect on EGFR downregulation, due to the 
residual levels of protein upon incomplete knockdown (see figure 4.1). As
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Figure 5.1. EGFR degradation is unaffected in single knockdown cells
HeLa cells were seeded onto 6-well plates and transfected twice with 40nM 
siRNA scrambled oligos and individual or pooled (Fig4) oligos specific for the 
indicated proteins over 72h. Cells were then serum starved overnight and the 
following day 100ng/ml mouse EGF added for the indicated time points, 
followed by lysis in NP40 lysis buffer. A) Proteins were resolved by 
SDS-PAGE, transferred to nitrocellulose and probed with a goat anti-EGFR 
antibody. Mouse anti-tubulin antibodies were used to probe tubulin levels and 
serve as a protein loading control. B) The amount of control EGFR remaining 
at each time point was quantified using Odyssey software, relative to control 
lysates loaded onto each separate gel. EGFR degradation is unperturbed 
following individual knockdown of each protein.
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such, several proteins were suppressed simultaneously to examine their 
combined effects. Whilst knockdown of PIKfyve on its own had no significant 
effect on EGFR downregulation, combination with either Vac14 or Fig4 
knockdown produced a subtle delay in its degradation (Figure 5.2 A). The 
percentage of EGFR remaining following 2 hours of EGF stimulation was 
quantified for each condition (Figure 5.2 B) using Odyssey software; levels of 
EGFR at 2 hours were assessed relative to EGFR levels at 0 hours, and 
were compared to the levels of a control protein lysate (not shown) to 
account for samples being run on separate gels.
5.2.3 Effect of PIKfyve inhibition on EGFR and c-Met downregulation
Given that residual PIKfyve protein remains following siRNA 
treatment, and that combined knockdowns incorporating PIKfyve produced a 
mild effect on EGFR downregulation, it was hypothesised that to see the 
effect of PIKfyve on this pathway may require a stronger suppression of 
PIKfyve activity, or a more dramatic acute loss of Ptdlns(3,5)P2. Indeed, 
acute pharmacological inhibition of PIKfyve activity with MF4 led to a much 
more pronounced delay in EGFR downregulation (Figure 5.3).
Initial experiments were performed with 3pM PIKfyve inhibitor (Figure
5.3 A). Upon observation of a strong effect, these experiments were 
repeated at a range of inhibitor concentrations, spanning the in vitro IC50 of 
the drug (23nM), in order to reduce the likelihood that MF4 could potentially 
be inhibiting other kinases. Severe effects on EGFR downregulation could 
be seen at concentrations beginning at approximately 1pM MF4 (Figure 5.3 
B). Experiments were subsequently repeated at 800nM, to match the
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Figure 5.2. A delay in EGFR degradation is observed following 
combination knockdowns incorporating PIKfyve.
HeLa cells were seeded onto 6-well plates and transfected twice with 
scrambled or individual or pooled (Fig4) specific oligos as indicated over 72h. 
Subsequently cells were serum starved overnight and then 100ng/ml mouse 
EGF added for the indicated timepoints. Cells were lysed in NP40 lysis buffer 
and 50pg run on an SDS-PAGE gel. A) Proteins were transferred to 
nitrocellulose and probed with goat anti-EGFR antibodies. Mouse anti-a 
tubulin antibodies were used to probe for tubulin as a protein loading control. 
B) The percentage of EGFR remaining after 2h EGF stimulation was 
quantified. Combined knockdown of either Vac14 or Flg4 with PIKfyve 
causes a delay in EGFR downregulation.
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Figure 5.3. EGFR downregulation is severely delayed following 
inhibition of PIKfyve kinase activity.
HeLa cells were seeded onto 6-well plates. The following day cells were 
treated with A) 3pM MF4 B) a range of different concentrations or C) 800nM 
EGF for 4 hours. 100ng/ml EGF was then added to the cells for the indicated 
timepoints (A and C) or 120mins (B). Cells were lysed in NP40 lysis buffer 
and 50pg protein was resolved on an SDS-PAGE gel. Proteins were 
transferred to nitrocellulose and probed with goat anti-EGFR antibodies. 
Mouse anti-atubulin antibodies were used to probe for tubulin as a protein 
loading control. C) The affect on downregulation was quantified using 
Odyssey software, N=3 +/- SEM, * p<0.05 ** p<0.01 (t-test). PIKfyve 
inhibition significantly delays the degradation of EGFR.
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concentration used in previous experiments (Jefferies et al., 2008). Although 
the effect was not as substantial at this lower dose, a statistically significant 
delay in EGFR downregulation was observed at later timepoints (Figure 5.3 
C) (N=3, p<0.05, student’s t-test).
In order to determine if this was a general effect on the degradative 
pathway, or specific to EGFR trafficking, I examined the downregulation of a 
second tyrosine kinase receptor. I found that downregulation of the 
hepatocyte growth factor receptor (c-Met) was also delayed in cells treated 
with 3pM PIKfyve inhibitor (Figure 5.4).
5.2.4 EGFR immunofluorescence following loss of PIKfyve activity
In order to dissect the mechanism by which the downregulation of 
tyrosine kinase receptors was perturbed in PIKfyve deficient cells, the 
immunofluorescence of EGFR was examined in siRNA and inhibitor treated 
cells. Individual oligos against WIPI-2 and pooled oligos against Fig4 were 
used and found to have no effect on cellular EGFR levels (Figure 5.5) as also 
observed by Western blotting (Figure 5.1). Interestingly, despite the 
observation that PIKfyve siRNA treatment on its own has no significant effect 
on EGFR degradation, as assessed by Western blotting (Figure 5.1), a 
residual amount of EGFR was detected in these cells by 
immunofluorescence after 4 hours of EGF stimulation, and a small amount 
remained following Vac14 knockdown also. This suggests that the effect of 
PIKfyve (and possibly Vac14) depletion is small and only detected by more 
sensitive methods.
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Figure 5.4. c-Met downregulation is also delayed in PIKfyve 
inhibitor treated cells
FleLa cells were seeded onto 6-well plates and the following day treated 
with 3pM MF4 or its inactive analogue for 4 hours. 100ng/ml FIGF was 
then added to the medium for the indicated timepoints. Cells were then 
lysed in NP40 lysis buffer and 50pg protein was resolved on an 
SDS-PAGE gel. Proteins were transferred to nitrocellulose and probed 
with mouse anti-Met antibodies. Mouse anti-oc tubulin antibodies were 
used as a protein loading control. The downregulation of Met receptor 
is perturbed following inhibition of PIKfyve.
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Chapter Five
In accordance with the Western blotting data for combination 
knockdown treatments, when cells were treated with combinations of siRNA 
oligos directed at PIKfyve with those directed at either Vac14 or Fig4, or 
when treated with 800nM PIKfyve inhibitor (Figure 5.6), there was a 
substantial accumulation of EGFR after 4 hours of ligand-induced EGFR 
downregulation, when compared to control cells.
The question was then raised as to how EGFR downregulation is 
affected. It was unclear whether the delay in downregulation occurred 
because the EGFR was unable to reach the lysosome, or if the EGFR 
reaches the lysosome but is not degraded as this compartment is improperly 
acidified. Furthermore, if it is unable to reach the lysosome, is this the result 
of an internalisation defect at the MVB or due to a failure in maturation of the 
MVB/late endosome and its ultimate fusion with the lysosome? Evidence 
from Drosophila, that the downregulation of wingless receptors is delayed but 
their signalling output is not prolonged, would suggest that the former 
explanation is unlikely (Rusten et al., 2006). In this study colocalisation of 
EGFR with an early endosomal marker EEA-1 revealed that a proportion of 
the EGFR appeared to have been internalised into the lumen of swollen early 
endosomes (Figure 5.6), suggesting that internalisation of EGFR was 
unaffected.
5.2.5 Effect of loss of PIKfyve on downstream signalling and internalisation
In order to further examine the question of the requirement for PIKfyve 
activity in EGFR degradation, the effect of loss of PIKfyve activity upon 
downstream signalling pathways was determined. The phosphorylation of
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Chapter Five
two downstream targets of activated EGFR was studied over the timecourse 
of EGF stimulation (Figure 5.7).
EGFR is activated by the binding of its ligands (ie. EGF), which 
triggers a series of events including dimérisation, autophosphorylation at 
several different intrinsic tyrosine residues, signal transduction by 
phosphorylation of downstream targets (Carpenter, 1987), and receptor 
internalisation onto the endocytic pathway (Dunn and Hubbard, 1984; Cohen 
and Fava, 1985; Carpentier et al., 1987). Two key downstream signalling 
events are the phosphorylation of mitogen activated protein kinase (MAPK) 
via the Ras/Raf pathway (Rozakis-Adcock et al., 1992; Avruch et al., 1994; 
Batzer et al., 1994; Robinson and Cobb, 1997), and phosphorylation of 
Akt/PKB by the Pl(3)-kinase pathway (Meisner et al., 1995; Fukazawa et al., 
1996).
Following internalisation, EGFR is targeted for degradation in the 
lysosome, but it has been shown to continue signalling from the surface of 
early endosomes prior to its internalisation into the MVB lumen where the 
signal is terminated (Kay etal., 1986; Lai et ai, 1989; Sorkin and Carpenter, 
1991; Di Guglielmo etal., 1994; Vieira etal., 1996). Thus, if there is a defect 
in EGFR internalisation, we might expect to find prolonged downstream 
signalling events. However, downregulation of pAKT/PKB and pMAPK was 
found to be similar to control cells. In fact, there appeared to be a more rapid 
downregulation of pAKT/PKB compared to control cells (Figure 5.7).
This suggests that the effects on EGFR downregulation occur at a 
point after internalisation into the MVB lumen. However, the question 
remains why there is a defect in EGFR downregulation. There are several
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Figure 5.7. pAKT and pMAPK signalling is not prolonged following 
loss of PIKfyve activity
HeLa cells were seeded onto 6-well plates and the following day treated 
with 3pM MF4 for 4 hours. EGF was added to the medium for the 
indicated timepoints. Cells were then lysed in NP40 lysis buffer and 
50pg protein was resolved on an SDS-PAGE gel. Proteins were 
transferred to nitrocellulose and probed with mouse anti-pMAPK and 
rabbit anti-pAKT. pAKT and pMAPK signalling was not prolonged by 
loss of PIKfyve activity.
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possible explanations. Once internalised into the MVB efficient degradation 
of the receptor depends upon it reaching a correctly functioning lysosome. 
Thus, there could be a defect in the fusion of the MVB/late endosome with 
the lysosome. Alternatively, the EGFR could reach a lysosomal 
compartment that is unable to function correctly due to improper acidification. 
In support of the latter hypothesis, the yeast vacuole in Fab1 mutant cells is 
not properly acidified (Gary et at., 1998). By immunofluorescence, a portion 
of the EGFR does not reside in the EEA-1 labelled compartments. I 
attempted to further identify the nature of the compartment to which this 
portion of the EGFR localised, and to determine the acidification of the 
endosomal compartments following loss of PIKfyve activity.
Using an acidotropic dye that accumulates in the lysosome, 
Lysotracker red, I determined that there is no defect in acidification of the 
endocytic compartments, and most likely this dye accumulates in lysosomes 
as in normal cells (figure 5.8). It labels swollen compartments that surround 
the large cytoplasmic vacuoles (most likely the EEA-1 labelled 
compartments), as well as non-swollen compartments throughout the 
cytoplasm (most likely the lysosomes observed by EM (see figure 4.3)). 
However, to be sure that the acidic compartments are lysosomes, it will be 
necessary to observe lysotracker colocalisation with endosomal markers. 
Due to the technical difficulty of fixing lysotracker dye in these cells, we were 
unable to perform these experiments. The lysotracker dye does not label the 
limiting membrane or the lumen of the large vacuoles. Although, this could 
be as a result of the large volume of these vacuoles and the fact that these 
are confocal slices, it seems likely that the large vacuoles are not acidic.
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MF4
Lysotracker red AF488-EGF Merge
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anti-DNP
Figure 5.8. Internalised EGF reaches some acidic compartments 
but not the non-acidified vacuoles.
A) HeLa cells were seeded onto coverslips, serum starved overnight 
and the following day treated with 800nM MF4 for 4h. 100ng/ml 
AF488-EGF was then added to cells for 4h and lysotracker red for 2h.
B) Alternatively cells were labelled with 5pg/ml Acridine orange for 10 
mins. As a negative control cells were pre-treated with the vacuolar 
proton pump inhibitor Concanamycin (100nM) for 1h. Cells were 
washed in PBS, mounted onto slides and examined live by confocal 
microscopy at 37°C. C) For DAMP staining HEK293A cells were 
labelled with DAMP for 1h, fixed and permeabilised as normal and 
stained for monoclonal anti-DNP antibodies. Scale bars represent 
20pm, dotted lines represent vacuoles. AF488-EGF is able to reach 
similar acidic compartments to control cells, but is not found in the large 
vacuoles that are poorly acidified.
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In this experiment I also examined the degradation of a fluorescently 
tagged ligand (AF488-EGF). Although some EGF remains even in control 
cells, as some of the fluorescent tag may fail to get degraded along with the 
ligand, the same trend was observed that more EGF remained in cells 
treated with MF4. The remaining EGF in both control and MF4 treated cells 
partially overlaps with Lysotracker-labelled, acidic compartments. Thus, at 
least some of the EGF-EGFR complex is able to reach acidified 
compartments. However, the exact nature of these acidic compartments 
remains unclear, as does the nature of the compartments to which both EGF 
(Figure 5.8) and EGFR (Figure 5.6) localise that are not acidic or labelled 
with EEA-1. Of course these compartments are not necessarily one and the 
same, the EGFR and EGF could be in both an acidic lysosome and in a 
swollen EEA-1 compartment, but the fact that the acidic compartments, to 
which the majority of EGF localises are swollen, suggests that these are the 
EEA-1 labelled compartments observed by immunofluorescence. Both 
LAMP-2 staining and EM suggests that the lysosomes are not swollen in 
these cells.
I also examined a number of other markers of acidification, both 
Acridine Orange and DAMP (3-(2,4-dinitroanilino)-3_-amino-N- 
methyldipropylamine) staining, in cells treated with MF4 (Figure 5.8 B and C). 
DAMP is a basic congener of dinitrophenol (DNP) that readily diffuses into 
intact cells where its primary and tertiary amino groups allow it to accumulate 
in acidic organelles, and where it can be detected by anti-DNP antibodies. 
Acridine orange is a fluorescent dye that becomes protonated upon entry into
acidic compartments, and trapped there. Both dyes show that although there
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are acidic compartments within the cell, the large vacuoles have very low 
levels of acidification. In the case of the acridine orange experiment these 
pictures were taken on a fluorescence microscope, not a confocal 
microscope, and should reflect the total fluorescence of these compartments 
rather than a slice through them.
5.3 Discussion
In this chapter we set out to further dissect the involvement of 
Ptdlns(3,5)P2 in endocytic trafficking pathways. Conflicting evidence from 
the literature showed impaired trafficking of ubiquitinated cargo 
Carboxypeptidase S to the vacuole in S. cerevisiae Fab1 mutants (Odorizzi 
et al., 1998), failure in degradation of Wingless and Notch receptors in 
Drosophila Fab1 mutants (Rusten et al., 2006), and defective formation of 
terminal lysosomes in C. elegans Fab1 mutants (Nicot et al., 2006), but in 
mammalian cells loss of PIKfyve activity had no effect on the downregulation 
of internalised receptors (Ikonomov et al., 2003a; Rutherford et al., 2006) 
despite causing a reduction in MVB/ECV formation (Sbrissa et al., 2007). In 
addition to these findings, it has also been shown that degradation of the 
EGFR is significantly reduced in cells overexpressing the proposed 
Ptdlns(3,5)P2 binding domain ofVps24 (Yan et al., 2005) and overexpressing 
the Ptdlns(3,5)P2 binding myotubularin MTM1 (Tsujita etal., 2004), although 
the specificity of Ptdlns(3,5)P2 binding of these proteins is unclear.
In this chapter we present evidence that loss of PIKfyve leads to a 
delay in the downregulation of tyrosine kinase receptors. We were able to 
confirm the finding that siRNA oligos against PIKfyve had no effect on
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receptor downregulation by Western blotting. However, a more sensitive 
immunofluorescence assay suggested that there was a minor effect on 
EGFR degradation. Given the residual protein left upon PIKfyve knockdown, 
it is possible that Ptdlns(3,5)P2 plays a role in this process, but with a 
relatively low threshold value. We therefore wondered if combined 
knockdown of PIKfyve with its allosteric activator Vac14 might have a 
synergistic effect on this pathway. Although a combined knockdown of 
Vac14 and PIKfyve does not increase the percentage of cells displaying the 
vacuolar phenotype, it does have a mild effect on the rate of EGFR 
degradation, suggesting that in cells where both PIKfyve and Vac14 are 
depleted, there is an additional suppression of Ptdlns(3,5)P2 production. 
Furthermore, it suggests that there is a role for Ptdlns(3,5)P2 in the trafficking 
of endocytosed receptors, but at a relatively low threshold value.
Interestingly, a combined knockdown of PIKfyve and the phosphatase 
Fig4 also showed a mild effect on EGFR depletion. We might expect that 
depletion of Fig4 would serve to counteract the effects of PIKfyve 
knockdown, particularly when we consider work from Shisheva and 
colleagues that suggests that knockdown of Sac3 (mammalian Fig4) causes 
an increase in cellular Ptdlns(3,5)P2 and in MVB formation (Sbrissa et al., 
2007), and thus we might expect to see an increase in EGFR 
downregulation. That we see the opposite effect is particularly interesting 
given recent data that suggests that the S. cerevisiae proteins Fab1, Vac14 
and Fig4 form a lipid kinase-signalling complex, and that Vac14 and Fig4 are 
co-dependent for interaction with the chaperonin-related domain of Fab1 
(Botelho et al., 2008). Previous work has established that Vac14 and Fig4
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form a complex in yeast that plays a dual role in both the synthesis and 
turnover of Ptdlns(3,5)P2 (Rudge et al., 2004; Duex et ai, 2006b). Studies in 
mammalian cells presented in this study (Figures 3.19 and 3.21) and in the 
literature have shown that the interaction between Vac14 and Fig4 is 
conserved in higher organisms (Sbrissa eta!., 2007). An interaction between 
Vac14 and PIKfyve has also been demonstrated (Sbrissa etal., 2004), and 
has lead to the suggestion that these three proteins also from a ternary 
complex in mammalian cells that tightly regulates the levels of Ptdlns(3,5)P2 
(Sbrissa et al., 2007). Thus the finding that a combined knockdown of 
PIKfyve with either Vac14 or Fig4 perturbs EGFR downregulation, suggests 
that these proteins may indeed be acting in a complex with PIKfyve to tightly 
regulate the levels of Ptdlns(3,5)P2. Indeed, the tight control of Ptdlns(3,5)P2 
levels has been shown to be important for mammalian cell resistance to 
selected bacterial pathogens. Some pathogens, such as Salmonella 
enterica, have evolved mechanisms to overcome this response. They 
secrete a phosphatase, SopB, which uses Ptdlns(3,5)P2 as one of its 
substrates, and is thought the promote the survival of the pathogen by 
preventing transport to the lysosome (Marcus et al., 2001; Hernandez et al., 
2004; Pizarro-Cerda and Cossart, 2004), providing further evidence that the 
tight regulation of Ptdlns(3,5)P2 levels is essential for this pathway.
There was no delay in EGFR downregulation following loss of Vac14 
or Fig4 or a combination of the two, suggesting either that PIKfyve is able to 
produce sufficient Ptdlns(3,5)P2 in the absence of other components of the 
complex, or that knockdown of these proteins alone is insufficient to greatly
perturb the levels of Ptdlns(3,5)P2 in the cell. Combined knockdown of
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Vac14 and Fig4 does not produce the cytoplasmic vacuoles typically 
associated with Ptdlns(3,5)P2 depletion, suggesting that depletion of 
Ptdlns(3,5)P2 under these conditions must be minimal. I previously 
demonstrated that the Ptdlns(3,5)P2 threshold value for EGFR degradation 
must be relatively low as PIKfyve knockdown alone has only a small effect, 
therefore it is unsurprising that this combination of knockdowns has no effect 
on this pathway. It is also possible that regulation of the lipid kinase activity 
of PIKfyve by the Vac14/Fig4 complex is only necessary under certain 
conditions to stimulate increased production of Ptdlns(3,5)P2 and 
subsequently ensure that they do not stay elevated for longer than 
necessary, such as during hyperosmotic or other stresses. This is supported 
by the observation that knockdown of either protein renders certain 
mammalian cells more susceptible to cytoplasmic vacuolation following 
treatment with ammonium chloride and by the finding that PIKfyve and Vac14 
are both involved in mediating the rise in Ptdlns(3,5)P2 levels during 
hyperosmotic stress in 3T3-L1 adipocytes (Sbrissa etal., 2004; Sbrissa and 
Shisheva, 2005; Sbrissa etal., 2007).
In accordance with a role for Ptdlns(3,5)P2 in tyrosine kinase receptor 
downregulation, an acute pharmacological inhibition of PIKfyve, at 
concentrations which do not produce any major perturbation in the levels of 
other 3-phosphoinositides (data supplied by Kevan Shokat, also shown for 
YM201636 (Jefferies et ai, 2008)), revealed a statistically significant delay in 
the degradation of EGFR and indicated that this delay was the same for 
other tyrosine kinase receptors such as c-Met, although this experiment was
performed only once. This was further reinforced by immunofluorescence
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studies, which demonstrated that following 4 hours of ligand-induced 
receptor internalisation, there was a large amount of residual EGFR in MF4 
treated and combination knockdown cells. However, it must be taken into 
account that a limitation of any small molecule inhibitor is that its effects may 
not be as specific as predicted by in vitro studies. It is possible that this 
PIKfyve inhibitor may affect not only other Pl(3)kinases, although the levels 
of Ptdlns(3)P were assessed to some extent by immunofluorescence of the 
tandem FYVE domain probe, but also other phosphoinositide kinases such 
as Pl(4)-kinases or even other non-phosphoinositide kinases. Any effect on 
the kinase PDK-1 for example, may explain the effects on pAKT and pMAPK 
that are observed. This must be taken into account when assessing the data 
in this chapter, although can be overcome to some extent with observations 
from multiple systems such as protein knockdown in parallel to inhibitor 
treatment.
The larger swollen vacuoles are surrounded by late endosomal 
markers (LAMP-2), and contain few intralumenal vesicles. One possible 
explanation for the effects on EGFR degradation, is a failure to internalise the 
receptor into the lumen of the MVB/late endosome. However, the 
appearance of a proportion of the EGFR in swollen endosomes labelled with 
EEA-1 suggests some internalisation is able to take place, and that this is not 
the major impediment in this case. This is further reinforced by Western blot 
analysis of the levels of phosphorylated MAPK and AKT/PKB, two 
downstream signalling targets of EGFR. A failure in internalisation of the 
EGFR into the lumen of the MVB, such as that observed in Hepatocyte 
growth factor regulated tyrosine kinase substrate (Hrs)-depleted cells,
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prolongs receptor signalling (Lloyd et al., 2002). The levels of pMAPK and 
pAKT are unaffected by loss of PIKfyve activity suggesting that the defect in 
receptor degradation occurs at a point after the receptor has been 
internalised into the MVB and signalling has been silenced. Thus we can 
reconcile the effects in mammalian cells with those observed in model 
organisms, suggesting that the downregulation of endocytosed receptors, 
such as Drosophila wingless, is affected but that their signalling output is not 
(Rusten et al., 2006).
In the previous chapter I demonstrated a failure in retrieval of ciM6PR 
to the TGN. This defect may lead to a failure in the effective delivery of 
lysosomal hydrolases to these compartments, which might further contribute 
to a failure in degradation of lysosomally directed cargo. This hypothesis is 
supported by recent data that showed a defect in the processing of 
Cathepsin D in Vac14 knockout mice (Zhang et al., 2007), suggesting that 
there is a failure in the delivery of this lysosomal enzyme. Normally pro- 
Cathepsin D is synthesised at the TGN and transported to endosomes where 
the propeptide is cleaved to give an intermediate form. In the lysosome, this 
intermediate form is further cleaved into two noncovalently linked fragments. 
It was shown that both the pro and intermediate forms of Cathepsin D 
accumulated in Vac14 knockout mice, suggesting that it is not correctly 
processed at the endocytic pathway. Alternatively other proteins may need 
to be retrieved from the MVB to allow its correct acidification, and given the 
demonstration that the retrieval of a number of proteins is perturbed, this may 
also contribute to improper acidification of this compartment following loss of 
PIKfyve activity.
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In conclusion, reduced ILV formation, inefficient lysosomal enzyme 
delivery and improper acidification may all contribute to the failure in 
maturation of a subset of MVBs and the phenotype observed following loss 
of PIKfyve activity.
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CHAPTER SIX
The Role of the W IPI Proteins in Mammalian Autophagy
6.1 Introduction
Thus far, the evidence presented has demonstrated a role for 
Ptdlns(3,5)P2 in retrieval to the TGN (chapter four) and lysosomal delivery of 
endocytosed material (chapter five). These findings could both be explained 
by a failure in endosomal maturation. As the endocytic pathway progresses, 
endocytosed material is sorted to either tubular retrieval pathways, or to 
vesicular degradative pathways. Ptdlns(3,5)P2 may function to coordinate 
these sorting events, such that following its depletion we observe a delayed 
retrieval to the TGN, and perturbed degradation of lysosomally targeted 
material. Interestingly, apart from PIKfyve, none of the other Ptdlns(3,5)P2 
associated proteins displayed any visible aberrant knockdown phenotype, or 
had any effect on either membrane retrieval or lysosomal degradation, 
unless combined with PIKfyve knockdown in the case of Vac14 and Fig4.
WIPI-2 is a member of a family of proposed downstream effectors of 
Ptdlns(3,5)P2 function (Jeffries et ai., 2004; Proikas-Cezanne et al., 2004). 
Another member of the WIPI family, WIPI-1 has been shown to play a role in 
membrane retrieval to the TGN, as has the yeast protein Atg18/Svp1 (Dove 
et al., 2004; Jeffries et al., 2004). Therefore, it is particular interesting that 
WIPI-2 had no effect on membrane retrieval pathways to the TGN. This 
suggests that, if it is indeed an effector of Ptdlns(3,5)P2, it does not function 
on these Ptdlns(3,5)P2-dependent pathways, and indeed members of the 
WIPI family may have different effector functions.
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Ptdlns(3)P has been shown to play an important role in autophagy, as 
discussed in section 1.9.3.2 (Herman and Emr, 1990; Kihara eta/., 2001; 
Byfield et al., 2005). The finding that the yeast protein Atg18/Svp1 and the 
mammalian WIPI family, are also proposed to play a role in autophagy, has 
implicated Ptdlns(3,5)P2 in this process (Barth et ai, 2001; Guan eta!., 2001; 
Dove et al., 2004; Stromhaug et at., 2004; Proikas-Cezanne et at., 2007). 
However, the precise role of these proteins and how this relates to their 
phosphoinositide binding capacity remains unclear.
In order to further examine the requirement of Ptdlns(3,5)P2 in 
autophagy, the role of the kinase, Fab1, has been examined to some extent. 
Consistent with its proposed role on the endocytic pathway, in Drosophila the 
kinase Fab1 was found to be necessary for the maturation of autolysosomes 
in autophagy, subsequent to the fusion of autophagosomes with the 
endosomal system (Rusten et al., 2007). Loss of Atg18 in S. cerevisiae has 
also been shown to inhibit the fusion of autophagosomal structures with the 
endocytic pathway (Barth et al., 2001). Atg18 is proposed to play a role in 
retrieval of the transmembrane protein Atg9 from the autophagosome prior to 
it’s completion, the precise function of which is not known (Reggiori et al., 
2004). It has been also suggested that the function of Atg18/Svp1 in 
autophagy is independent of its binding to Ptdlns(3,5)P2 (Dove et al., 2004). 
In mammalian studies WIPI-1 has been linked to autophagy in human tumour 
cells, dependent on its capacity to bind Ptdlns(3)P (Proikas-Cezanne et al., 
2007) but the role of WIPI-2 in mammalian autophagy has yet to be 
investigated. The aim of this chapter was to begin to answer some of these 
questions.
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1) To examine the role of Ptdlns(3,5)P2 in mammalian autophagy.
2) To assess the function of WIPI-2 in mammalian autophagy in general and 
in relation to its role as an effector of Ptdlns(3,5)P2.
6.2 Results
6.2.1 Autophagy assay
In order to examine the role of Ptdlns(3,5)P2 and WIPI-2 in autophagy, 
we made use of an established autophagy assay using a HEK293A cell line 
stably transfected with GFP-LC3, hereafter referred to as 2GL9 cells (Chan 
et a/., 2007). The autophagy protein LC3 is proposed to be a marker of 
autophagosome formation. As discussed in section 1.9.3.3, following 
induction of autophagy, LC3 is conjugated to a lipid, PE by means of a 
conserved ubiquitin-like conjugation system (Kabeya et al., 2000; Ohsumi 
and Mizushima, 2004). Conjugated, membrane-associated LC3 protein (LC3 
II) localises to punctate structures in the cell, whereas unconjugated LC3 
(LC3 I) is distributed throughout the cytoplasm.
This can be expoited for monitoring mammalian autophagy in two 
ways. Firstly, by visualising the accumulation of GFP-LC3 II at 
autophagosomal membranes (GFP-LC3 II puncta formation) by 
immunofluorescence. Secondly, the conjugation corresponds to a shift in 
molecular weight on an SDS-PAGE gel. Thus the ratio of LC3 II to total LC3 
(LC3 I + LC3 II) can also be examined (Mizushima, 2004).
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6.2.2 Role of PIKfyve in autophagy
Although the role of the yeast protein in autophagy has been 
examined to some extent, the role of the mammalian protein PIKfyve has not. 
Therefore, I began by assessing the effect of PIKfyve siRNA treatment in the 
established autophagy assay. It caused a modest increase in the ratio of 
GFP-LC3 II to total GFP-LC3 (Figure 6.1 A and C). Three oligos were used 
to assess the robustness of this effect, two oligos that had previously been 
shown to suppress the levels of endogenous PIKfyve, and one that had 
exhibited no effect (as demonstrated in figure 4.1). However, reassessment 
of siRNA efficiency, demonstrated that all three oligos suppressed PIKfyve 
protein levels in this case (Figure 6.1 B). Only one of the three oligos was 
found to have a significant effect on GFP-LC3 ratios (Figure 6.1 C) (N=3,
p<0.01).
Given the inefficiency of PIKfyve knockdown, and the residual protein 
remaining after 72 hours of transfection, the effects of the PIKfyve inhibitor 
were examined. Acute pharmacological inhibition of PIKfyve caused a 
significant increase in the ratio of GFP-LC3 II to total GFP-LC3 following 
starvation induction of autophagy (Figure 6.2 A and quantified in B) (N=3, 
p<0.01). There was no effect on the basal ratio (in fed cells), and an inactive 
analogue of the PIKfyve inhibitor had no effect. This accumulation could be 
as a result of either an increase in autophagosome formation, or a decrease 
in their degradation.
Treatment with the protease inhibitor Leupeptin following starvation 
induction of autophagy causes a further increase in the ratio of GFP-LC3 II to 
total GFP-LC3, as autophagosomes are no longer efficiently degraded. In
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A Control PIKfyve oligo 1
PIKfyve 
oligo 4
PIKfyve 
oligo 3
GFP-LC3 I 
GFP-LC3II
Tubulin
Fed Starved Fed Starved Fed Starved Fed Starved
B mmmmmmmmmmm PIKfyve 
Mock Oligo 1 Oligo 4 Oligo 3
fed starved fed starved fed starved
Figure 6.1. PIKfyve knockdown causes an accumulation of lipidated 
GFP-LC3 following starvation induction of autophagy.
2GL9 cells were seeded onto 12-well plates and transfected twice with 
40nM PIKfyve oligos over 72h, then starved or fed for 2h.
A) Cells were lysed in 1X sample buffer containing 1mM DTT and 10pg 
protein resolved by SDS-PAGE. Protein was transferred to nitrocellulose 
and probed with polyclonal GFP antibodies.
B) 50pg NP40 lysates were resolved by SDS-PAGE and the resulting 
nitrocelluose probed with anti-PIKfyve antibodies.
C) The ratio of GFP-LC3II to total GFP-LC3 was quantified using LiCor 
Odyssey software (N=3, +/-SEM, ** p<0.01, Student’s T-test).
PIKfyve knockdown causes a mild accumulation in GFP-LC3 lipidation 
following starvation induction of autophagy, but has no effect on basal levels 
of lipidation. All three oligos suppress the levels of endogenous PIKfyve, 
and two of the three oligos give a corresponding increase in GFP-LC3II.
A -GFP-LC3 I 
-GFP-LC3 II
Tubulin
Fed Starved Sta™ ed + Fed Starved Starved +  Fed Starved Starved + 
Leupeptin Leupeptin Leupeptin
Control Inactive analogue MF4
B
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m
y 0.25-
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Figure 6.2. PIKfyve inhibition causes a significant accumulation of 
lipidated GFP-LC3 following starvation induction of autophagy.
2GL9 cells were seeded onto 12-well plates with coverslips for IF. Following 
treatment with 800nM MF4 for 4 hours cells were fed or starved 2h, with 
0.25mg/ml Leupeptin where indicated.
A) Cells were lysed in 1X sample buffer containing 1mM DTT and 10pg 
lysates resolved by SDS-PAGE, transferred to nitrocellulose and probed 
with polyclonal anti-GFP antibodies.
B) The ratio of GFP-LC3II to total GFP-LC3 was quantified. N=3, +/- SEM, 
** p<0.01, Students t-test.
C) Cells were fixed in 3% PFA/PBS and GFP-LC3II positive puncta 
formation examined.
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control cells and those treated with an inactive analogue of the inhibitor, 
Leupeptin treatment caused a further 50% increase in lipidation. Whilst 
PIKfyve inhibitor treatment also caused a further increased in lipidation 
following Leupeptin treatment, the level of increase was not the same, which 
suggests that there is a defect in protein degradation rather than an increase 
in autophagosome formation. Therefore the effects of inhibiting PIKfyve 
(MF4 treatment) and lysosomal protease inhibition (Leupeptin treatment) 
most likely overlap, as the effect is not additive. The effect of inhibition of 
PIKfyve can also be seen by immunofluorescence. There is an accumulation 
of GFP-LC3 II positive punctae in PIKfyve inhibitor treated cells following 
starvation induction of autophagy (Figure 6.2 C).
6.2.3 Opposing roles of WIPI-2 and PIKfye
Next, the effects of of Vac14, WIPI-2, WIPI-1, Fig4 and PIKfyve 
knockdown were examined in parallel (Figure 6.3). Knockdown of Vac14, 
WIPI-1 and Fig4 had no significant effect on lipidated GFP-LC3 levels. The 
slight decrease observed with Vac14 was not reproducible but the increase 
following knockdown of PIKfyve is reiterated in this figure. Interestingly, 
knockdown of the Ptdlns(3,5)P2 effector WIPI-2 had the opposite effect to 
knockdown of PIKfyve, causing a decrease in the ratio of GFP-LC3 II to total 
GFP-LC3. Thus, PIKfyve and WIPI-2 were found to have the opposite effect 
on GFP-LC3 lipidation in this assay.
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6.2.4 Dissecting the role of WIPI-2 in autophagy
The role of WIPI-2 in autophagy was subsequently examined in more 
detail. Using the WIPI-2 antibody characterised in Chapter three, we were 
able to show that starvation-induced autophagy causes a 5-fold increase in 
the number of WIPI-2 puncta (Figure 6.4), initially seen at a low level in fed 
cells for both endogenous and overexpressed protein (Figures 3.16 and 3.12 
respectively). Punctae were quantified from a number of images taken with 
the same laser settings and subsequently thresholded using Image J 
software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, _Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2008). Punctate 
and cytosolic staining was lost following WIPI-2 siRNA treatment, indicating 
that the punctae are specific to WIPI-2. It was subsequently shown that 
approximately 37% of the WIPI-2 punctae colocalise with the 
autophagosome marker GFP-LC3. Attempts were made to identify the 
nature of the non-autophagosomal pool of WIPI-2 (Figure 6.5). However, 
there was no colocalisation with any of the markers used.
WIPI-2 is a proposed downstream effector of Ptdlns(3,5)P2 function 
and yet loss of Ptdlns(3,5)P2 (as judged by inhibition or knockdown of 
PIKfyve) and loss of WIPI-2 have the opposite effect. Given that the function 
of Svp1/Atg18 in autophagy has been proposed to be independent of its 
binding of Ptdlns(3,5)P2 (Dove et a/., 2004), and that mammalian WIPI-1 
punctae formation is dependent on Ptdlns(3)P binding (Proikas-Cezanne et 
al., 2007), I examined the effects of PIKfyve and Pl(3)-kinase inhibitors on 
WIPI-2 punctae formation (Figure 6.6). Treatment with PIKfyve inhibitor
causes a corresponding accumulation of WIPI-2 punctae, in addition to the
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Figure 6.5. WIPI-2 puncta do not colocalise with endosomal or ER 
markers.
HeLa cells were seeded onto coverslips and fixed in 3% PFA/PBS, 
permeabilised in 0.2% TX100 and stained with WIPI-2, EEA-1 (early 
endosome), LAMP-2 (late endosome) and KDEL (ER) markers. Scale bars 
represent 20pm.
GFP-LC3 WIPI-2 Merge
Figure 6.6. WIPI-2 and GFP-LC3 starvation-induced punctae formation 
is dependent on the activity of Ptdlns(3)-kinase but not PIKfyve.
2GL9 cells were seeded onto 12-well plates with coverslips for IF. Following 
treatment with 800nM PIKfyve inhibitor for 4 hours cells were fed in full 
DMEM or starved in EBSS for 2h, with 100nM Wortmannin for the final 30 
minutes where indicated. Cells were fixed in 3% PFA/PBS, permeabilised in 
0.2% TX-100 and stained with WIPI-2 antibody. Wortmannin causes the 
ablation of both GFP-LC3 and WIPI-2 puncta, whereas PIKfyve inhibitor 
causes their accumulation. Scale bars represent 20pm.
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accumulation of GFP-LC3 II punctae. Treatment with the Pl(3)-kinase 
inhibitor Wortmannin, on the other hand, causes ablation of both forms of 
punctae.
Decrease in the ratio of GFP-LC3 II to total GFP-LC3 following WIPI-2 
knockdown was found to be robust (Figure 6.7). This effect was also shown 
to be dependent on the level of WIPI-2 protein knockdown, the greater the 
level of WIPI-2 knockdown the greater the effect on GFP-LC3 lipidation (6.7 
A and quantified in B) (N=3, p<0.01). An oligo that does not suppress WIPI-2 
protein has no effect on GFP-LC3 II levels.
Given that a reduction in GFP-LC3 II could represent either a 
decreased formation of autophagosomes or an increase in turnover of 
autophagosomes at the lysosome, I assessed the additional effects of 
Leupeptin and MF4 treatment in combination with WIPI-2 siRNA (Figure 6.8). 
A significant decrease in lipidation is observed once again following WIPI-2 
knockdown (N=3, p<0.01). Following Leupeptin treatment in WIPI-2 siRNA 
cells there is a typical level of increase in lipidation. MF4 treatment brings 
lipidation levels in WIPI-2 siRNA cells back to those seen in control cells, but 
not to a level comparable with Leupeptin treatment.
In order to further dissect the role of WIPI-2 in autophagy, its effect on 
GFP-LC3 lipidation was compared to other autophagy genes known to be 
involved in the initial stages of autophagosome formation. ULK-1 is a serine 
threonine kinase that is an integral part of the autophagy-inducing complex 
as discussed in section 1.9.3.1 (Chan et al., 2007) whilst Beclin is part of the 
Pl(3)-kinase complex involved in autophagy, as also discussed in section
1.9.3.2 (Liang eta!., 1999; Boya etal., 2005; Zeng eta /., 2006).
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B
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fed starved fed starved fed starved
Figure 6.7. WIPI-2 knockdown causes a reduction in GFP-LC3 
lipidation following starvation induction of autophagy.
2GL9 cells were seeded onto 12-well plates and transfected twice with 
40nM individual WIPI-2 oligos over 72h. A) Cells were lysed in 1X sample 
buffer containing 1mM DTT and 10pg protein resolved by SDS-PAGE. 
Protein was transferred to nitrocellulose and probed with polyclonal GFP 
antibodies. B) The ratio of GFP-LC3II to total GFP-LC3 was quantified 
using LiCor Odyssey software (N=3, +/-SEM, * p<0.05, Student’s T-test). 
WIPI-2 knockdown causes a reduction in GFP-LC3 lipidation following 
starvation induction of autophagy, but has no effect on basal levels of 
lipidation. The effect is knockdown efficiency dependent, such that the 
greatest level of protein knockdown gives the greatest effect on lipidation.
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Figure 6.8. The effects of WIPI-2 knockdown are partially reversed 
following treatment with Leupeptin or MF4.
2GL9 cells were seeded onto 12-well plates and transfected twice with 40nM 
WIPI-2 oligos over 72h. 0.25mg/ml Leupeptin and 800nM MF4 were added 
where indicated. Cells were starved in EBSS for 2 hours.
A) Cells were lysed in 1X sample buffer containing 1mM DTT and 10pg 
protein resolved by SDS-PAGE. Protein was transferred to nitrocellulose and 
probed with polyclonal GFP antibodies.
B) The ratio of GFP-LC3II to total GFP-LC3 was quantified using LiCor 
Odyssey software (N=3, +/-SEM, * p<0.05, Student’s T-test).
Treatment with Leupeptin or MF4 partially counteracts the effects of WIPI-2 
knockdown, bringing LC3 lipidation back to the levels of control starved cells.
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WIPI-2 produces a similar effect on GFP-LC3 lipidation as the key autophagy 
protein ULK-1 (Figure 6.9). Furthermore, a combined knockdown of both 
WIPI-2 and ULK-1 has an additive effect on GFP-LC3 lipidation. Efficient 
knockdown of Beclin could not be established, therefore I was unable to 
compare the effects of WIPI-2 knockdown to Beclin knockdown or examine 
the effects of their combined knockdown.
To further establish that the effects of WIPI-2 knockdown on lipidation 
are due directly to a loss of WIPI-2 protein, it was subsequently 
demonstrated that overexpression of siRNA resistant WIPI-2 could rescue 
these effects (Figure 6.10). This can also be observed by 
immunofluorescence (Figure 6.11). The number of GFP-LC3 II positive 
punctae was counted in all the cells in each of 5 fields for each condition. As 
before this was performed in images taken with the same laser settings that 
were subsequently thresholded and quantified in Image J. Where constructs 
were transfected into cells the counts were divided into those in cells 
expressing the construct of interest and those not transfected. In cells not 
expressing the siRNA resistant myc-WIPI-2, one would expect to see the 
same phenotype as the WIPI-2 siRNA treated cells.
As demonstrated using the SDS-PAGE shift assay, there was a 
reduction in GFP-LC3 II positive punctae in cells treated with WIPI-2 siRNA. 
Control cells had an average of 21 ±1.3 GFP-LC3 II punctae, whereas those 
treated with WIPI-2 siRNA had 12.8 ± 1.18. In cells transfected with siRNA 
resistant myc-WIPI-2, the number of GFP-LC3 II punctae was similar to 
control cells (25.6 ± 2). In non-transfected cells in the same field there was 
also a slight increase compared to WIPI-2 siRNA treated cells, but still less
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Figure 6.9. WIPI-2 and ULK-1 have comparable effects in autophagy, 
and their combined knockdown has an additive effect.
2GL9 cells were seeded onto 12-well plates and transfected twice with 
40nM of the indicated individual oligos over 72h.
A) Cells were lysed in 1X sample buffer containing 1mM DTT and 10pg 
protein resolved by SDS-PAGE. Protein was transferred to nitrocellulose 
and probed with polyclonal GFP antibodies.
B) The ratio of GFP-LC3II to total GFP-LC3 was quantified using LiCor 
Odyssey software (N=3, +/-SEM,** p<0.01, Student’s T-test).
Loss of WIPI-2 has a comparable effect to that of ULK-1. Combined 
knockdown of the two has an additive effect on GFP-LC3 lipidation.
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Figure 6.10. Overexpression of siRNA resistant WIPI-2 rescues the 
WIPI-2 knockdown phenotype.
2GL9 cells were seeded onto 12-well plates and transfected twice with 
40nM individual WIPI-2 oligos over 72h and transfected with siRNA resistant 
WIPI-2 once for 24h.
A) Cells were lysed in 1X sample buffer containing 1mM DTT and 10pg 
protein resolved by SDS-PAGE. Protein was transferred to nitrocellulose 
and probed with polyclonal GFP antibodies.
B) The ratio of GFP-LC3II to total GFP-LC3 was quantified using LiCor 
Odyssey software (N=3, +/-SEM, * p<0.05 ** p<0.01, Student’s T-test).
The effect of loss of WIPI-2 can be rescued by overexpression of a 
knockdown resistant construct.
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Figure 6.11. myc-WIPI-2 overexpression rescues the WIPI-2 siRNA 
phenotype as examined by immunofluorescence.
2GL9 cells were seeded onto coverslips and transfected twice with 40nM 
WIPI-2 siRNA oligos over 72h and with overexpression constructs for 24h.
A) Cells were fixed in 3% PFA/PBS, permeabilised in 0.2% TX100 and 
stained with WIPI-2 antibodies.
B) The number of GFP-LC3 II punctae in each cell in five fields were counted 
for each condition and quantified as fold change from control. Scale bars 
represent 20pm. T= transfected UT = untransfected.
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than control. These cells could be transfected with the overexpression 
constructs but expressing the protein at levels below the detection threshold 
of the myc antibody by immunofluorescence.
6.2.5 A role for WIPI-1
WIPI-1 has previously been shown to redistribute to punctate 
structures following starvation induction of autophagy in human tumour cells 
(Proikas-Cezanne et a i, 2007). Overexpression of myc-WIPI-1 caused a 
reduction in the number of WIPI-2 punctae, suggesting the two are possibly 
competing for the same binding sites (Figure 6.12). However, we were 
unable to find any effect of WIPI-1 knockdown on autophagosome formation 
(Figure 6.3 and 6.13) and a combined knockdown of WIPI-1 and WIPI-2 had 
the same effect as knockdown of WIPI-2 alone (Figure 6.13). It was difficult 
to assess the levels of WIPI-1 knockdown, as WIPI-1 antibodies were unable 
to detect endogenous WIPI-1 in this cell line. Thus the lack of effect could 
have been due to ineffective suppression of WIPI-1 or because the levels of 
WIPI-1 are negligible in this cell line.
6.3 Discussion
The work presented in this chapter examined the role of Ptdlns(3,5)P2 
and one of its proposed downstream effectors, WIPI-2, in mammalian 
autophagy. Previous work has established that the yeast proteins 
Atg18/Svp1 and the mammalian WIPI family member, WIPI-1, play a role in 
autophagy in both organisms (Barth et ai, 2001; Dove et ai, 2004; Jeffries et 
al., 2004; Proikas-Cezanne et ai, 2004). Given that these proteins have
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Figure 6.13. WIPI-1 has no effect on GFP-LC3 lipidation following 
starvation induced autophagy.
2GL9 cells were seeded onto 12-well plates and transfected twice with 
40nM of the indicated individual (WIPI-2) or pooled (WIPI-1) oligos over 72h. 
Cells were fed in DMEM or starved in EBSS for 2h.
A) Cells were lysed in 1X sample buffer containing 1mM DTT and 10pg 
protein resolved by SDS-PAGE. Protein was transferred to nitrocellulose 
and probed with polyclonal GFP antibodies.
B) The ratio of GFP-LC3II to total GFP-LC3 was quantified using LiCor 
Odyssey software (N=3, +/-SEM, * p<0.05, Student’s T-test). WIPI-1 has no 
effect on GFP-LC3 lipidation, although the protein may not be suppressed 
effectively.
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been shown to bind both Ptdlns(3)P and Ptdlns(3,5)P2, this lead to the 
suggestion of a role for Ptdlns(3,5)P2 in autophagy. In S. cerevisiae, 
however, the role of Svp1 is thought to be independent of its Ptdlns(3,5)P2 
binding capacity (Dove et al., 2004). In this chapter I set out to examine the 
potential roles of Ptdlns(3,5)P2 and the WIPI proteins in mammalian 
autophagy.
6.3.1 The role of Ptdlns(3,5)P2 in mammalian autophagy
Autophagy occurs at a basal level in most cells and contributes to 
turnover of cytoplasmic components. However, in response to starvation or 
cellular insults, autophagic activity is increased to ensure cellular survival 
(Schworer and Mortimore, 1979; Mortimore and Poso, 1987). Portions of the 
cytoplasm are engulfed by a double membrane bound autophagosome that 
then fuses with the endolysosomal system, where its contents are degraded 
in the lysosome (Arstila and Trump, 1968; Gordon and Seglen, 1988; 
Stromhaug and Seglen, 1993). Induction of autophagosome formation 
requires Ptdlns(3)P (Petiot et al., 2000), isolation membranes of unknown 
origin, and two ubiquitin-like modification systems (Ohsumi and Mizushima, 
2004). One of these modifications is the conjugation of Atg8/LC3 to PE, 
which was used to assay autophagosome formation in this study.
By examining the knockdown of PIKfyve protein and inhibition of its 
activity, we clearly demonstrate that loss of PIKfyve activity causes a 
significant increase in GFP-LC3 lipidation, and a large accumulation of GFP- 
LC3 II positive punctae by immunofluorescence. This suggests that loss of 
PIKfyve either causes an increase in autophagosome formation, or a
245
Chapter Six
reduction in their degradation. The protease inhibitor Leupeptin causes an 
increase in GFP-LC3 lipidation for the latter reason. Therefore, comparing 
the effects of Leupeptin on control cells and those treated with PIKfyve 
inhibitor should give an idea of what effect loss of PIKfyve activity is having. 
If it is causing an increase in autophagosome formation, then treatment with 
both Leupeptin and PIKfyve inhibitor should have an additive effect on GFP- 
LC3 lipidation. However, following Leupeptin treatment, there is only a very 
slight further increase in GFP-LC3 lipidation (Figure 6.2). This suggests that 
the two effects must overlap with one another and that PIKfyve inhibition is 
exerting a similar effect to Leupeptin on autophagy. This finding 
complements the existing literature in Drosophila, which showed that Fab1 
mutants displayed an accumulation of amphisomes subsequent to fusion 
with the endocytic pathway, rather than autophagosomes (Rusten et ai, 
2007). Furthermore, PIKfyve inhibition was found to cause a decrease in 
protein degradation (Jefferies et at., 2008). Taken together these data, and 
the defect in EGFR degradation demonstrated in chapter five, indicate that 
Ptdlns(3,5)P2 most likely has an indirect effect on the autophagy pathway. 
Autophagosomes are able to fuse with the endocytic pathway to form 
amphisomes, but defects in maturation of the MVB/late endosome mean that 
subsequent degradation of the autophagosome is not achieved, just as 
EGFR is not effectively degraded. It would be interesting to examine the 
acidification of GFP-LC3 labelled compartments in these cells to further 
elucidate the specific effect on degradation; due to technical difficulties I was 
unable to do these experiments in this study.
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6.3.2 The role of WIPI-2 in mammalian autophagy
Ptdlns(3,5)P2 was first linked to autophagy through the identification of 
its downstream effectors Atg18/Svp1 and Atg21 in yeast, and the mammalian 
WIPI family, which play a role in this cellular process, as described in section 
1.9.3.4. Atg18/Svp1 has been shown to bind the transmembrane protein 
Atg9, an autophagy protein that localises to the forming autophagosome and 
other unknown punctate structures, and is not present on the completed 
autophagosome, suggesting that it is recycled from the forming 
autophagosome membrane at some point. Atg18/Svp1 is proposed to be 
involved in the cycling of Atg9 as it binds both Atg9 and the Atg1-Atg13 
complex that governs Atg9 cycling (Reggiori et al., 2004). Evidence 
suggests that this function may be independent of its binding of Ptdlns(3,5)P2 
in yeast, but the mammalian proteins have not yet been examined in any 
detail. One member of this family, WIPI-1 has been proposed to be involved 
in retrograde transport to the TGN and has also been shown to play a role in 
autophagy in human tumour cells (Jeffries etal., 2004; Proikas-Cezanne et 
al., 2004). WIPI-1 has also been shown to bind both Ptdlns(3)Pand 
Ptdlns(3,5)P2 in vitro, but any parallel role in mammalian Atg9 cycling has yet 
to be clearly established, nor in fact has any clear understanding of their 
precise function in autophagy.
In this study we find that knockdown of WIPI-2 causes a significant 
and reproducible decrease in GFP-LC3 lipidation, which is confirmed by the 
use of several siRNA oligos that suppress WIPI-2 protein levels. The 
specificity of this effect is further demonstrated by the fact that an oligo that 
does not suppress WIPI-2 protein levels does not affect GFP-LC3 lipidation,
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and that overexpression of siRNA resistant WIPI-2 is able to rescue the 
phenotype. Loss of WIPI-2 could be causing either a decrease in 
autophagosome formation or an increase in lysosomal degradation but the 
finding that there is the same degree of response to Leupeptin treatment. 
The fact that PIKfyve inhibition also reverses the WIPI-2 phenotype again 
reinforces the idea that PIKfyve functions at a later stage of the autophagy 
pathway in regulating degradation.
In a manner similar to LC3, WIPI-2 is recruited to membrane bound 
structures during starvation induced autophagy. There was a basal level of 
WIPI-2 punctae, most likely representing the basal level of autophagy 
occurring in these cells. Over a third of WIPI-2 punctae colocalised with the 
autophagosome marker GFP-LC3 II, suggesting that WIPI-2 is recruited to 
the autophagosome to perform its autophagic function. I was unable to 
characterise the punctae that did not colocalise with GFP-LC3 in starved 
cells. It has been suggested that GFP-LC3 may be quenched once the 
autophagosome fuses with acidic compartments, thus these WIPI-2 punctae 
could represent a later pool of amphisomes or acidic autophagosomes. In 
order to assess this, I attempted to examine the colocalisation of each set of 
punctae with both endogenous LC3 and Lysotracker markers, however for 
technical reasons I was unable to make the required observations. It is clear 
however that these punctae do not colocalise with early or late endosomal 
markers suggesting that WIPI-2 does not localise to these endosomal 
compartments. Colocalisation with an ER marker was also examined, given 
that one of the proposed origins of the autophagosomal membranes is the
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ER (Dunn, 1994; Kovacs et ai, 2000), but again no significant colocalisation 
was observed.
WIPI-2 and PIKfyve produce opposite effects on autophagy assays. 
The role of Atg18 has been shown to be independent of its binding to 
Ptdlnd(3,5)P2 in yeast and my data suggest that this may also the case with 
the mammalian proteins. This hypothesis was confirmed by treating cells 
with the Pl(3)-kinase inhibitor wortmannin, which was found to ablate the 
formation of both WIPI-2 and GFP-LC3 II punctae. Although it is possible 
that this is an indirect effect of reducing the levels of Ptdlns(3,5)P2 due to 
loss of its precursor Ptdlns(3)P, it was subsequently shown that treatment 
with PIKfyve inhibitor had the opposite effect, causing an accumulation of 
WIPI-2 and GFP-LC3 II punctae. This suggests that WIPI-2 is recruited to 
autophagic membranes through its binding of Ptdlns(3)P and not 
Ptdlns(3,5)P2, although this does not rule out subsequent binding to 
Ptdlns(3,5)P2 and further autophagic functions.
Through further experiments I began to dissect the role of WIPI-2 in 
autophagy in more detail. By comparison with known autophagy protein 
ULK-1 it was demonstrated that these proteins have a comparable effect on 
autophagosome formation. ULK-1 is a serine threonine protein kinase and 
the mammalian homologue of the yeast protein Atg1, which is thought to 
form an essential part of the autophagy-inducing complex downstream of 
TOR signalling. Knockdown of ULK-1 has previously been shown to cause a 
reduction in GFP-LC3 lipidation (Chan e ta i, 2007). That WIPI-2 and ULK-1 
exert similar effects on lipidation, suggests that they may have equally
important roles in autophagy. However, as WIPI-2 is recruited to the
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autophagic membrane in a Ptdlns(3)P dependent manner, then it would most 
likely be involved in a different part of the autophagic pathway to ULK-1, as 
Ptdlns(3)P is formed by the action of the Vp34/Beclin complex that is 
recruited to the forming autophagosome membrane after autophagy has 
been induced by the autophagy inducing complex incorporating ULK-1. To 
test this hypothesis a combined knockdown of ULK-1 and WIPI-2 were 
examined. If WIPI-2 and ULK-1 exert their effects on different parts of the 
autophagy machinery (induction and autophagosome formation) then a 
combined knockdown should produce an additive effect on GFP-LC3 
lipidation, which it did. However, it must also be taken into account that in 
yeast, the Atg1-Atg13 complex is also proposed to regulate Atg9 cycling 
along with Atg18/Svp1 (Reggiori et al., 2004), a function that may also be 
conserved for the mammalian protein ULK-1 (Young etal., 2006). Therefore, 
the conclusion that WIPI-2 and ULK-1 knockdown affect two independent 
parts of the autophagy pathway is not absolutely clear, as knockdown of 
ULK-1 could be having an indirect effect on WIPI-2 if the interactions for the 
yeast proteins hold true for their mammalian counterparts. Interestingly, 
WIPI-2 has the opposite phenotype to Atg18 in autophagy, suggesting that 
perhaps the WIPI family may have a more complex role in autophagy that the 
yeast proteins.
6.3.3 A role for WIPI-1
Finally, I reexamined the potential role of WIPI-1 in autophagy. It has 
previously been shown that WIPI-1 is recruited to autophagic structures 
following starvation (Proikas-Cezanne etal., 2007), as demonstrated in this
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study with WIPI-2, suggesting that the two proteins may have similar 
functions, and may display some functional redundancy. In accordance with 
this, I found that overexpression of WIPI-1 caused a reduction in the 
recruitment of endogenous WIPI-2 to autophagic structures. However, I was 
unable to demonstrate an effect of WIPI-1 knockdown on GFP-LC3 lipidation. 
Furthermore, a combined knockdown of WIPI-1 and WIPI-2 had only the 
same effect as WIPI-2 knockdown alone. This suggested either that the 
expression of this protein is negligible in this cell line, given that an effect for 
WIPI-1 was demonstrated in a different cell line, or that the knockdown of 
WIPI-1 was inefficient. Indeed, detection of endogenous WIPI-1 in these 
cells was difficult, and the knockdown efficiency could not be effectively 
determined. WIPI-1 antibodies were obtained through the course of 
collaborative work. As such, they had previously been tested in other cell 
lines and shown to specifically detect both overexpressed and endogenous 
WIPI-1 (personal communication Dr Hannah Poison).
6.3.4 Conclusions
In conclusion, the work presented in this chapter, summarised in 
figure 6.14, demonstrates that the main role of Ptdlns(3,5)P2 in mammalian 
autophagy is most likely indirect. In combination with data outlined in 
chapters four and five it suggests that Ptdlns(3,5)P2 functions primarily in 
coordinating the maturation of the MVB/late endosome such that it is capable 
of fusing with a degradative compartment or acquiring a degradative 
capacity. Thus, cargo targeted for lysosomal degradation, such as EGFR or 
the contents of the autophagosome, fails to be properly degraded.
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Despite its capacity to bind Ptdlns(3,5)P2, the function of WIPI-2 in 
autophagy appears to be at an earlier stage in autophagosome formation, 
where it is most likely recruited to autophagic membranes through its binding 
of Ptdlns(3)P. The function of WIPI-2 as a Ptdlns(3,5)P2 effector, either at a 
later stage in autophagy or in a different cellular process remains to be 
determined.
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Figure 6.14. PIKfyve and WIPI-2 play opposing roles in mammalian 
autophagy.
WIPI-2 is recruited to the autophagosome following Ptdlns(3)P production 
by the Beclin-Vps34 complex. Here it is proposed to be involved in 
recruiting membrane to the expanding autophagosome. Supporting this 
hypothesis a loss of WIPI-2 leads to a reduction in lipidated LC3, 
suggesting that autophagosome formation is reduced. PIKfyve on the other 
hand causes an increase in lipidated LC3. Its localisation to early 
endosomes, combined with the finding that loss of its activity does not affect 
WIPI-2 localisation and reduces long-lived protein degradation suggest that 
it may affect autophagy indirectly. Once autophagosomes have fused to the 
endocytic pathway their subsequent fate is partially dependent on 
Ptdlns(3,5)P2. Loss of PIKfyve causes a failure in degradation of the 
contents of autophagosomes in a similar manner to its effects on 
internalised EGFR.
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CHAPTER SEVEN
Conclusion
This chapter will summarise the key findings of the work presented in 
this thesis, in the context of the current literature, whilst highlighting the key 
questions arising from this and the work of others that remain to be 
addressed. My work has focussed on the characterisation of four proteins 
associated with the metabolism of the phosphoinositide lipid Ptdlns(3,5)P2. 
The main aim of this work was to dissect the roles of these proteins in 
mammalian cells in relation to a variety of membrane trafficking pathways on 
which Ptdlns(3,5)P2 is proposed to play a role. An interest in this lipid stems 
from previous work in the lab characterising the roles of a group of 
phosphoinositide 3-phosphatases, the Myotubularins, and the aim to further 
characterise the putative mammalian 5-phosphatase Fig4, as at the time this 
protein had not been examined in any detail. However, the main body of the 
work has, over the course of my studies, been redirected to focus on the 
further characterisation of PIKfyve, as explained in more detail in this 
concluding chapter.
7.1 Summary and context of the current findings
7.1.1 Generation and use of key reagants
A key outcome of this work is the production and characterisation of 
invaluable tools and resources, such as antibodies, expression constructs, 
and purified protein, to permit continuation of research in this area. 
Furthermore, this assisted in the characterisation of three relatively poorly
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examined Ptdlns(3,5)P2 associated mammalian proteins in unison, in a range 
of different cellular contexts. In addition to this, characterisation of the effects 
of a small molecule inhibitor of PIKfyve complements the pre-existing body of 
literature on this protein in mammalian cells.
In chapter three, the production and initial uses of these tools and 
reagents was outlined. Antibodies against Vac14 and WIPI-2 were found to 
be effective in detecting both overexpressed and endogenous protein in 
mammalian cells. These antibodies were subsequently used to validate 
protein knockdown for siRNA studies, and to assess the role of WIPI-2 in 
mammalian autophagy, as discussed later. A direct interaction between 
Vac14 and Fig4 was demonstrated by two independent methods, confirming 
the yeast literature, and at the time elucidating a novel interaction for the 
mammalian proteins, though this has since been demonstrated by another 
group (Sbrissa et al., 2007). A small amount of Vac14 protein was purified 
from bacterial cells. The key purpose of protein purification was to obtain 
both Vac14 and Fig4, and to assess the substrate specificity of Fig4 and the 
nature of its interaction with Vac14, thus this was not pursued further due to 
the limited success of Fig4 protein production.
My biochemical data intriguingly indicated that Vac14 stabilises Fig4 in
mammalian cells. In yeast the vacuole association of Fig4 is dependent on
the presence ofVac14 (Rudge ef al., 2004), and more recently in mammalian
cells, a loss of Vac14 has been shown to affect the immunofluorescent
localisation of Fig4 to punctate structures (Sbrissa et al., 2007). Recently,
phosphatase activity has been established for mammalian Fig4,
demonstrating that this protein hydrolyses Ptdlns(3,5)P2 in vitro, and that
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ablation of Fig4 leads to a slight but significant increase in Ptdlns(3,5)P2 in 
intact cells. It was also found that Fig4 coimmunoprecipitates with both 
Vac14 and PIKfyve, and that ablation of Fig4 leads to an unexpected 
increase in Ptdlns(3)P levels (Sbrissa et al., 2007). These data suggest that 
the Vac14/Fig4 complex observed in yeast is conserved in higher organisms. 
Whilst Fig4 is clearly able to turnover Ptdlns(3,5)P2 in mammalian cells, as in 
yeast, it may also play a more complex role in regulating the activation of 
PIKfyve kinase activity through its interaction with Vac14, and potentially in a 
ternary complex between all three proteins. Purification of Fig4 protein 
therefore remains an important objective, such that the nature of the 
interaction between Vac14 and Fig4 may be assessed in more detail.
7.1.2 PIKfyve knockdown vs acute inhibition
Another key aim of this thesis was to examine the knockdown
phenotypes associated with each protein. However, apart from PIKfyve, the
proteins examined had no effect on these pathways. Previously, Vac14 and
Fig4 depletion in other mammalian cell lines have not demonstrated the
cytoplasmic vacuolation associated with PIKfyve knockdown, but instead
rendered cells prone to vacuolation following osmotic stress (Sbrissa et al.,
2004; Sbrissa et al., 2007). Only in cells taken from knockdown animals or
patients with neurodegenerative diseases involving mutations of Fig4, were
cytoplasmic vacuoles observed (Chow et al., 2007; Zhang et al., 2007).
Interestingly, my work showed that combined knockdowns of Vac14 and Fig4
with PIKfyve, although not increasing the percentage of cells with
cytoplasmic vacuolation increased the effect on several endosomal pathways
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examined, possibly because these three proteins act in a common complex 
to tightly regulate the levels of the lipid.
A source of the recently identified small molecule inhibitor of PIKfyve 
was also obtained. PIKfyve knockdown studies have the following 
drawbacks: i) PIKfyve has proven hard to completely deplete, such that 
residual enzymatic activity could produce sufficient Ptdlns(3,5)P2 ii) it is 
unclear if the phenotypes observed are due to a loss of enzymatic activity or 
some other function of the protein in) depletion is gradual and therefore any 
effect may be an indirect result of a loss of protein over a prolonged time 
period, and any compensatory mechanisms employed by the cell as a result. 
The small molecule inhibitor of PIKfyve has recently been characterised in 
the literature (Jefferies et al., 2008), but has not been directly compared 
against PIKfyve siRNA to examine the role of PIKfyve on endosomal 
trafficking pathways. Therefore, the work presented in chapters four and five 
reassessed common membrane trafficking phenotypes attributed to loss of 
PIKfyve through siRNA treatment and overexpression studies, and made a 
direct comparison with the effects of acute inhibition of this protein. A 
summary of the key phenotypes associated with loss of PIKfyve in the 
context of other findings from yeast and higher eukaryotes is shown in table 
7.1.
7.1.3 Endosomal maturation
Ptdlns(3,5)P2 was first linked to the endosomal system by the
observation that yeast Fab1 deletion mutants display markedly swollen
vacuoles (Gary et al., 1998; Odorizzi et al., 1998). This is also true in
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mammals, where PIKfyve siRNA treatment or overexpression of a kinase- 
deficient mutant leads to the dilation of endosomal compartments and 
formation of cytoplasmic vacuoles (Sbrissa et al., 1999; Rutherford et al., 
2006). I therefore chose to re-examine the characteristics of these swollen 
vacuoles in cells treated with PIKfyve inhibitor and to assess the possible 
mechanisms that lead to their formation. The large cytoplasmic are 
surrounded by swollen early and late endosomes and its limiting membrane 
is closely associated with LAMP-2. They have few ILVs and are poorly 
accessible to markers of fluid phase endocytosis. A number of lines of 
evidence have attributed this phenotype to a role of Ptdlns(3,5)P2 in 
membrane retrieval pathways, endosomal membrane homeostasis and 
terminal maturation of lysosomes (Nicot et al., 2006; Rüsten et al., 2006; 
Rutherford et al., 2006), therefore I compared the effects of PIKfyve 
knockdown and acute pharmalogical inhibition on these cellular processes.
Both PIKfyve knockdown and inhibition affected the distribution of a 
number of different proteins that cycle between endosomes and the TGN, 
that utilise both retromer-dependent and independent sorting mechanisms, 
including the trans-Golgi resident protein TGN46 and ciM6PR, responsible 
for transport of newly synthesised lysosomal enzymes. As well as the steady 
state distribution, the kinetics of transport from the cell surface, via the 
endosome, to the TGN are also perturbed for a range of proteins, including 
the Shiga toxin B subunit, and CD8-ciM6PR and Furin reporter constructs. 
These results confirm previous observations that PIKfyve plays a role on this 
pathway (Rutherford et al., 2006), and furthermore suggests that PIKfyve
258
Chapter seven: Conclusion
enzymatic activity and generation of Ptdlns(3,5)P2 is important for the 
general retrieval of membrane from various stages of the endocytic pathway.
Conflicting evidence from the literature suggests that Ptdlns(3,5)P2 
may also be involved in ILV formation, sorting of endocytosed receptors into 
the lumen of the MVB or lysosomal degradation. Therefore, I examined the 
effects of pharmacological inhibition of PIKfyve on tyrosine kinase receptor 
degradation. Knockdown of PIKfyve alone had no effect on EGFR 
degradation, as previously shown in other studies (Rutherford et al., 2006), 
however combined knockdown of PIKfyve and its activator Vac14 caused a 
delay in EGFR downregulation. Consistent with these observations, 
pharmacological inhibition of PIKfyve, at concentrations which do not 
produce any major perturbation in the levels of 3-phosphoinositides, revealed 
a strong block to EGFR and a second tyrosine kinase receptor, c-Met, 
downregulation. This data suggests that loss of PIKfyve enzymatic activity 
causes a defect in the lysosomal degradation of endocytosed receptors, but 
with a relatively low threshold value. Despite the possibility that components 
of the ESCRT complex may bind to Ptdlns(3,5)P2 (Whitley et al., 2003), and 
that cytoplasmic vacuoles appear to be endosomal compartments with few 
ILVs (Ikonomov et al., 2003a), the observed effect on EGFR degradation was 
shown to occur subsequent to its translocation into the lumen of the MVB. 
This finding is in agreement with previous work in Drosophila, which found a 
delay in the degradation but not internalisation of Wingless and Notch 
receptors (Rusten et al., 2006).
These data suggest that Ptdlns(3,5)P2 may coordinate the maturation
of at least a subset of MVBs. Cargo is delivered to the endocytic pathway
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but is unable to recycle back to the TGN, therefore disrupting the balance of 
membrane delivery and retrieval and leading to a swelling of endosomal 
compartments. Furthermore, a defect in ciM6PR recycling perturbs the 
delivery of lysosomal enzymes and possibly the retrieval of certain proteins 
necessary for correct acidification of the MVB. Each of these defects may 
lead to a failure in the correct maturation of the MVB such that it is rendered 
refractory to fusion with the lysosome.
Further work is needed to clarify the role of Ptdlns(3,5)P2 in
endosomal progression. Other groups have suggested that PIKfyve
negatively regulates early to late endosomal fusion, thus leading to the
formation of enlarged late endosomes (Ikonomov et al., 2006). They also
showed that other undefined fusion events may be regulated by PIKfyve,
such as ILV fusion with the MVB limiting membrane, thereby explaining the
reduced number of ILVs observed by EM. Perhaps PIKfyve mediated
conversion of Ptdlns(3)P to Ptdlns(3,5)P2 switches the balance from early-
late endosome fusion to late endosome-lysosome fusion, a model that would
consolidate my findings with these. Immuno-EM studies examining the
distribution of markers previously examined by IF following loss of PIKfyve
may help to build a clearer picture of the precise point of the block in these
trafficking pathways. It may also prove interesting to examine the distribution
of Rab proteins and to further examine fusion rates following loss of PIKfyve
enzymatic activity. A recent paper described the combination of live-cell
imaging techniques with new software to analyse the conversion of Rab5 to
Rab7 in early to late endosome transport (Rink et ai, 2005). Although the
steady-state localisation of Rab5 and Rab7 has been examined (Ikonomov et
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a/., 2006), such techniques could potentially be applied to examine early to 
late endosome dynamics following PIKfyve knockdown.
7.1.4 Autophagy
Another proposed cellular function of Ptdlns(3,5)P2 is in autophagy. 
Although a role for Ptdlns(3)P has been established, the precise function of 
Ptdlns(3,5)P2 remains elusive. It has been suggested to act through the 
downstream effector Svp1/Atg18, however, at least in yeast the role of Svp1 
is thought to be independent of its binding to Ptdlns(3,5)P2 (Dove et al., 
2004). Groups working on the mammalian protein WIPI-1 have also 
identified a potential role for this protein in autophagy (Proikas-Cezanne et 
al., 2004; Proikas-Cezanne et al., 2007). I therefore chose to examine the 
role of each of the four Ptdlns(3,5)P2 associated proteins in mammalian 
autophagy for a number of reasons: 1) to attempt to assess the contribution 
of PIKfyve enzymatic activity, and therefore Ptdlns(3,5)P2 in autophagy, 
through the use of PIKfyve inhibitor 2) to examine the role of WIPI-2 in 
autophagy (given that only WIPI-1 has been assessed in this context, and 
that WIPI-2 had no effect on other endosomal trafficking pathways) and 3) to 
determine how the role of WIPI-2 relates to its role as an effector of 
Ptdlns(3,5 )P2.
The work described in chapter six determined that loss of PIKfyve
enzymatic activity lead to an accumulation of the autophagosomal marker
GFP-LC3 II, whereas loss of WIPI-2 had the opposite effect, causing a
decrease in GFP-LC3 II. WIPI-2 was shown to be recruited to
autophagosomal structures following starvation-induction of autophagy, an
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effect that was subsequently shown to be ablated by wortmannin but not 
PIKfyve inhibitor treatment, suggesting that WIPI-2 recruitment to 
autophagosomes is independent of its potential capacity to bind 
Ptdlns(3,5)P2. Further analysis suggested that loss of WIPI-2 gave a similar 
phenotype to loss of the integral autophagy protein ULK-1, part of the 
autophagy-inducing complex in yeast. Furthermore, combined knockdown of 
the two proteins lead to an even more dramatic loss of GFP-LC3 II. The 
evidence suggests that PIKfyve and WIPI-2 have different roles in 
autophagy. Interestingly, WIPI-2 also has the opposite effect to the yeast 
Fab1 mutant, suggesting that the relationship between the yeast and 
mammalian proteins may be more complicated than originally suspected. 
PIKfyve most likely exerts an indirect effect on the autophagy pathway, by 
affecting the progression of autophagosomal content to the lysosome in a 
similar manner to its role in EGFR degradation. However, WIPI-2 appears to 
be a more integral part of the autophagy machinery, potentially mimicking its 
role in Atg9 cycling in yeast, although its precise role remains to be dissected 
in detail.
Further work is needed to determine the lipid binding capacity of WIPI-
2, as this has only been assessed for WIPI-1, and it seems that it may
preferentially bind to Ptdlns(3)P (Jeffries et ai, 2004). If WIPI-2 does bind to
both Ptdlns(3)P and Ptdlns(3,5)P2 in a cellular context, then its role as a
Ptdlns(3,5)P2 effector and how its lipid-binding capacity relates to its effect in
autophagy, remain to be determined. Currently, work is being undertaken to
determine if the ability of overexpression of WIPI-2 to rescue the WIPI-2
knockdown phenotype is dependent on its lipid binding capacity, by
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production of a lipid-binding mutant. Furthermore, a yeast-two hybrid screen 
to identify novel binding partners of the WIPI proteins is underway to 
determine other potential functions of these proteins.
7.2 Limitations of the study
The data presented in the current study have been assessed in the 
context of the current literature, but the limitations of the various techniques 
used must also be taken into consideration. Although treatment with a 
specific inhibitor of PIKfyve allows us to overcome some of the caveats of 
overexpression and siRNA studies, it has limitations of its own. In this study 
the levels of phosphoinositide levels following treatment with either siRNA 
suppression of PIKfyve or Fig4 enzymes, or inhibition of PIKfyve, were not 
assessed due to the technical demands of the techniques involved. The 
levels of lipids have been examined for the structurally similar YM201636, 
but this does not mean that the two compounds have the same effects. MF4 
appears to have a more substantial effect on Pl(3)-kinases than YM201636, 
and although this could be explained by the use of different ATP 
concentrations when measuring IC50 values, this could mean that MF4 is 
affecting other phosphoinositide kinases. The levels of Ptdlns(3)P were 
assessed by immunofluorescence to address this issue to some extent and 
results were compared directly with PIKfyve siRNA treatment to help us to 
draw general trends in loss of PIKfyve phenotypes, but in order to be certain 
that this inhibitor is specific for PIKfyve and affects only Ptdlns(3,5)P2 levels 
the phosphoinositide levels need to be measured. Therefore, we must bear
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in mind that where PIKfyve inhibitor is used we make the assumption that the 
observed results are as a direct result of loss of PIKfyve activity alone.
A key limitation of the work presented in chapter four is that data 
presented are morphological studies and do not give any quantitative 
assessment of these phenotypes. In order to reinforce this data, it would be 
prudent to assess these phenotypes using image analysis software. The key 
phenotype of PIKfyve deficient cells is the formation of swollen cytoplasmic 
vacuoles, and the very presence of these vacuoles may cause morphological 
disruption to cells, such that retrieval of cargo to the TGN is perturbed for this 
reason rather than effects on the trafficking machinery. The assessment of 
TGN46 in comparison to other golgi proteins suggests that golgi structure at 
least remains intact.
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Figure 7.1. Ptdlns(3,5)P2 regulates endosomal membrane dynamics.
In a normal cell (left) endocytosed material passes through the 
compartments of the endocytic pathway where it is gradually sorted into 
tubular or vacuolar partitions of endosomes. Cargo sorted into tubules is 
transported to various cellular localisations, whereas vacuoles accumulate 
in the maturing MVB, sorting cargo for lysosomal degradation. Loss of 
PIKfyve activity (right) produces swollen early and MVB/late endosomes 
with fewer intralumenal vesicles (EM inset). EGFR is internalised into 
MVBs where signalling is terminated, but a proportion of the receptor fails to 
get degraded. EGFR is able to reach acidified compartments, but fails to 
get degraded as the MVB is refractory to fusion with the lysosome. A 
variety of retromer-dependent and independent TGN retrieval pathways are 
perturbed as formation of recycling tubules is affected.
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